Proteinaceous particle

The discovery and isolation of Thrombospondin Encapsulated Dense particles (ThrEDs) address the challenge of EV heterogeneity, offering improved therapeutic delivery and functional efficacy through precise subpopulation analysis and calcium-stabilized isolation.

WO2026234268A1PCT designated stage Publication Date: 2026-11-12OXFORD UNIVERSITY INNOVATION LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063489
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing technologies struggle to accurately classify and enrich distinct subpopulations of extracellular vesicles (EVs) due to heterogeneity, leading to inefficient therapeutic delivery and diluted functional effects, as current markers like tetraspanins can lead to misclassification and low cellular uptake.

Method used

Identification and isolation of a novel subtype of proteinaceous particles, Thrombospondin Encapsulated Dense particles (ThrEDs), characterized by a dense thrombospondin shell and non-cytotoxic core, which are distinguished through high-density gradient ultracentrifugation and calcium-stabilized storage, enabling precise subpopulation analysis and therapeutic applications.

Benefits of technology

ThrEDs provide a new therapeutic delivery tool with enhanced wound healing and fibrosis reversal capabilities, overcoming the limitations of conventional EVs by ensuring precise cargo delivery and functional efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000034_0001
    Figure IMGF000034_0001
  • Figure IMGF000036_0001
    Figure IMGF000036_0001
  • Figure IMGF000038_0001
    Figure IMGF000038_0001
Patent Text Reader

Abstract

The invention relates to an isolated and / or engineered proteinaceous particle; and associated products, methods and uses.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PROTEINACEOUS PARTICLE

[0002] Field of invention

[0003] The invention relates to an isolated and / or engineered proteinaceous particle; and associated products, methods and uses.

[0004] Background of the invention

[0005] Extracellular Particles (EPs) are mediators of intercellular communication. One type of EP, extracellular vesicles (EVs) are capable of transferring bioactive molecules in a protected lipid bilayer, influencing various physiological and pathological processes. EV populations are not homogenous but rather comprise distinct subpopulations with diverse characteristics and functional roles. Understanding subpopulations is therefore important and / or essential for the accurate classification, efficient purification, and comprehensive understanding of their bioactivities. Tetraspanin proteins, CD63, CD81 and CD9 are abundant on EVs and have been linked with important vesicular functions. They were among the first discovered common EV proteins and the first used to describe different subpopulations, based on EV tetraspanin profile. CD63, CD81 and CD9 positive vesicles are often classified as exosomes given their enrichment on the multivesicular body (MVB) and intraluminal vesicle (ILV) membranes in wild type cells. However, some studies have cautioned against their use as defining criteria given tetraspanins are also present in the plasma membrane (PM), the site of microvesicle biogenesis which could lead to their misclassification. Gaining a better understanding of EP subpopulation markers and cargo will improve the ability to discern functional differences, the effects of which may be diluted through heterogenous preparations.

[0006] Immune cell derived EVs are a strong example of extracellular particle subpopulations’ ability to elicit different responses in target cells due to the transfer of bioactive proteins. Looking at EV subpopulations, dendritic cell (DC) EVs were shown to coordinate the immune response through activation of T cells into either helper T cell (Th) or cytotoxic T lymphocytes (CTLs). In naive DCs, large DC-EVs contain Th2 cytokines (IL-4, IL-5, IL-10, IL-13), while small DC-EVs carry Thl cytokines (IFN- y, IL-2, TNF-B) which mediate distinct immune responses. In turn, CTLs then release EP subpopulations oftheir own. In addition to EVs, CTLs also release a type of non-vesicular extracellular particle (NVEP) called Supramolecular Attack Particles (SMAPs). At the immune synapse (IS), where T cells bind their target, both trans-synaptic vesicles (tSVs), carrying CD40L, and SMAPs, carrying Granzyme and Perforin, cooperate towards a similar aim as indirect and direct cytotoxic effectors. CTLs release two different EP subpopulations to efficiently arm the immune system against antigen presenting cells (APCs).

[0007] Beyond cells, the extracellular matrix (ECM) is another example where EV subpopulations have diverse roles and functions impacting both physiology and pathology. Matrix vesicles from osteoblasts and chondrocytes concentrate calcium and phosphate to promote bone and cartilage formation. While EVs from mesenchymal stem cell (MSC) attenuate proteolysis supporting the strengthening of the ECM through additional deposition of elastic matrix components by surrounding cells. Similarly, MSCs contain many ECM related proteins and may promote wound healing directly or indirectly through matrix deposition or signalling. However, under pathological conditions, excess dysregulated deposition of ECM leads to tissue fibrosis. EVs released from fibroblast cells promoted increased matrix stiffness and scar tissue leading to pulmonary fibrosis.

[0008] Conversely, EVs released from cancer cells contribute to ECM turnover largely mediated by matrix metalloproteinases and glycosidases which ultimately initiate metastasis via cell migration and invasion in the pre-metastatic niche. Interestingly, EV-ECM subtypes involved in cancer and fibrosis have intertwined roles as it has been shown that the formation of fibrotic tissue around a tumour inhibits immune cell and chemotherapeutic infiltration.

[0009] The origins of EP heterogeneity include cell differentiation state, environmental stimuli, and biogenic origin, among others. For example, the DC cell maturation abolishes cargo mediated functional differences between large and small EV. Mature DC-EVs carry Thl cytokines exclusively. The consequence of a lack of subpopulation understanding is the dilution of potency thought heterogeneity. For example, insufficient EV anchor / marker colocalization with fusogenic proteins and paired engineered cargo (due to mutually exclusive sorting into different EV subtypes) leads to low cellular / tissue uptake, inefficient cytosolic delivery, and a lack of functional and therapeutic efficacy. The variability presented by subpopulations is difficult to control as it is not yet well understood. For example, tetraspanins are often used as engineering anchors to deliver therapeutics cargo via EVs, however these strategies have shown limited success, ultimately incurring a lackof therapeutic translation. The proteinaceous particles of the present invention represent a distinct opportunity for engineering.

[0010] It is therefore an object of the invention to provide further and / or improved isolated and / or engineered proteinaceous particle; and associated products, methods and uses.

[0011] Summary of the invention

[0012] Extracellular particles (EP) released by cells are bioactive. Therefore, it is of importance to classify and enrich relevant subpopulations defined by size, origin, and composition. To investigate differential subpopulation marker expression 15 fluorescent protein chimeras of putative EV markers were stably expressed in four non-cytotoxic adherent cell lines. Nanoflow cytometry identified TSPAN14 as a superior EP marker in three cell lines. However, <50% of EPs were labelled by any EV markers in two cell lines. The EV marker negative population were detergent resistant, lipophilic stain negative, and glycoprotein positive. dSTORM revealed dense ~80-200nm Thrombospondin shells, like SMAPs, lacking cytotoxic cargo or activity. Rather, their dense core of extracellular matrix regulators function in wound healing and fibrosis reversal. The discovery of proteinaceous particles with distinct, non-cytotoxic function that are ubiquitous in both cell lines and human tissue identifies a second major subtype of proteinaceous particles, which may be termed -Thrombospondin-Encapsulated Dense particles (ThrEDs).

[0013] Thus, the analysis conducted by the inventors not only revealed significant cell-cell EV heterogeneity but surprisingly highlighted the existence of a novel and advantageous, constitutive population of proteinaceous Thrombospondin Encapsulated Dense particles (ThrEDs). The inventors demonstrated that ThrEDs had a similar in morphology to SMAPs but with distinct cargo and function. Thrombospondin Encapsulated Dense particles (ThrEDs) were also found to increase wound healing as well as reverse myofibroblasts fibrotic phenotype in Dupuytren’s Disease. ThrEDs provide a new landscape for understanding the heterogeneity of extracellular particles and a novel therapeutic delivery tool which presents significant advantages over extracellular vesicles.

[0014] Thrombospondins are the main, common molecular signature between Thrombospondin Encapsulated Dense particles (ThrEDs) and Supramolecular Attack Particles (SMAPs). In cells, thrombospondins are a secreted extracellular matrix glycoprotein with many roles including angiogenesis inhibition, cell adhesion, tissue repairand re-modelling, and matrix metalloproteinase modulation. In SMAPs and ThrEDs, they form a calcium stabilized, protective shell carrying abundant bioactive cargo from a donor to the recipient cell. There are at 5 thrombospondin genes in humans, which are named THBS1, THSB2, THBS3, THBS4 and THBS5 (COMP). THSB1 and THBS4 have been found and validated as components of the outer shell of SMAPs. ThrEDs have been found to contain THBS1, THBS4 and COMP (also referred to as TSP-1, TSP-4 and TSP-5) as major shell components with additional content reflecting the producer and its cellular state. ThrEDs further, lack cytotoxic activity, which is a hallmark of SMAPs, and ThrEDs are thus distinct from SMAPs.

[0015] ThrEDs represent a new class of proteinaceous particles. ThrEDs are released constitutively by all cell types in culture and human tissue. CD8+ cells release ThrEDs while at rest and following activation in the absence of a bound target. Upon target binding, activated CD8+ cells release SMAPs instead of ThrEDs. Other specialized cells may release ThrED subtypes that function both extracellularly and through uptake into cells. ThrEDs may also perform cooperative functions with EVs, as has been shown for SMAPs. Given their morphological and compositional similarity, the potential for synergistic interactions between vesicular and non-vesicular EPs is of great interest.

[0016] Particularly, given ThrEDs ECM modulation which may facilitate EP access to cells.

[0017] ThrEDs have thus far gone unnoticed in EV preparations for several reasons. They co-isolate with EVs even under stringent isolation methods including ultracentrifugation, size exclusion chromatography, and ultrafiltration (including all these steps together). High density gradients, such as those used herein, were required to achieve separation. In addition, ThrEDs may require calcium in their storage media to maintain their shell’s stability and this ion is frequently absent from solutions used to manipulate EPs during isolation and testing. Thus, the inventions also highlights the importance of single particle and high-resolution analysis to distinguish EP subpopulations and their distinct requirements.

[0018] Accordingly, the following is provided.

[0019] [1] an isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, further wherein:

[0020] (a) the particle or core comprises or consists of one or more of an extracellular matrix component, a protein, a glycoprotein, a proteoglycan such as serglycin, and a polysaccharide; and(b) the particle or shell comprises or consists of one or more of full-length protein selected from a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 or TSP-5, serglycin, calreticulin, calmodulin, calumenin, cathepsinD, HRNBPA2B1, HS90AA1, HSPA8, syndecan such as cleaved syndecan-1, BASP1, galectin-1 or galectin-7; or a fragment, variant or orthologue of anyone thereof;

[0021] [2] a cell capable of producing the particle of the invention;

[0022] [3] a method of producing a modified cell capable of producing the particle of the invention, the method comprising introducing into the cell a nucleotide sequence encoding the core, shell, moiety and / or cargo molecule;

[0023] [4] a method of isolating the particle of the invention from a cell, cell lysate, conditioned media, and / or physiological fluid such as plasma, blood, urine, bile, saliva, interstitial fluid or cerebrospinal fluid, the method comprising:

[0024] (a) providing the cell in a liquid suspension, cell lysate, the conditioned media, and / or the physiological fluid;

[0025] (b) centrifuging and / or filtering the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid, to form a cell-free and debris-free liquid; and / or

[0026] (c) centrifuging and / or filtering the cell-free and debris-free liquid to collect the particle;

[0027] [5] a method of isolating the particle of the invention from a cell, cell lysate, conditioned media and / or physiological fluid, the method comprising:

[0028] (a) contacting the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid with a substrate, wherein the particle adheres to the substrate, optionally wherein the cell also adheres to the substrate;

[0029] (b) washing the substrate to leave the particle adhered to the substrate; and

[0030] (c) collecting the particle by eluting the particle from the substrate;

[0031] [6] a particle obtained or obtainable by the method of the invention;

[0032] [7] a composition comprising the particle of the invention;

[0033] [8] a method of treating or preventing disease in a subject comprising administering to a subject the particle and / or composition of the invention;

[0034] [9] an in vitro or ex vivo use of the particle and / or composition of the invention as a research tool, a diagnostic tool, an imaging tool, a biological reference material, anexperimental control and / or an experimental standard; optionally wherein the particle or the composition is immobilised to a solid support;

[0035]

[0010] an isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, wherein:

[0036] (a) the core comprises one or more extracellular matrix component selected from a collagen, a proteoglycan, a glycoprotein, a SERPIN, and an ITIH protein;

[0037] (b) the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5), or fragments, variants or orthologues thereof; and

[0038] (c) the particle does not comprise a lipid bilayer;

[0039]

[0011] an isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, wherein:

[0040] (a) the core comprises one or more extracellular matrix component;

[0041] (b) the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5); (c) the particle does not comprise a lipid bilayer;

[0042] (d) the particle does not comprise granzyme B and / or perforin-1; and

[0043] (e) the particle is not cytotoxic;

[0044]

[0012] a method of isolating the particle of

[0010] or

[0011] , the method comprising:

[0045] (a) providing conditioned media from a cell cultured for at least 48 hours, at least 72 hours or about 96 hours;

[0046] (b) subjecting the conditioned media to iodixanol density gradient ultracentrifugation; and

[0047] (c) collecting the particle from the 40% and / or 60% iodixanol fraction; optionally wherein Ca2+ is present during one or more steps at a concentration of 0.5mM to 9mM;

[0048]

[0013] an in vitro method of identifying or distinguishing ThrEDs from SMAPs in a sample, the method comprising detecting the presence of TSP-5 (COMP) in the sample, wherein the presence of TSP-5 (COMP) is indicative of ThrEDs; and

[0049]

[0014] a population of particles, wherein each particle in the population comprises a core and a shell surrounding the core, wherein the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5), the particle does not comprise a lipid bilayer, and at least 30% of the particles in the population are TSP-1 positive and TSP-5 positive.

[0050] Brief description of the figuresFigure 1: Screening putative Extracellular Vesicle markers in common cell lines. (A) Schematic depicting part of the custom lentiviral vector backbone used to clone 14 EV marker proteins classified into tetraspanin, single pass and cytosolic. Linker is the “chain”; and tag is the “ball”. (B) Nanoflow cytometry dot plot of the top EV protein marker in each cell line, showing both labelled and unlabelled populations. (C) Percentage of GFP+ (mClover3+) and (D) Mean Fluorescence Intensity (MFI) of EVs quantified by nanoFCM single-vesicle flow cytometry from conditioned media of 60 stable cell lines expressing EV marker constructs fused to mClover3. Final summary column represents the average across all 4 cell lines tested. (E) Average particle concentration measured in particles / mL via nanoFCM in HEK-293T, A549, HeLa and MSC(CB). (F) Average mean EV diameter of TSPAN14 and CD63 - mClover3 EVs measured by nanoFCM. (G) Number of molecules per EV calculated from the MFI of each EV using custom bead supported lipid bilayer (BSLB) calibration beads and MESF beads for TSPAN14 and CD63 - mClover3 EVs. Data are presented as the mean ± SEM, n = 3 biological replicates, n.s. P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001.

[0051] Figure 2: Determination of subpopulation composition using single particle flow cytometry. (A) Schematic of nanoparticle subpopulations released from cells. Particle colours are representative of quadrants in (B) (Nu = nucleus, arrow = a general representation for particle release). (B) Representative plot of single particle flow cytometry data of nanoparticle samples isolated from TSPAN14-mClover3 stable cell lines by SEC and stained with CD63-PE (Pl = top right quadrant; P2 = top left quadrant; P3 = bottom left quadrant; P4 - bottom right quadrant.) Panels (C - E) are single particle nanoflow cytometry results investigating the double negative population in (B). (C) Nanoparticle preparations from TSPAN14-mClover expressing cells isolated using SEC are probed for ApoE. Particles / mL of ApoE+ and ApoE- populations are shown. (D) Nanoparticles preparations from TSPAN14-mClover3 expressing cells isolated using SEC are measured to determine baseline particles / mL values. Samples were then treated with 0.2% Triton-X-100 and remeasured to determine the proportion of detergent resistant nanoparticles (non-membrane bound) measured in Particles / mL. (E) Nanoparticle preparations from wild type HEK-293T, A549, HeLa, and MSC(CB) cells isolated by SEC are stained with CellMask488 (membrane dye) and WGA-AF647 (glycosylated protein dye) to determine the proportion of proteinaceous ThrEDs in each cell line. Representativediagrams are shown; Pl = top right quadrant; P2 = top left quadrant; P3 = bottom left quadrant; P4 - bottom right quadrant. (F) Data from (B-E) are represented as percent composition of nanoparticle subpopulations for each cell line (legend corresponds to the order of each group in the bar chart; therefore, for example: “ThrED” is the bottom group in each bar; “CD63- TSPAN14- particle” is the top group in each of the HeLa, A549 and MSC bars; and “CD63+ TSPAN14+ EV” is the top group in the HEK bar). Data are presented as the mean ± SEM, n = 3 biological replicates.

[0052] Figure 3: Novel NVEP subtype density -based purification and morphological characterization. (A) Schematic of iodixanol density gradient isolation protocol to generate enriched preparations of ThrED particles for morphological and compositional analysis. EVs are depicted in fractions 3-6 and ThrED particles are depicted in fraction 11-12. Hybrid particles of intermediate density are depicted in f7-8. ‘S’ denotes samples. (B) Migration profile of Extracellular Particles (EPs) isolated at a 48 hour, a 96 hour time point, and a 96 hour time point treated with 0.3% Triton-X-100, following iodixanol density -based ultracentrifuge fractionation (DGUC). EV fractions are shown in the box -Peak 1 - encompassing fractions 3-6. Novel NVEP particle (ThrEDs) fractions are shown in the box - Peak 3 - encompassing fractions 11 and 12. EPs of intermediate density are shown in the box - Peak 2 - encompassing fraction 7-8. Corresponding iodixanol percentages are indicated below fraction number. (C-D) Fraction 12 particles are stained with CellMask488 and WGA-AF647 for nanoflow cytometry or DiR and WGA- AF488 for 2D SMLM dSTORM to determine the purity of particles. Representative panels and images are chosen. (E-F) Compositional analysis of Fraction 12 particles. F12 particles are probed for Thbsl and Srgn using nanoflow cytometry. 2D SMLM are stained similarly, with the addition of DiR membrane dye. Representative panels and images are chosen. (G) Representative negative stain electron microscopy micrographs of fractions 4, 8 and 12 are shown. (H) Western blots of pooled fraction 11+12 (ThrEDs) and Whole Cell Lysates (WCL) in wild type HEK-293T and A549. ThrED particles and WCL are blotted against Thrombospondin- 1. A loading control is not present or known. (I) The effect of PBS supplemented with calcium on ThrED particle stability and concentration analysed using nanoflow cytometry of F12 (no CaCh left bars with lower values; with CaCh right bars with higher values). (J-K) Nanoparticles preparations from wild type cells and human tissue isolated using SEC are measured to determine baseline particles / mL values.

[0053] Samples are then treated with 0.2% Triton-X-100 and remeasured to determine theproportion of detergent resistant nanoparticles (non-membrane bound) measured in Particles / mL. In (J): left bars with a higher value are “Wild type”; right bars with lower values are “0.2% Triton-X-100” Data are presented as the mean ± SEM, n = 3 biological replicates.

[0054] Figure 4: ThrEDs in human tissue are released constitutively and non-cytotoxic. (A) Migration profile of Extracellular Particles (EP), isolated in PBS at a 96-hour time point, following iodixanol density-based ultracentrifuge fractionation. EV fractions are shown in the box encompassing fractions 3-5 and novel NVEP particle fractions are shown in the box encompassing fractions 10-12. EPs of intermediate density shown in the box encompassing fraction 8. Corresponding iodixanol percentages are indicated below fraction number. (B) Representative negative stain electron microscopy micrographs of fractions 4, 8 and 12 are shown. (C) Plasma ThrEDs (F12) were probed for Thbsl, Srgn and Thbs5 (COMP) using nanoflow cytometry. (D, E) 2D SMLM dSTORM images of single ThrEDs probed for WGA (glycosylated protein dye), Thbsl and Thbs5 to show ring structures. (F) ThrEDs from CD8+ resting T cells, cytotoxic T lymphocytes (CTLs) and plasma were probed for Granzyme B and Perforin 1 using nanoflow cytometry (cytotoxic SMAP cargo effectors). (G) Nalm6 cytotoxicity assay using SMAPs and ThrEDs to kill target cells quantified looking at cell death using a live-dead stain and Granzyme B dependent cell death by probing cleaved Caspase 3 in Nalm6 cells. (H) Representative flow plots for the quantifications in (I) are shown for each condition. (J) Ven diagram illustrating the comparative protein profiles of ThrEDs and SMAPs. (K) Schematic illustrating the difference between NVEP subtypes in CTLs. Cytotoxic SMAPs released to kill antigen presenting cells (APCs) and ThrEDs released constitutively into the extracellular space. Data are presented as the mean ± SEM, n = 3 biological replicates, n.s. P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001.

[0055] Figure 5: ThrEDs protein composition - inter / intra particle interactions and ECM function. (A) Venn diagram of proteomics profiles in A549, HEK-293T and PANCI highlighting common structural and signalling ECM proteins. (B) Identification of COMP (Thbs5) as a novel biomarker for ThrEDs given lack of immune cells expression and ubiquitous and abundant expression in non-immune ThrEDs. (C) Overall protein matrix composition in A549, HEK-293T and PANCI is similar and composed of collagens, proteoglycan and glycoproteins. Additional proteins are classed ECM regulators, matrix affiliated proteins (signalling, regulation, positive and negative feedback) and secretedfactors. Bars from top to bottom are: secreted factors matrix affiliated, ECM regulators, Glycoproteins, Proteoglycans, and Collagens. (D) Protein-protein binding interaction matrix of proteins in (C) including abundant calcium binding proteins. (E) Protein-protein binding interaction matrix based on the isoelectric point of proteins depicting chargecharge interactions between Thrombospondin shell proteins and ECM regulators. Filtered for highest confidence of binding affinity (charge-charge and protein-protein). (F) Full protein composition of ThrEDs plotted based on isoelectric point and abundance.

[0056] Thrombospondin shell and ECM components are largely acidic and negatively charged. (G) Number of cellular polarity related GO terms associated with proteins identified in the whole cell lysates of A549 and HEK-293T cells and (H) the proteins common to the greatest number of polarity GO terms. Early, Mid and Late represent the different stages of initiating, establishing and maintain cellular polarity. (I) Number of extracellular matrix related GO terms associated with proteins identified in the whole cell lysates of A549 and HEK-293T cells and (H) the proteins common to the greatest number of ECM GO terms. Data represents n=3 biological replicates.

[0057] Figure 6: ThrEDs accelerate wound healing by promoting migration and reversing fibrotic phenotypes. (A) Confluence of wound of A549 ThrEDs on myofibroblasts cells. (B) Relative wound density for A549 ThrEDs on myofibroblasts. (C) Representative images of myofibroblast cells from Dupuytren’s Disease patients treated with PBS, EVs, Hybrids and ThrEDs at T:0hr, 38 hrs, 94hrs (to show cell morphology). (D) Peptide coverage on Fibronectin 1 (FN1), Collagen lai (Collal) and Collagen la2 (Colla2) proteins. (E) Confocal images of myofibroblasts treated with PBS or ThrEDs strained with Phalloidin and Smooth Muscle Actin (SMA), a fibrotic marker. (F) Associated quantification of colocalization between Phalloidin and SMA to determine amount of organized, fibrillar SMA at 24hrs post ThrEDs treatment, using Pearson (PCC) and Manders (Ml). (G) Western blot probing SMA at 24hrs of the WCL of myofibroblasts treated with PBS, EVs, Hybrids and ThrEDs. Fast green is the loading control showing whole protein stain. (H) Confocal imaging of Racl / 2 / 3 and phoso-Focal Adhesion Kinase (p-FAK) 24 hrs post scratch wounding in myofibroblast cells, with associated MFI quantification in (I, J). (K) Collagen 1 and Fibronectin 1 confocal imaging 24 hrs post scratch wound in myofibroblast cells. (L) Quantification of the amount of FN1+, Coll+. Actin+ (Phalloidin), and DNA+ (NucSpot) particles ranging from 0-500nm in diameter deposited / present within the scratch wound gap area at 24 hrs.Figure 7: Engineering ThrEDs as a novel therapeutic vehicle. (A) Extracellular Particle (EP) pool from conditioned media measured using nanoflow cytometry for GFP+ particles pre and post treatment with 0.2% Triton-X-100. (B) Number of GFP+ particles and (C) their respective sizes. (D) Migration profile of Extracellular Particles (EP), isolated in PBS+0.9mM CaC12 at a 96-hour time point, following iodixanol density -based ultracentrifuge fractionation (GFP+ particle curve is the top curve for fractions 8-12). (E) Diameter of GFP+ and GFP- particles migrating to F12. (F) Diagram of anti GFP nanobody based ThrEDs capture on cell surface mimic supported lipid bilayer (SLB). (G-H) Representative confocal image micrographs of SLB capture with and without anti -GFP nanobody (H) and associated quantification of particles. (I) 2D SMLM dSTORM image of a single GFP+ ThrED showing maintenance of ring structure following GFP C-terminal Thbsl fusion. Data are presented as the mean ± SEM, n = 1 (A-E) n=3 (G-H) biological replicates, n.s. P > 0.05, * P < 0.05, ** P< 0.01, *** P < 0.001.

[0058] Figure 8: Validating an EV marker screening assay for single particle analysis. (A) Schematic representing the EV marker screening assay protocol. (B) Percentage of GFP+ (mClover3) EVs from transiently transfected HEK-293T cells isolated by CM or SEC protocols. Data are presented as the mean ± SEM, n = 3 biological replicates, n.s. P > 0.05, * P < 0.05.

[0059] Figure 9: EP subpopulation dSTORM imaging confirms presence of proteinaceous particles. Single vesicle 2D SMLM dSTORM image analysis of nanoparticles from TSPAN14-mClover3 expressing stable cell lines in (A) HEK-293T, (B) A549, (C) HeLa, and (D) MSC(CB). Nanoparticles isolated by SEC are stained with DiR (far red membrane intercalating dye), WGA-AF568 (wheat germ agglutinin; binds N-linked glycosylated protein residues) to detect glycosylation PTMs, and anti-GFP-AF488. Scale bar 20pm in full field of view and lOOnm in single particle zoom panels. Representative images of TSPAN14+ EVs, TSPAN14- EVs, and WGA+ spherical protein particles are shown. (E) Box plot of particle diameter (nm) calculated using the ONI CODI software are shown for EVs (DiR+ particles) and protein particles (DiR- particles) in each cell line (pair of bars from left to right correspond to HEK, A549, HeLa and MSC). Data represents n=20 nanoparticles per group.

[0060] Figure 10: Proteinaceous, Thrombospondin Encapsulated Dense particle release kinetics. (A) Plot of A549 live cell concentration in cells / mL (bottom curve) and viability (top curve) at timepoints across 5 days of collection with (B) representative micrographs ofcell confluence and morphology at each day. (C) Western blot whole cell lysates from Day 1 through 5 probing Thrombospondin 1 and Serglycin with associated quantification of the mean grey value of each band. (D) Nanoflow cytometry analysis of extracellular particles pools from conditioned media at days 2 and 4 probing protein (WGA) and lipid (Cell Mask) biomolecules (E) Thbsl and Srgn and (F) COMP (Thbs5). (G) Migration profile of Extracellular Particles (EP), isolated in isosmotic buffer with 4.5mM CaC12 at time points Day 1 through 5, following iodixanol density-based ultracentrifuge fractionation. (H) Concentrations of Fl-12 total particles, F12+11 ThrEDs, F7+8 Hybrids, across time points and (I) the proportion of Fl 1+12 ThrEDs relative to the proportion of F4+5 EVs across time points. (J) Nanoflow cytometry analysis of F4, F8 and F12 probing protein (WGA) and lipid (Cell Mask) biomolecules and (K) F12 probing Thbsl and Srgn, all at the Day 4 time point. (L) Size profiles of EVs in F4 and ThrEDs in F12 determined by side scatter using nanoflow cytometry across time points Day 1 to 5. (M) Significant GO terms from proteomics analysis carried out on A549 whole cell lysates at Day 4 involved in protein stress response and unfolded protein response and (N) Proteins detected in ThrEDs involved in the UPR, cellular stress and ER stress pathways involved in ThrEDs biogenesis and cargo loading. Data represented is from n=l biological replicate. Kinetics studies were conducted in an n=2.

[0061] Figure 11: Calcium is important and / or critical in the formation and stabilization of ThrEDs. (A) Concentration of EPs in fractions 1 to 12 following isolation from A549 at Day 4 with and without calcium determined by nanoflow cytometry. Migration profile of A549 EPs isolated at 96 hours with and without calcium in the buffer highlight. (B) changes in concentration of peak 2 and 3 but not peak 1. (C) The effect of increasing amount of CaC12 in an isosmotic buffer on ThrEDs F12 particle concentration. Samples were isolated from 2 plates, 10 plates and 20 plates, purified with constant calcium (0.9mM CaC12) or proportional amounts of calcium at 0.9mM, 4.5mM and 9mM for 2, 10 and 20 plates, respectively. (D) Diagram representing the stabilization of ThrEDs through calcium given the abundance of Thrombospondin and other calcium binding proteins. (E) fl2 particle concentration following treatment with 0.5mM EDTA and the (F) associated change in particle size with raw size distribution plots shown in (G). (E-G) were generated from 10 plates isolated in 4.5mM CaC12. (H) TEM image of fl2 ThrEDs from plasma and A549 without calcium highlights a dense core and less bulky shell. (I-K) Demonstrate the effect of calcium stabilization on ThrEDs morphology in f8 before + / - Ca2+ and + / - EDTAtreatment. Calcium stabilization of Thrombospondin subunits is seen in (J) with dense particles abundant among EVs (hybrid population) and the loss of large ThrEDs following EDTA treatment while EVs morphology and concentration remain unchanged (K). (L) Extracellular Particles were isolated in 4.5mM calcium and then treated with 1% Triton-X-100 before iodixanol density centrifugation. The EP isolation profile was achieved following iodixanol density -based ultracentrifuge fractionation for triton treated samples. Particles in peak 2 (f7-8) and peak 3 (fl 0-12) contain detergent resistant NVEPs. (M) Following a typical protocol without Triton-X-100, F8 fractions from HEK-293T and A549 were stained for Cell Mask which labelled lipids (EVs), showing two populations in F8. n.s. P > 0.05, * P < 0.05, ** P < 0.01. (A) n=l, (C-G) n=3 biological replicates.

[0062] Figure 12: ThrEDs proteomics matrix profile highlight core and associated matrix proteins. (A) PCA plots for the proteins identified in Fl 1+12 ThrEDs and whole cell lysates of HEK293, A549, and PANCI cells. (B) Volcano plots of proteins identified in ThrEDs. (C-D) Heat maps of proteins identified in ThrEDs in A549, HEK293, PANCI and U373 sorted into protein classes and functional groupings.

[0063] Figure 13: Common proteins identified in ThrEDs samples across cell lines have ECM signature. (A) Venn diagram identifying overlap between proteomics matrices on HEK293, A549 and PANCI samples. (B) Common proteins classified based on suspected function relating to Biogenesis, Matrix Component, Thbs Shell, Migration / Adhesion, Anti-Fibrotic and Plasma Protein.

[0064] Figure 14: ECM protein matrix composed of charged interactions stabilized by divalent ions. (A) Complete matrix of protein-protein interactions highlighting the isoelectric point of each protein (expanded from Figure 5E). Acidic proteins shown with binding partners with many connections to associated basic proteins highlight condensate nature of ThrEDs. (B) All proteins identified in ThrEDs sorted based on pl with the average isoelectric point indicated by the vertical line.

[0065] Figure 15: GO term analysis of ThrEDs proteins have complementary and opposing biological and molecular function. Significant Gene Ontology terms present in at least 2 ThrEDs sources of HEK, A549, PANCI from (A) Molecular Function, (B) Biological Process, (C) Biological Process - specifically for enriched extracellular matrix proteins in ThrEDs.

[0066] Figure 16: GO term analysis revealed the importance of cell polarity and link to ECM function. (A) GO term network analysis of polarity terms identified in A549 wholecell lysates. (B) GO term network analysis on ThrEDs proteins from HEK293 and A549 involved in general ECM biology and ECM formation and (C) ECM function.

[0067] Figure 17: BASP1 is a Thrombospondin Encapsulated Dense Particle protein in fraction 12. (A) Diagram of Brain Acid Soluble Protein 1 (BASP1) a membrane associated cytosolic protein which has typically been described as an extracellular vesicle protein marker (was therefore included in the screen in Figure 1). (B) BASP1 is one of 59 proteins present is all ThrED F12 protein samples. (C) Shows the raw FITC readings from the nanoflow cytometer when measuring BASPl-mClover and associated dot plot. The horizontal dotted line represents where a gate would typically be placed resulting in the incorrect gating on BASPl-mClover3 presence in EP samples and a nearly 100% positive FITC population, as has been previously published. (D) Demonstrates where the gate should be placed based on the high background in the sample. (E) Shows the size profile of BASP1 positive and negative extracellular particles with a greater average diameter in positive particles (top curve is “total”). (F-H) Demonstrate the same data from samples isolated using Size Exclusion Chromatography instead of crude conditioned media. (F) Shows lower background when soluble BASP1 proteins are separated from EPs during purification and (G) shows the correct gating. (H) Identified a similar size profile in BASP1 positive and negative populations (top curve is “total”).

[0068] Figure 18: Isolation and characterization of ThrEDs from donor matched human tissue. (A) Schematic diagram illustrating the isolating protocol timing for ThrEDs from Donor Matched tissues. Fasted blood is collected from donors to generate Platelet Free Plasma, resting CD8+ cells and Cytotoxic T lymphocyte (CTLs) starting producer cells. Medias used at each step and timing for ThrEDs collection is highlighted. (B) Western blot of whole cell lysate form donor resting CD8+ T cells and cytotoxic T lymphocytes probed with Perforin 1 and Granzyme B antibodies to confirm positive cellular expression. (C) Nanoflow cytometry analysis of Donor 2 ThrEDs samples from resting CD8+ cells and CTLs probing Thrombospondin 1 and Serglycin.

[0069] Figure 19: Functional analysis of ThrEDs in wound healing of lung adenocarcinoma cells. (A) Representative images of scratch wounds in A549 cells treated with PBS, A549 ThrEDs and Plasma ThrEDs. Initial scratch is shown with a border line and the wound area is shown in light grey (the central region). At the 24-hour time point the scratch wound mask fails to recognize certain migrating cells in ThrEDs treated samples because the cell morphology changes drastically following particle administrationto promote migration. (B) Relative wound density of A549 wounds treated with A549 and Plasma ThrEDs from (A) at 2 different doses showing a dose response. (C) Relative wound density of A549 wounds treated with PBS, EVs, Hybrids and ThrEDs. (D) Confocal imaging of Racl / 2 / 3 and p-FAK in A549 wounds treated with PBS and ThrEDs at 24 hrs with associated MFI quantification of images (E).

[0070] Figure 20: Function analysis of ThrEDs on myofibroblasts from patients with Dupuytren’s Disease. (A) Representative images of scratch wounds in myofibroblasts treated with PBS, EVs, Hybrids and ThrEDs. The initial scratch is shown with the exterior line, the scratch border is shown with the interior line and confluence is shown throughout. The abundance of yellow borders is a proxy measure of fibrotic cell morphology.

[0071] Myofibroblasts have a spread cell morphology with less “absent confluence” while fibroblasts have a spindle cell morphology with more “absent confluence”. These images also explain the results from Figures 6A and B where the effect appears moderate, however this is because the change in morphology makes the confluence and relative wound density metrics analysis different that representative images (Figures 6C and 20). (B) Full field of view of 20x images in SMA staining with zooms.

[0072] Figure 21: Extracellular particle isolation protocol enriches ThrEDs from the EP pool. Diagram for the isolation protocol of extracellular particles highlighting key isolation steps with the associated sample content at each step. Following differential centrifugation (500xg and 4000xg) live cells, dead cells, large cell debris and apoptotic bodies are removed, yielding conditioned media. Following conditioned media concentration and isolation on a size exclusion column (CaptoCore 700) all components <700kDa including free proteins, small aggregates and nucleic acids are retained in the column. All components >700kDa elute, yielding the extracellular particle (EP) pool. The EP pool is then subjected to a density gradient ultracentrifugation step (DGUC; 110,000xg, 16 hrs) to yield fractions separated based on density. Fractions 1-2 contain low density lipoproteins, fractions 3-6 contain extracellular vesicles (EV) and fractions 11-12 contain Thrombospondin Encapsulated Dense particles (ThrEDs).

[0073] Figure 22: Thrombospondin composition of A549 derived ThrEDs - TSP-1, TSP-4 and TSP-5 (COMP). (A) NanoFCM dot plots of the EP pool (first column), EP pool + 0.3% Triton-X-100 (second column) and ThrEDs (fl 1-12; third column) each stained with either TSP-l-Atto488, TSP-4-AF488, or TSP-5-AF488. The red populations (top / grey populations) are the Thrombospondin positive particles. (B) Sizing data determined bynanoFCM for ThrEDs (fl 1-12) stained with either TSP-l-Atto488, TSP-4-AF488, or TSP-5-AF488 from (A). The red (grey) peaks are the sizes of particles which are Thrombospondin positive. The black peaks are total population size profile. (C) Fluorescence intensity plots of TSP-1 -4 and -5 staining for samples measured using the Cytek Northern Lights flow cytometer. The EP pool is compared to isotype control (first column) and ThrEDs (fl 1-12) are compared to isotype control (second column) as well as EP pool compared to ThrEDs (third column). All plots are normalized to the mode. In the left and middle columns, the isotype control (Isotype Ctl) is the black curve. For the right column, the ThrED curve is the curve towards the right. (D) Summary of nanoFCM nanoflow cytometry data and Cytek Northern Lights flow cytometry data to show similarity of Thrombospondin labelling between techniques. Data also highlights the changing proportion of TSP+ particles in different EP preparation steps [EP pool=EV, lipoproteins, NVEPs, ThrEDs, other], [EP pool + Triton = NVEPs, ThrEDs, other], [ThrEDs (fl 1-12) = ThrEDs], Data represent an n=l biological replicate. In Figure 22D, the labels running top to bottom in the legend correspond to each of the five bars running from left to right (e.g. the left bars in the first, second and third groups all correspond to the Cytek EP Pool).

[0074] Figure 23: Gating strategy for nanofl ow cytometry (nanoFCM) and flow cytometry (Cytek). (A) Description of the gating strategy for nanoFCM using TSP5-AF488 as a representative example. First, antibody only control (in sample buffer), TSP-5-AF488 only, yields a FITC background of 40±20 and no FITC EP signal (8 FITC positive particles (2.2%)). Then an isotype control for TSP-5 (anti-CD4-AF488 (IgGl kappa) with EP pool) yields higher FITC background of 75±35, a strong EP signal, but no FITC EP signal (59 FITC positive particles (0.5%). The isotype control plot is shifted up as there is no background correction for the nanoFCM, therefore the background is determined by the baseline of the FITC signal then fluorescent particles are determined by FITC signal above the baseline. Finally, the ThrEDs (fl 1-12) sample stained with TSP-5-AF488 yields the lowest background (15±10) and a strong FITC+ EP (ThrEDs) signal. Therefore, the gate is placed based on the FITC intensity plot showing low background and strong ThrEDs TSP5+ signal. (Right hand dot plot - correct gating) in the third column. (B) Description of the gating strategy for Cytek Northern Lights flow cytometer using MilliQ, MilliQ+4.5mM CaC12 (sample buffer), unstained EPs, and EPs stained with Cell Mask Far Red (stains EP lipid bilayers) and WGA-AF488 (stains glycosylated Glc-Nac proteins).First, MilliQ was run alone to ensure no signal appears. Then MilliQ 4.5mM CaC12 was analysed to gate population 1 (Pl) which contains background signal from small components including salt and protein from the EP samples. Next, the unstained EP sample is run to determine whether small extracellular particles can be detected on the Northern Lights Cytek flow cytometer. The population 2 gate is placed around the unstained EPs following confirmation of EP signal in the pseudocolor dot plot. Finally, the Pl and P2 gates are validated using EPs stained with Cell Mask Far Red and WGA-AF488. Pl contains background signal from the soluble stains and P2 contains a significant population of double positive (CellMask+WGA+) particles, consistent with EPs. (C) Gating strategy used to generate the %488+ particles from Figure 22. TSP-l-Atto488, TSP-4-AF488 and TSP-5-AF488 are compared against their respective isotype controls to determine the percent 488 positive value determined by the Northern Lights Cytek spectral flow cytometer. The isotype control is the black curve.

[0075] Figure 24: Scatter and sizing profiles of unstained EPs by nanoflow cytometry and flow cytometry. (A) NanoFCM data for the side scatter (SS) intensity of unstained ThrEDs (fl 1-12, left hand graph). The associated dot plot of unstained ThrEDs (fl 1-12) based on SS-A against FITC-A (center plot). The associated ThrEDs sizing profile graph is shown for the unstained ThrEDs determined based on instrument calibration with QC and Sizing beads (right hand graph). (B) The dot plots from unstained EP pool and ThrEDs (fl 1-12) determined by flow cytometry (Cytek Northern Lights) showing SSC-A against FSC-A. The same gating is used for both EPs and ThrEDs.

[0076] Detailed description of the invention

[0077] General Definitions

[0078] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention belongs.

[0079] In general, the term “comprising" and “comprises" is intended to mean including but not limited to. For example, the phrase “the particle comprises a core and a shell" should be interpreted to mean that the particle includes a core and a shell, but the particlemay also comprise further components. The particle may therefore for example comprise a cargo and / or one or more further components.

[0080] The terms “protein” and “polypeptide” are used interchangeably herein, and are intended to refer to a polymeric chain of amino acids of any length.

[0081] The term “around”, “about” and “~” and their grammatical equivalents are used interchangeably here, and are intended to refer to a reference numerical value and its grammatical equivalents as used herein can include the numerical value itself, such as a point value or the end point(s) of a range, and a range of values plus or minus 10% from that numerical value. The term “around" in relation to a reference numerical value can also include a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value. For example, around -60-70% refers to percentage values of 54%-66%, 63%-77%, and 54% to 77%.

[0082] The term “between ” in relation to a pair of reference numerical values and its grammatical equivalents (such as as used herein can include the numerical values themselves and the range of values between the reference numerical values. For example, the term “10-25nm” may refer to lOnm or 25nm, or any value falling within the range of lOnm to 25 nm, such as 1 Inm or 19nm.

[0083] The term “mean” and its mathematical and grammatical equivalents as used herein can be calculated by counting the total of all data points within a population and then dividing by the total number of data points. For example, the term “mean diameter f 100 nm” of a particle may refer to a population of 100 particles wherein each particles has a diameter of 100 nm. Alternatively, the term may refer to a population of 1000 particles wherein 250 particles in the population each have a diameter of 50 nm, 500 particles in the population each have a diameter of 100 nm, and 250 particles in the population of particles each have a diameter of 150 nm.

[0084] The singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a particle” includes two or more particles.

[0085] All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

[0086] Proteinaceous particleA proteinaceous particle is a particle comprising a protein. The particle may be isolated, such as isolated from the cell producing the particle, and / or from components used to obtain and / or purify the particle. The particle may be engineered, for example by genetically engineering a cell producing the particle and / or chemically modifying

[0087] The isolated and / or engineered proteinaceous particle of the invention is a small three dimensional particle. The particle may be a spherical or substantially spherical particle (e.g. an ellipsoidal particle or substantially ellipsoidal particle), that can range in size from 10 to 1000 nanometres (nm) in diameter (e.g. major diameter or minor diameter in the case of an ellipsoidal or substantially ellipsoidal particle). The term diameter is used herein to refer to the diameter of a spherical particle, the major diameter of an ellipsoidal or substantially ellipsoidal particle, and / or the minor diameter of an ellipsoidal or substantially ellipsoidal particle. The term particle may be used interchangeably herein. A particle of the invention may be used as a therapeutic agent, such as to enhance wound healing. Alternatively or additionally, particle of the invention may be used as a biomarker, such as a disease biomarker when isolated from blood or other tissues of an individual during a diagnostic or therapeutic procedure. Alternatively or additionally, a particle of the invention may be used to deliver one or more bioactive molecule. In any embodiment of the invention, the bioactive molecule may be partially or fully encapsulated by the particle. Alternatively or additionally, the bioactive molecule may be partially or fully on the surface of the particle. A bioactive molecule may be attached to a particle by dissolving or dispersing within the particle, covalent linkage to the particle, or non-covalent linkage to the particle.

[0088] Particles of the invention may be solid or substantially solid, comprising or consisting of a solid matrix. Alternatively, particles of the invention may have a core in a physical state on the continuum from solid to gel to liquid, the liquid condensate being contained by the shell. Alternatively, particles of the invention may be hollow, having a lumen that may contain a cargo such as a bioactive molecule. Particles of the invention may comprise a shell surrounding a core, a shell substantially surrounding a core, or a shell partially surrounding a core, wherein the shell and core may comprise different materials. Particles or the invention may have one or more pore on the surface and / or core. The shell protein may or may not be PEGylated.

[0089] The shell of the particle may comprise more than one subunits. A subunit may comprise any one or more of the proteins (or fragments, variants or orthologues thereof)present in the shell of the particle as specified anywhere herein. For example, a subunit may be a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 and / or TSP-5. The shell of the particle may comprise at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 25 or at least 50 individual subunits. Thus, the shell may comprise 4-5 subunits, 4-6 subunits, 4-7 subunits, 4-8 subunits, 4-9 subunits, 4-10 subunits, 4-15 subunits, 4-25 subunits, 4-50 subunits, 5-6 subunits, 5-7 subunits, 5-8 subunits, 5-9 subunits, 5-10 subunits, 5-15 subunits, 5-25 subunits, 5-50 subunits, 6-7 subunits, 6-8 subunits, 6-9 subunits, 6-10 subunits, 6-15 subunits, 6-25 subunits, 6-50 subunits, 7-8 subunits, 7-9 subunits, 7-10 subunits, 7-15 subunits, 7-25 subunits, 7-50 subunits, 8-9 subunits, 8-10 subunits, 8-15 subunits, 8-25 subunits, 8-50 subunits, 9-10 subunits, 9-15 subunits, 9-25 subunits, 9-50 subunits, 10-15 subunits, 10-25 subunits, 10-50 subunits, 15-25 subunits, 15-50 subunits or 25-50 subunits. The subunits in each particle may all be the same. Alternatively, there may be at least 2, at least 3, at least 4, at least 5 or at least 10 different subunits forming the shell of each particle. The subunits in a particle may together fully surround the core of the particle, substantially surround the core of the particle, or partially surround the core of the particle. Thus, particle of the invention may comprise a shell surrounding a core, a shell substantially surrounding a core, or a shell partially surrounding a core.

[0090] The invention relates to a single particle or a population comprising a plurality of particles. The population may comprise or consist of a homogenous population of particles, a substantially homogenous population of particles, or a heterogenous population of particles. A “substantially homogenous population of particles” is a population of particles within which a reference numerical value for at least 85%, at least 90%, at least 95%, at least 98% or at least 99% of each individual particle in the population has a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value. For example, a substantially homogenous population of particles may comprise particles in which 95% of the particles have a density within 5% of 1 g / mL (i.e. 0.95 g / mL to 1.05 g / mL) and / or 98% of the particles have a size of within 10% of 100 pm (i.e. 90 nm to 110 nm).

[0091] Thus, the present invention relates both to individual particles and populations comprising individual particles, as will be clear to the skilled person. A population of particles may comprise at least 2, at least 10, at least 100, at least 1000, at least 10000, at least 100000, at least 1000000, at least 10000000, at least 100000000, at least 1000000000or at least 10000000000 individual particles. A population of particles according to the invention may comprise at most 2, at most 10, at most 100, at most 1000, at most 10000, at most 100000, at most 1000000, at most 10000000, at most 100000000, at most 1000000000 or at most 10000000000 individual particles. Thus, the population of particles according to the invention may have 2-10, 2-100, 2-1000, 2-10000, 2-100000, 2-1000000, 2-10000000, 2-100000000, 2-1000000000, 2-10000000000, 10-100, 10-1000, 10-10000, 10-100000, 10-1000000, 10-10000000, 10-100000000, 10-1000000000, 10-10000000000, 100-1000, 100-10000, 100-100000, 100-1000000, 100-10000000, 100-100000000, 100-1000000000, 100-10000000000, 1000-10000, 1000-100000, 1000-1000000, 1000-10000000, 1000-100000000, 1000-1000000000, 1000-10000000000, 10000-100000, 10000-1000000, 10000-10000000, 10000-100000000, 10000-1000000000, 10000-10000000000, 100000-1000000, 100000-10000000, 100000-100000000, 100000-1000000000, 100000-10000000000, 1000000-10000000, 1000000-100000000, 1000000-1000000000, 1000000-10000000000, 10000000-100000000, 10000000-1000000000, 10000000-10000000000, 100000000-1000000000, 100000000-10000000000 or 1000000000-10000000000 individual particles.

[0092] Where the invention relates to a heterogenous population of particles, there may be at least 2, at least 10, at least 100, at least 1000 or at least 10000 different homogenous particles in said heterogenous population. Thus, the population of particles may have 2-10, 2-100, 2-1000, 2-10000, 10-100, 10-1000, 10-10000, 100-1000, 100-10000 or 1000-10000 different homogenous particles.

[0093] The particle and populations thereof may be characterised by one or more particular features, such as density, size, composition, and surface moiety and copies thereof. Where the feature relates to a population of particles, said feature may be defined as a mean value or range of values.

[0094] The particle and / or particle core may be relatively dense comparted to other particles such as exosomes. Suitable techniques for measuring density are known to the skilled person. The particle and / or particle core may for instance have a density of at least 0.1 g / mL, at least 0.50 g / mL, at least 1.00 g / mL, at least 1.25 g / mL, at least 1.50 g / mL, at least 2.00 g / mL or at least 5.00 g / mL. For example, the particle and / or particle core may have a density of 0.50-1.00 g / mL, 0.50-1.25 g / mL, 0.50-1.50 g / mL, 0.50-2.00 g / mL, 1.00-1.25 g / mL, 1.00-1.50 g / mL, 1.00-2.00 g / mL, 1.25-1.50 g / mL, 1.25-2.00 g / mL or 1.50-2.00 g / mL. Similarly, the population of particles and / or particle cores may have a mean densityof at least 0.1 g / mL, at least 0.50 g / mL, at least 1.00 g / mL, at least 1.25 g / mL, at least 1.50 g / mL, at least 2.00 g / mL or at least 5.00 g / mL. For example, the population of particles and / or particle cores may have a mean density of 0.50-1.00 g / mL, 0.50-1.25 g / mL, 0.50-1.50 g / mL, 0.50-2.00 g / mL, 1.00-1.25 g / mL, 1.00-1.50 g / mL, 1.00-2.00 g / mL, 1.25-1.50 g / mL, 1.25-2.00 g / mL or 1.50-2.00 g / mL. Generally, loaded particles (i.e. particles comprising a cargo) will be more dense overall than their equivalent empty (i.e. nonloaded) particles. For example, loaded particles may be 1.1x, 1.2x, 1.5x or 2.0 times more dense overall than their equivalent empty particles.

[0095] The particle may have a diameter of 5 to 1000 nm, such as 5-500 nm. For example, the particle of the invention may have a diameter of at least 5 nm, at least 10 nm, at least 30 nm, at least 50 nm, at least 100 nm, at least 250 nm, or at least 500 nm. Alternatively or in addition, the particle of the invention may have a diameter of at most 50 nm, at most 100 nm, at most 250 nm, at most 500 nm or at most 1000 nm. Thus, the particle of the invention may have a diameter of for example 5-50 nm, 5-100 nm, 5-250 nm, 5-500 nm, 10-50 nm, 10-100 nm, 10-250 nm, 10-500 nm, 30-50 nm, 30-100 nm, 30-250 nm, 30-500 nm, 50-100 nm, 50-250 nm, 50-500 nm, 100-250 nm, 100-500 nm or 250-500 nm. In one preferable embodiment, the particle may have a diameter of about 50 nm and / or a minimum diameter of 30 nm. The diameter of the particle may be measured by any suitable means known to the skilled person. For example, the diameter of a particle may be measured by any suitable microscopy technique, such as by analysing electron microscopy images such as that set out in Figure 3G. The diameter of the particle may be measured manually and / or using a suitable automated algorithm such as a suitable ImageJ algorithm, nanoFCM, an Oxford Nanoimaging (ONI) microscope, nanoparticle tracking analysis (NTA) and / or dynamic light scattering (DLS).

[0096] The population of particles may have a mean diameter of 1 to 1000 nm, such as 5-500 nm. For example, the population of particles of the invention may have a mean diameter of at least 5 nm, at least 10 nm, at least 30 nm, at least 50 nm, at least 100 nm, at least 250 nm, or at least 500 nm. Alternatively or in addition, the population of particles of the invention may have a mean diameter of at most 50 nm, at most 100 nm, at most 250 nm, at most 500 nm or at most 1000 nm. Thus, the population of particles of the invention may have a mean diameter of for example 5-50 nm, 5-100 nm, 5-250 nm, 5-500 nm, 10-50 nm, 10-100 nm, 10-250 nm, 10-500 nm, 30-50 nm, 30-100 nm, 30-250 nm, 30-500 nm, 50-100 nm, 50-250 nm, 50-500 nm, 100-250 nm, 100-500 nm or 250-500 nm. In onepreferable embodiment, the population of particles may have a mean diameter of about 50 nm and / or a minimum mean diameter of about 30 nm.

[0097] The particle or population of particles may comprise or consist of one or more of any suitable an extracellular matrix component, a protein, a lipid, a phospholipid, a glycoprotein, a proteoglycan such as serglycin, and a polysaccharide. Alternatively or in addition, the particle or population of particles may comprise or consist of a full-length protein selected from a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 or TSP-5, serglycin, calreticulin, calmodulin, calumenin, cathepsinD, HRNBPA2B1, HS90AA1, HSPA8, syndecan such as cleaved syndecan-1, BASP1, galectin-1 or galectin-7; or a fragment, variant or orthologue of anyone thereof. The core of the particle or population of particles may comprise or consist of one or more of any suitable an extracellular matrix component, a protein, a lipid, a phospholipid, a glycoprotein, a proteoglycan such as serglycin, and a polysaccharide. The shell of the particle or population of particles may comprise of consist of a full-length protein selected from a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 or TSP-5, serglycin, calreticulin, calmodulin, calumenin, cathepsinD, HRNBPA2B1, HS90AA1, HSPA8, syndecan such as cleaved syndecan-1, BASP1, galectin-1 or galectin-7; or a fragment, variant or orthologue of anyone thereof. Alternatively or additionally, the shell of the particle or population of particles may comprise or consist of one or more of a protein, a lipid, a phospholipid, a glycoprotein, a proteoglycan, and a polysaccharide. The core of the particle or population of particles may comprise or consist of one or more of any suitable an extracellular matrix component, a protein, a lipid, a phospholipid, a glycoprotein, a proteoglycan such as serglycin, and a polysaccharide; and the shell of the particle or population of particles may comprise of consist of a full-length protein selected from a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 or TSP-5, serglycin, calreticulin, calmodulin, calumenin, cathepsinD, HRNBPA2B1, HS90AA1, HSPA8, syndecan such as cleaved syndecan-1, BASP1, galectin-1 or galectin-7; or a fragment, variant or orthologue of anyone thereof. The core of the particle may comprise components of the cell from which the particle is produced, such as a protein, a lipid, a phospholipid, a glycoprotein, a proteoglycan and / or a polysaccharide present in the cell from which the particle is produced. Alternatively or additionally, the shell of the particle may comprise components of the cell from which the particle is produced, such as a protein, a lipid, a phospholipid, a glycoprotein, aproteoglycan and / or a polysaccharide present in the cell from which the particle is produced. For instance:

[0098] (1) the particle or population of particles may comprise or consist of one or more of GZMB, ITIH1, ITIH2, ITIH3, ITIH4, collagen such as collagen 1A, a SERPIN such as SERPINA2, SERPINB3, SERPINE1, SERPINF1, SERPINF2, SERPINH1 and / or SERPINI1, SDC1, FSLT1, IGFBP6, FLG2, PTPRK, CLSTIN1, CNTN1, CSTA, NRCAM, a Granzyme such as GranzymeB, a perforin such as perforin- 1, and D SCI; or a fragment, variant or orthologue of anyone thereof;

[0099] (2) the core of the particle or population of particles may comprise or consist of one or more of GZMB, ITIH1, ITIH2, ITIH3, ITIH4, collagen such as collagen 1A, a SERPIN such as SERPINA2, SERPINB3, SERPINE1, SERPINF1, SERPINF2, SERPINH1 and / or SERPINI1, SDC1, FSLT1, IGFBP6, FLG2, PTPRK, CLSTIN1, CNTN1, CSTA, NRCAM, a Granzyme such as GranzymeB, a perforin such as perforin- 1, and D SCI; or a fragment, variant or orthologue of anyone thereof;

[0100] (3) the particle or population of particles may not comprise a lipid bilayer, a lipid and / or a phospholipid; or a fragment, variant or orthologue of anyone thereof;

[0101] (4) the core of the particle or population of particles may not comprise a lipid and / or a phospholipid or a fragment, variant or orthologue of anyone thereof;

[0102] (5) the particle or population of particles may comprise or consist of one or more of full-length WGA, LGALS1, TSP-1, TSP-4, TSP-5 and a protein set out in Table 1 below; or a fragment, variant or orthologue of anyone thereof;

[0103] (6) the shell of the particle or population of particles may comprise or consist of one or more of full-length WGA, LGALS1, TSP-1, TSP-4, TSP-5 and a protein set out in Table 1 below; or a fragment, variant or orthologue of anyone thereof;

[0104] (7) the particle or population of particles may comprise or consist of one or more of full-length TSP-1, TSP-4 and TSP-5; such as full-length TSP-5;

[0105] (8) the shell of the particle or population of particles may comprise or consist of one or more of full-length TSP-1, TSP-4 and TSP-5; such as full-length TSP-5;

[0106] (9) the particle or population of particles may not comprise a lipid bilayer, a plasma membrane, a lipid, a phospholipid membrane, a Granzyme such as GranzymeB, Perforin, CD63, CD81, CD9, TSG101, and / or Alix; or a fragment, variant or orthologue of anyone thereof;(10) the shell of the particle or population of particles may not comprise a lipid bilayer, a plasma membrane, a lipid, a phospholipid membrane, a Granzyme such as GranzymeB, Perforin, CD63, CD81, CD9, TSG101, and / or Alix; or a fragment, variant or orthologue of anyone thereof; and / or

[0107] (11) the shell of the particle may comprise TSP-1 and TSP-5 but not TSP-4. In some aspects, the particle may not comprise granzyme B and / or perforin-1. In some aspects, the particle may not be cytotoxic. In a population of particles, at least 30% of the particles may be TSP-1 positive and TSP-5 positive. In some aspects, up to about 30% of the particles in a population may be triple positive for TSP-1, TSP-4 and TSP-5. TSP-5 / COMP may serve as a marker to distinguish ThrEDs from SMAPs.

[0108] Table 1 - Analysis of abundant ThrEDs proteins with hypothesised roles (Information for general function of proteins extracted from NIH Library of Medicine gene database and from the Uniprot database)

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116] In one preferable embodiment, the particle, population or particles, shell of the particle or sell of the population of particles may not comprise a lipid bilayer or a plasma membrane.

[0117] The presence or absence of the components of the particle may be measured by any suitable technique. For example, any suitable microscopy technique and appropriate fluorescence molecules, such as dSTORM and appropriate fluorescent dyes.

[0118] The above features (l)-(l 1) may be combined in any technically sensible order, combination or permutation, such as:{(1)} {(2)} {(3)} {(4)} {(5)} {(6)} {(7)} {(8)} {(9)} {(10)} {(11)};

[0119] {(1),(2)} {(1 ),(3)} {(1),(4)} {(1 ),(5)} {(1),(6)} {(1),(7)} {(1),(8)} {(1),(9)} {(1 ),(10)} {(1),(11)} {(2), (3)} {(2), (4) } {(2), (5)} {(2), (6)} {(2), (7)} {(2), (8)} {(2), (9)} {(2), (10)} {(2),(11)} {(3), (4)} {(3), (5)} {(3), (6)} {(3), (7)} {(3), (8)} {(3),( 9)} {(3), (10)} {(3),(11)} {(4), (5)} {(4), (6)} {(4), (7)} {(4), (8)} {(4), (9)} {(4), (10)} {(4),(11)} {(5), (6)} {(5), (7)} {(5), (8)} {(5), (9)} {(5), (10)} {(5),(11)} {(6), (7)} {(6), (8)} {(6), (9)} {(6), (10)} {(6),(11)} {(7), (8)} {(7), (9)} {(7), (10)} {(7),(11)} { (8), (9)} {(8), (10)} {(8),(11)} {(9), (10)} {(9),(11)} {(10), (11)};

[0120] {(1),(2),(3)} {(1),(2),(4)} {(1),(2),(5)} {(1),(2),(6)} {(1),(2),(7)} {(1),(2),(8)} {(1),(2),(9)} {(l),(2),(10)} {(1),(2),(11)} {(1),(3),(4)} {(1),(3),(5)} {(1),(3),(6)} {(1),(3),(7)} {(1),(3),(8)} {(1),(3),(9)} {(l),(3),(10)} {(1),(3),(11)} {(1),(4),(5)} {(1),(4),(6)} {(1),(4),(7)} {(1),(4),(8)} {(1),(4),(9)} {(l),(4),(10)} {(1),(4),(11)} {(1),(5),(6)} {(1),(5),(7)} {(1),(5),( 8)} {(1),(5),(9)} {(l),(5),(10)} {(1),(5),(11)} {(1),(6),(7)} {(1),(6),(8)} {(1),(6),(9)} {(l),(6),(10)} {(1),(6),(11)} {(1),(7),(8)} {(1),(7),(9)} {(l),(7),(10)} {(1),(7),(11)} {(1),(8),(9)} {(l),(8),(10)} {(1),(8),(11)} {(l),(9),(10)} {(1),(9),(11)} {(1),(10), (11)} {(2), (3), (4)} {(2), (3), (5)} {(2), (3), (6)} {(2), (3), (7)} {(2), (3), (8)} {(2), (3), (9)} {(2), (3), (10)} {(2),(3),(11)} {( 2), (4), (5)} {(2), (4), (6)} {(2), (4), (7)} {(2), (4), (8)} {(2), (4), (9)} {(2), (4), (10)} {(2),(4),(11)} {(2), (5), (6)} {(2), (5), (7)} {(2 ),(5),(8)} {(2), (5), (9)} {(2), (5), (10)} {(2),(5),(11)} {(2), (6), (7)} {(2), (6), (8)} {(2), (6), (9)} {(2),(6),(10)} {(2),(6),(11)} {( 2), (7), (8)} {(2), (7), (9)} {(2), (7), (10)} {(2),(7),(11)} {(2), (8), (9)} {(2), (8), (10)} {(2),(8),(11)} {(2), (9), (10)} {(2),(9),(11 )} {(2),(10),(l 1)} {(3), (4), (5)} {(3), (4), (6)} {(3), (4), (7)} {(3), (4), (8)} {(3), (4), (9)} {(3), (4), (10)} {(3),(4),(11)} {(3),(5),( 6)} {(3), (5), (7)} {(3), (5), (8)} {(3), (5), (9)} {(3), (5), (10)} {(3),(5),(11)} {(3), (6), (7)} {(3), (6), (8)} {(3), (6), (9)} {(3),(6),(1 0)} {(3),(6),(11)} {(3), (7), (8)} {(3), (7), (9)} {(3), (7), (10)} {(3),(7),(11)} {(3), (8), (9)} {(3), (8), (10)} {(3),(8),(11)} {(3), (9 ),(10)} {(3),(9),(11)} {(3),(10),(l 1)} {(4), (5), (6)} {(4), (5), (7)} {(4), (5), (8)} {(4), (5), (9)} {(4), (5), (10)} {(4),(5),(11)} {(4 ),(6),(7)} {(4), (6), (8)} {(4), (6), (9)} {(4), (6), (10)} {(4),(6),(11)} {(4), (7), (8)} {(4), (7), (9)} {(4), (7), (10)} {(4),(7),(11)} {( 4), (8), (9)} {(4), (8), (10)} {(4),(8),(11)} {(4), (9), (10)} {(4),(9),(11)} {(4),(10),(l 1)} {(5), (6), (7)} {(5), (6), (8)} {(5), (6), (9 )} {(5), (6), (10)} {(5),(6),(11)} {(5), (7), (8)} {(5), (7), (9)} {(5), (7), (10)} {(5),(7),(11)} {(5), (8), (9)} {(5), (8), (10)} {(5), (8),(11)} {(5),(9),(10)} {(5),(9),(11 )} {(5),(10),(l 1 )} {(6), (7), (8)} {(6), (7), (9)} {(6),(7),(10)} {(6),(7),(11 )} {(6), (8), (9)} {( 6),(8),(10)} {(6),(8),(11 )} {(6),(9),(10)} {(6),(9),(11 )} {(6),(10),(l 1 )} {(7), (8), (9)} {(7),(8),(10)} {(7),(8),(11 )} {(7), (9), (10)} {(7),(9),(11)} {(7),(10),(l 1)} {(8), (9), (10)} {(8),(9),(11)} {(8),(10),(l 1)} {(9),(10),(l 1)};

[0121] {(1),(2),(3),(4)} {(1),(2),(3),(5)} {(1),(2),(3),(6)} {(1),(2),(3),(7)} {(1),(2),(3),(8)} {(1),(2),(3),(9)} {(1),(2),(3), (10)} {(1),(2),(3),(11)} {(1),(2),(4),(5)} {(1),(2),(4),(6)} {(1),(2),(4),(7)} {(1),(2),(4),(8)} {(1),(2),(4),(9)} {(1),(2),(4),( 10)} {(1),(2),(4),(11)} {(1),(2),(5),(6)} {(1),(2),(5),(7)} {(1),(2),(5),(8)} {(1),(2),(5),(9)} {(l),(2),(5),(10)} {(1),(2),(5),( 11)} {(1),(2),(6),(7)} {(1),(2),(6),(8)} {(1),(2),(6),(9)} {(l),(2),(6),(10)} {(1),(2),(6),(11)} {(1),(2),(7),(8)} {(1),(2),(7),( 9)} {(l),(2),(7),(10)} {(1),(2),(7),(11)} {(1),(2),(8),(9)} {(l),(2),(8),(10)} {(1),(2),(8),(11)} {(l),(2),(9),(10)} {(1),(2),(9 ),(11)} {(l),(2),(10),(l 1)} {(1),(3),(4),(5)} {(1),(3),(4),(6)} {(1),(3),(4),(7)} {(1),(3),(4),(8)} {(1),(3),(4),(9)} {(1),(3),(4 ),(10)} {(1),(3),(4),(11)} {(1),(3),(5),(6)} {(1),(3),(5),(7)} {(1),(3),(5),(8)} {(1),(3),(5),(9)} {(l),(3),(5),(10)} {(1),(3),(5 ),(11)} {(1),(3),(6),(7)} {(1),(3),(6),(8)} {(1),(3),(6),(9)} {(l),(3),(6),(10)} {(1),(3),(6),(11)} {(1),(3),(7),(8)} {(1),(3),(7 ),(9)} {(l),(3),(7),(10)} {(1),(3),(7),(11)} {(1),(3),(8),(9)} {(l),(3),(8),(10)} {(1),(3),(8),(11)} {(l),(3),(9),(10)} {(1 ),(3),(9),(11)} {(l),(3),(10),(l 1)} {(1),(4),(5),(6)} {(1),(4),(5),(7)} {(1),(4),(5),(8)} {(1),(4),(5),(9)} {(l),(4),(5),(10)} {(1),( 4),(5),(11)} {(1),(4),(6),(7)} {(1),(4),(6),(8)} {(1),(4),(6),(9)} {(l),(4),(6),(10)} {(1),(4),(6),(11)} {(1),(4),(7),(8)} {(1),( 4), (7), (9)} {(l),(4),(7),(10)} {(1),(4),(7),(11)} {(1),(4),(8),(9)} {(l),(4),(8),(10)} {(1),(4),(8),(11)} {(l),(4),(9),(10)} {(1 ),(4),(9),(11)} {(l),(4),(10),(l 1)} {(1),(5),(6),(7)} {(1),(5),(6),(8)} {(1),(5),(6),(9)} {(l),(5),(6),(10)} {(1),(5),(6),(11)} {(1),(5),(7),(8)} {(1),(5),(7),(9)} {(l),(5),(7),(10)} {(1),(5),(7),(11)} {(1),(5),(8),(9)} {(l),(5),(8),(10)} {(1),(5),(8),(11) } {(l),(5),(9),(10)} {(1),(5),(9),(11)} {(l),(5),(10),(l 1)} {(1),(6),(7),(8)} {(1),(6),(7),(9)} {(l),(6),(7),(10)} {(1),(6),(7), (11)} {(1),(6),(8),(9)} {(l),(6),(8),(10)} {(1),(6),(8),(11)} {(l),(6),(9),(10)} {(1),(6),(9),(11)} {(l),(6),(10),(l 1)} {(1),(7 ),(8),(9)} {(l),(7),(8),(10)} {(1),(7),(8),(11)} {(l),(7),(9),(10)} {(1),(7),(9),(11)} {(l),(7),(10),(l 1)} {(l),(8),(9),(10)} {(1 ),(8),(9),(11 )} {(1 ),(8),(10),(l 1)} {(1 ),(9),(10),(l 1 )} {(2),(3),(4),(5)} {(2), (3), (4), (6)} {(2), (3), (4), (7)} {(2), (3), (4), (8) } {(2),(3),(4),(9)} {(2),(3),(4),(10)} {(2),(3),(4),(11)} {(2), (3), (5), (6)} {(2), (3), (5), (7)} {(2), (3), (5), (8)} {(2), (3), (5), (9)} {(2),(3),(5),(10)} {(2),(3),(5),(11)} {(2), (3), (6), (7)} {(2), (3), (6), (8)} {(2), (3), (6), (9)} {(2),(3),(6),( 10)} {(2),(3),(6),(11 ) } {(2),(3),(7),(8)} {(2),(3),(7),(9)} {(2),(3),(7),(10)} {(2),(3),(7),(11)} {(2), (3), (8), (9)} {(2),(3),(8),(10)} {(2),(3),(8),(1 1 )} { (2),(3 ),(9),( 10) } { (2),(3 ),(9),( 11 )} { (2),(3 ),( 10),( 11 )} { (2),(4),(5),(6) } {(2), (4), (5), (7)} { (2), (4), (5), (8) } {(2),(4),(5),(9)} {(2), (4), (5), (10)} {(2),(4),(5),(11 )} {(2), (4), (6), (7)} {(2), (4), (6), (8)} {(2),(4),(6),(9)} {(2),(4),(6),(10)} {(2), (4), (6),(H)} {(2), (4), (7), (8)} {(2), (4), (7), (9)} {(2),(4),(7),(10)} {(2),(4),(7),(11 )} {(2), (4), (8), (9)} {(2),(4),(8),(10)} {(2),(4),( 8),(11 )} {(2), (4), (9), (10)} {(2),(4),(9),(11 )} {(2),(4),(10),(l 1 )} {(2), (5), (6), (7)} {(2), (5), (6), (8)} {(2), (5), (6), (9)} {(2), (5 ),(6),(10)} {(2),(5),(6),(11 )} {(2), (5), (7), (8)} {(2), (5), (7), (9)} {(2), (5), (7), (10)} {(2),(5),(7),(11 )} {(2), (5), (8), (9)} {(2),( 5), (8), (10)} {(2),(5),(8),( 11 )} {(2), (5), (9), (10)} {(2),(5),(9),(11 )} {(2),(5),(10),(l 1)} {(2), (6), (7), (8)} {(2), (6), (7), (9)} {( 2), (6), (7), (10)} {(2),(6),(7),(11 )} {(2), (6), (8), (9)} {(2), (6), (8), (10)} {(2),(6),(8),(11 )} {(2), (6), (9), (10)} {(2),(6),(9),(11 )} {(2),(6),(10),(l 1 )} {(2), (7), (8), (9)} {(2), (7), (8), (10)} {(2),(7),(8),(11 )} {(2), (7), (9), (10)} {(2),(7),(9),(11 )} {(2),(7),(1 0),(l 1 )} {(2), (8), (9), (10)} {(2),(8),(9),(11 )} {(2),(8),(10),(l 1)} {(2),(9),(10),(l 1)} {(3), (4), (5), (6)} {(3), (4), (5), (7)} {(3),(4),(5),(8)} {(3), (4), (5), (9)} {(3), (4), (5), (10)} {(3),(4),(5),(11)} {(3), (4), (6), (7)} {(3), (4), (6), (8)} {(3), (4), (6), (9)} {(3),( 4), (6), (10)} {(3),(4),(6),(11)} {(3), (4), (7), (8)} {(3), (4), (7), (9)} {(3), (4), (7), (10)} {(3),(4),(7),(11 )} {(3), (4), (8), (9)} {(3),(4),(8),(10)} {(3),(4),(8),(11)} {(3), (4), (9), (10)} {(3),(4),(9),(11)} {(3),(4),(10),(l 1)} {(3), (5), (6), (7)} {(3), (5), (6), (8)} {(3), (5), (6), (9)} {(3), (5), (6), (10)} {(3),(5),(6),(11)} {(3), (5), (7), (8)} {(3), (5), (7), (9)} {(3), (5), (7), (10)} {(3),(5),(7),(11) } {(3), (5), (8), (9)} {(3), (5), (8), (10)} {(3),(5),(8),(11)} {(3), (5), (9), (10)} {(3),(5),(9),(11)} {(3),(5),(10),(l 1)} {(3), (6), (7),(8)} {(3), (6), (7), (9)} {(3), (6), (7), (10)} {(3),(6),(7),(11 )} {(3), (6), (8), (9)} {(3), (6), (8), (10)} {(3),(6),(8),(11)} {(3),(6),( 9), (10)} {(3),(6),(9),(11)} { (3),(6),(10),(l 1)} {(3), (7), (8), (9)} {(3), (7), (8), (10)} {(3),(7),(8),(11)} {(3), (7), (9), (10)} {(3),(7),(9),(11)} {(3),(7),(10),(l 1 )} {(3), (8), (9), (10)} {(3),(8),(9),(11 )} {(3),(8),(10),(l 1 )} {(3),(9),(10),(l 1 )} {(4),(5),(6),( 7)} {(4), (5), (6), (8)} {(4), (5), (6), (9)} {(4), (5), (6), (10)} {(4),(5),(6),(11 )} {(4), (5), (7), (8)} {(4), (5), (7), (9)} {(4),(5),(7),(1 0)} {(4),(5),(7),(11 )} {(4), (5), (8), (9)} {(4),(5),(8),(10)} {(4),(5),(8),(11 )} {(4),(5),(9),(10)} {(4),(5),(9),(11 )} { (4),(5),( 1 0),(l 1 )} {(4), (6), (7), (8)} {(4), (6), (7), (9)} {(4),(6),(7),(10)} {(4),(6),(7),(11 )} {(4), (6), (8), (9)} {(4),(6),(8),(10)} {(4), (6),(8),(11)} {(4), (6), (9), (10)} {(4),(6),(9),(11)} {(4),(6),(10),(l 1)} {(4), (7), (8), (9)} {(4), (7), (8), (10)} {(4),(7),(8),(11)} {( 4), (7), (9), (10)} {(4),(7),(9),(11)} {(4),(7),(10),(l 1)} {(4), (8), (9), (10)} {(4),(8),(9),(11)} {(4),(8),(10),(l 1 )} {(4), (9), (10 );(11)} {(5), (6), (7), (8)} {(5), (6), (7), (9)} {(5),(6),(7),(10)} {(5),(6),(7),(11 )} {(5), (6), (8), (9)} {(5),(6),(8),(10)} {(5),(6),( 8),(11)} {(5), (6), (9), (10)} {(5),(6),(9),(11)} {(5),(6),(10),(l 1 )} {(5), (7), (8), (9)} {(5), (7), (8), (10)} {(5),(7),(8),(11)} {(5),(7),(9),(10)} {(5),(7),(9),(11)} {(5),(7),(10),(l 1 )} {(5), (8), (9), (10)} {(5),(8),(9),(11 )} {(5),(8),(10),(l 1 )} {(5),(9),(10),( 11)} {(6), (7), (8), (9)} {(6), (7), (8), (10)} {(6),(7),(8),(11)} {(6), (7), (9), (10)} {(6),(7),(9),(11)} {(6),(7),(10),(l 1)} {(6), (8),(9), (10)} {(6),(8),(9),(11)} {(6),(8),(10),(l 1 )} {(6),(9),(10),(l 1 )} {(7), (8), (9), (10)} {(7),(8),(9),(11)} {(7),(8),(10),(l 1 ) } {(7), (9), (10), (11)} {(8), (9), (10), (11)};

[0122] {(1),(2),(3),(4),(5)} {(1),(2),(3),(4),(6)} {(1),(2),(3),(4),(7)} {(1),(2),(3),(4),(8)} {(1),(2),(3),(4),(9)} {(1),(2),(3 ),(4),(10)} {(1),(2),(3),(4),(11)} {(1),(2),(3),(5),(6)} {(1),(2),(3),(5),(7)} {(1),(2),(3),(5),(8)} {(1),(2),(3),(5),(9)} {(1),( 2), (3), (5), (10)} {(1),(2),(3),(5),(11)} {(1),(2),(3),(6),(7)} {(1),(2),(3),(6),(8)} {(1),(2),(3),(6),(9)} {(1), (2), (3), (6), (10)} {(1),(2),(3),(6),(11)} {(1),(2),(3),(7),(8)} {(1),(2),(3),(7),(9)} {(1), (2), (3), (7), (10)} {(1),(2),(3),(7),(11)} {(1),(2),(3),(8 ),(9)} {(1), (2), (3), (8), (10)} {(1),(2),(3),(8),(11)} {(1), (2), (3), (9), (10)} {(1),(2),(3),(9),(11)} {(l),(2),(3),(10),(l 1)} {(1), (2), (4), (5), (6)} {(1),(2),(4),(5),(7)} {(1),(2),(4),(5),(8)} {(1),(2),(4),(5),(9)} {(1), (2), (4), (5), (10)} {(1),(2),(4),(5),(11)} {(1),(2),(4),(6),(7)} {(1),(2),(4),(6),(8)} {(1),(2),(4),(6),(9)} {(1), (2), (4), (6), (10)} {(1),(2),(4),(6),(11)} {(1),(2),(4),(7), (8)} {(1),(2),(4),(7),(9)} {(1 ),(2),(4),(7),(10)} {(1),(2),(4),(7),(11 )} {(1 ),(2),(4),(8),(9)} {(1 ),(2),(4),(8),(10)} {(1 ),(2),(4 ),(8),(11 )} {(1), (2), (4), (9), (10)} {(1),(2),(4),(9),(11)} {(l),(2),(4),(10),(l 1)} {(1),(2),(5),(6),(7)} {(1),(2),(5),(6),(8)} {( 1),(2),(5),(6),(9)} {(1), (2), (5), (6), (10)} {(1),(2),(5),(6),(11)} {(1),(2),(5),(7),(8)} {(1),(2),(5),(7),(9)} {(1),(2),(5),(7),(1

[0123]

[0124] 4),(7),(8),(10)} {(2),(4),(7),(8),(11 )} {(2),(4);(7);(9);(10)} {(2);(4);(7);(9);(11)} {(2);(4);(7);(10);(l 1)} {(2),(4),(8),(9),( 10)} {(2),(4),(8),(9),(11 )} {(2),(4),(8),(10),(l 1 )} {(2);(4);(9);(10);(l 1)} {(2),(5),(6),(7),(8)} {(2);(5);(6);(7);(9)} {(2);(5 ),(6),(7),( 10)} {(2),(5),(6),(7),(11 )} {(2), (5), (6), (8), (9)} {(2);(5);(6);(8);(10)} { (2),(5),(6),(8),( 11 )} {(2);(5);(6);(9);(10) } {(2),(5),(6),(9),(11 )} {(2),(5),(6),(10),(l 1 )} {(2);(5);(7);(8);(9)} { (2);(5);(7);(8);(10)} {(2);(5);(7);(8);(11)} {(2);(5);(7 ),(9),(10)} {(2),(5),(7),(9),(11 )} { (2),(5),(7),(10),(l 1 )} {(2);(5);(8);(9);(10)} {(2),(5),(8),(9),(11 )} {(2);(5);(8);(10);(l 1) } {(2),(5),(9),(10),(l 1 )} {(2),(6),(7),(8),(9)} {(2);(6);(7);(8);(10)} {(2);(6);(7);(8);(11)} {(2);(6);(7);(9);(10)} {(2);(6);(7 ),(9),(11 )} {(2),(6),(7),(10),(l 1)} {(2),(6),(8),(9),(10)} {(2);(6);(8);(9);(11)} {(2);(6);(8);(10);(l 1)} {(2),(6),(9),(10),(l 1)} {(2), (7), (8), (9), (10)} {(2),(7),(8),(9),(11 )} {(2);(7);(8);(10);(l 1)} {(2);(7);(9);(10);(l 1)} {(2);(8);(9);(10);(l 1)} {(3), (4),(5),(6),(7)} {(3),(4),(5),(6),(8)} {(3);(4);(5);(6);(9)} {(3);(4);(5);(6);(10)} {(3);(4);(5);(6);(11)} {(3);(4);(5);(7);(8)} {(3),(4),(5),(7),(9)} {(3),(4),(5),(7),(10)} {(3),(4),(5),(7),(11 )} {(3);(4);(5);(8);(9)} {(3);(4);(5);(8);(10)} {(3);(4);(5);(8 ),( 11 ) } { (3 ),(4),(5),(9),( 10) } { (3 ),(4),(5),(9),( 11)1 {(3),(4);(5);(10);(l 1 )} { (3 );(4);(6);(7);(8) } { (3),(4),(6),(7),(9) } { (3),( 4),(6),(7),(10)} {(3),(4),(6),(7),(11 )} {(3),(4);(6);(8);(9)} {(3);(4);(6);(8);(10)} {(3);(4);(6);(8);(11)} {(3);(4);(6);(9);(10 )} {(3),(4),(6),(9),(11 )} {(3),(4),(6),(10),(l 1 )} {(3);(4);(7);(8);(9)} {(3);(4);(7);(8);(10)} {(3);(4);(7);(8);(11)} {(3);(4);( 7),(9),(10)} {(3),(4),(7),(9),(11 )} {(3),(4),(7),(10),(l 1 )} {(3);(4);(8);(9);(10)} {(3);(4);(8);(9);(11)} {(3);(4);(8);(10);(l 1 )} {(3),(4),(9),(10),(l 1 )} { (3 ),(5),(6),(7),(8) } { (3 );(5);(6);(7);(9) } {(3);(5);(6);(7);(10)} { (3);(5);(6);(7);( 11 )} { (3 );(5);( 6), (8), (9)} {(3),(5),(6),(8),(10)} {(3);(5);(6);(8);(11)} {(3);(5);(6);(9);(10)} {(3);(5);(6);(9);(11)} {(3);(5);(6);(10);(l 1)} {(3),(5),(7),(8),(9)} {(3),(5),(7),(8),(10)} {(3);(5);(7);(8);(11)} {(3);(5);(7);(9);(10)} {(3);(5);(7);(9);(11)} {(3),(5),(7),( 10),(l 1 )} {(3), (5), (8), (9), (10)} {(3),(5),(8),(9),(11 )} {(3);(5);(8);(10),(l 1 )} {(3);(5);(9);(10),(l 1 )} {(3), (6), (7), (8), (9)} { (3),(6),(7),(8),(10)} {(3),(6),(7),(8),(11 )} {(3);(6);(7);(9);(10)} {(3);(6);(7);(9);(11 )} {(3);(6);(7);(10);(l 1 )} {(3);(6);(8);(9), (10)} {(3),(6),(8),(9),(11)} {(3),(6),(8),(10),(l 1)} {(3);(6);(9);(10);(l 1)} {(3), (7), (8), (9), (10)} {(3),(7),(8),(9),(11)} {(3),(7),(8),(10),(l 1 )} {(3),(7),(9),(10),(l 1 )} {(3);(8);(9);(10);(l 1)} {(4);(5);(6);(7);(8)} {(4);(5);(6);(7);(9)} {(4);(5);(6 ),(7),(10)} {(4),(5),(6),(7),(11 )} {(4), (5), (6), (8), (9)} {(4);(5);(6);(8);(10)} {(4);(5);(6);(8);(11 )} {(4);(5);(6);(9);(10)} {( 4),(5),(6),(9),(11)} {(4),(5),(6),(10),(l 1)} {(4);(5);(7);(8);(9)} {(4);(5);(7);(8);(10)} {(4);(5);(7);(8);(11)} {(4);(5);(7);(9 ),(10)} {(4),(5),(7),(9),(11)} {(4),(5),(7),(10),(l 1)} {(4), (5), (8), (9), (10)} {(4),(5),(8),(9),(11)} {(4);(5);(8);(10);(l 1)} {( 4),(5),(9),(10),(l 1 )} {(4), (6), (7), (8), (9)} {(4);(6);(7);(8);(10)} {(4);(6);(7);(8);(11)} {(4);(6);(7);(9);(10)} {(4);(6);(7);(9 );(11 )} {(4),(6),(7),(10),(l 1 )} {(4),(6),(8),(9),(10)} {(4),(6),(8),(9),(11 )} {(4),(6),(8),(10),(l 1 )} {(4),(6),(9),(10),(l 1 )} { (4), (7), (8), (9), (10)} {(4),(7),(8),(9),(11)} {(4);(7);(8);(10);(l 1)} {(4);(7);(9);(10);(l 1)} {(4),(8),(9),(10),(l 1 )} {(5);(6);( 7), (8), (9)} {(5), (6), (7), (8), (10)} {(5);(6);(7);(8);(11)} {(5);(6);(7);(9);(10)} {(5);(6);(7);(9);(11)} {(5);(6);(7);(10);(l 1)} {(5), (6), (8), (9), (10)} {(5),(6),(8),(9),(11)} {(5);(6);(8);(10);(l 1)} {(5);(6);(9);(10);(l 1)} {(5), (7), (8), (9), (10)} {(5),(7),( 8),(9),( 11 )} {(5),(7),(8),(10),(l 1 )} {(5),(7),(9),(10),(l 1 )} {(5);(8);(9);(10),(l 1 )} {(6),(7),(8),(9),(10)} {(6),(7),(8),(9),( 11)} {(6),(7),(8),(10),(l 1 )} {(6),(7),(9),(10),(l 1)} {(6),(8),(9),(10),(l 1)} {(7),(8),(9),(10),(l 1)};

[0125] {(1), (2), (3), (4), (5), (6)} {(1), (2), (3), (4), (5), (7)} {(1);(2);(3);(4);(5);(8)} {(1);(2);(3);(4);(5);(9)} {(1);(2);(3);(4);(5),(10)} {(1 ),(2),(3),(4),(5),(11 )} {(1);(2),(3),(4),(6),(7)} {(1);(2);(3);(4);(6);(8)} {(1);(2);(3);(4);(6);(9)} {(1),(2);(3);( 4), (6), (10)} {(1 ),(2),(3),(4),(6),( 11 )} {(1);(2),(3),(4),(7),(8)} {(1);(2);(3);(4);(7);(9)} {(1);(2);(3);(4);(7);(1O)} {(1),(2);( 3),(4),(7),(11)} {(1), (2), (3), (4), (8), (9)} {(l);(2);(3);(4);(8);(10)} {(1);(2);(3);(4);(8);(11)} {(l);(2);(3);(4);(9);(10)} {(1),(2),(3),(4),(9),(11)} {(1 ),(2),(3),(4),(10),(l 1 )} {(1);(2);(3);(5);(6);(7)} {(1);(2);(3);(5);(6);(8)} {(1);(2);(3);(5);(6);(9)} {(1), (2), (3), (5), (6), (10)} {(1 ),(2),(3),(5),(6),(11 )} {(1),(2);(3);(5);(7);(8)} {(1);(2);(3);(5);(7);(9)} { (1 );(2);(3);(5);(7);(1 0)} {( 1 ),(2),(3),(5),(7),(11 )} {(1);(2),(3),(5),(8),(9)} {(1 );(2);(3);(5);(8);(10)} {( 1 ),(2),(3),(5),(8),(11 )} {(1 ),(2);(3);(5);( 9), (10)} {(1 ),(2),(3),(5),(9),(11 )} {(1 ),(2),(3),(5),(10),(l 1 )} {(1);(2);(3);(6);(7);(8)} {(1);(2);(3);(6);(7);(9)} {(1),(2);(3),(6),(7),(10)} {( 1 ),(2),(3),(6),(7),(11 )} {(1);(2),(3),(6),(8),(9)} {(1);(2);(3);(6);(8);(1O)} {(1);(2);(3);(6);(8);(11)} {(1);( 2),(3),(6),(9),(10)} {(1 ),(2),(3),(6),(9),(11 )} {(1 );(2);(3);(6);(10);(l 1 )} {(1 );(2);(3);(7);(8);(9)} {(1 );(2);(3);(7);(8);(10) } {(1 ),(2),(3),(7),(8),(11 )} {(1 ),(2),(3),(7),(9),(10)} {(1 );(2);(3);(7);(9);(11 )} {(1 );(2);(3);(7);(10);(l 1 )} { ( 1 ),(2),(3 ),(8),

[0126]

[0127] (7),(8),(9),(10),(l 1 )} {(2),(3),(4),(5),(6),(7)} {(2), (3), (4), (5), (6), (8)} {(2), (3), (4), (5), (6), (9)} {(2), (3), (4), (5), (6), (10)} { (2),(3),(4),(5),(6),(11 )} {(2),(3),(4),(5),(7),(8)} {(2), (3), (4), (5), (7), (9)} {(2), (3), (4), (5), (7), (10)} {(2), (3), (4), (5), (7), (11 )} {(2),(3),(4),(5),(8),(9)} { (2),(3),(4),(5),(8),(10)} {(2), (3), (4), (5), (8), (11)} {(2),(3),(4),(5),(9),(10)} {(2), (3), (4), (5), (9 ),( 11 ) } {(2),(3),(4),(5),(10),(l 1 )} { (2),(3),(4),(6),(7),(8) } { (2),(3 ),(4),(6),(7),(9) } {(2),(3),(4),(6),(7),(10)} { (2),(3 ),(4),( 6),(7),( 11 )} {(2), (3), (4), (6), (8), (9)} {(2),(3),(4),(6),(8),(10)} { (2),(3 ),(4),(6),(8),( 11 )} {(2),(3),(4),(6),(9),(10)} { (2),(3 ),(4),(6),(9),(11 )} {(2),(3),(4),(6),(10),(l 1 )} {(2), (3), (4), (7), (8), (9)} {(2),(3),(4),(7),(8),(10)} {(2), (3), (4), (7), (8), (11)} { (2), (3), (4), (7), (9), (10)} {(2),(3),(4),(7),(9),(11 )} {(2), (3), (4), (7), (10), (11)} {(2), (3), (4), (8), (9), (10)} {(2), (3), (4), (8), (9),(H)} {(2),(3),(4),(8),(10),(l 1 )} {(2),(3),(4),(9),(10),(l 1 )} {(2), (3), (5), (6), (7), (8)} {(2), (3), (5), (6), (7), (9)} {(2), (3), (5), (6), (7), (10)} {(2),(3),(5),(6),(7),(11 )} {(2), (3), (5), (6), (8), (9)} {(2), (3), (5), (6), (8), (10)} {(2),(3),(5),(6),(8),(11 )} {(2), (3 ),(5),(6),(9),(10)} {(2), (3), (5), (6), (9), (11)} {(2),(3),(5),(6),(10),(l 1)} {(2), (3), (5), (7), (8), (9)} {(2), (3), (5), (7), (8), (10)} {(2),(3),(5),(7),(8),(11 )} {(2), (3), (5), (7), (9), (10)} {(2),(3),(5),(7),(9),(11 )} {(2),(3),(5),(7),(10),(l 1)} {(2),(3),(5),(8),( 9), (10)} {(2),(3),(5),(8),(9),(11 )} {(2),(3),(5),(8),(10),(l 1)} {(2),(3),(5),(9),(10),(l 1)} {(2), (3), (6), (7), (8), (9)} {(2),(3),( 6), (7), (8), (10)} {(2), (3), (6), (7), (8), (11)} {(2), (3), (6), (7), (9), (10)} {(2),(3),(6),(7),(9),(11)} {(2),(3),(6),(7),(10),(l 1)} {( 2), (3), (6), (8), (9), (10)} {(2),(3),(6),(8),(9),(11 )} {(2),(3),(6),(8),( 10),(l 1 )} {(2),(3),(6),(9),(10),(l 1 )} {(2), (3), (7), (8), (9 ),(10)} {(2),(3),(7),(8),(9),(11 )} { (2),(3),(7),(8),(10),(l 1 )} {(2),(3),(7),(9),(10),(l 1 )} {(2),(3),(8),(9),(10),(l 1)} {(2), (4),(5),(6),(7),(8)} {(2), (4), (5), (6), (7), (9)} {(2), (4), (5), (6), (7), (10)} {(2),(4),(5),(6),(7),(11)} {(2), (4), (5), (6), (8), (9)} {(2),( 4), (5), (6), (8), (10)} {(2),(4),(5),(6),(8),(11)} {(2),(4),(5),(6),(9),(10)} {(2),(4),(5),(6),(9),(11)} {(2),(4),(5),(6),(10),(l 1 )} {(2), (4), (5), (7), (8), (9)} {(2), (4), (5), (7), (8), (10)} {(2),(4),(5),(7),(8),(11)} {(2), (4), (5), (7), (9), (10)} {(2), (4), (5), (7), (9 );(11)} {(2),(4),(5),(7),(10),(l 1 )} {(2),(4),(5),(8),(9),(10)} {(2), (4), (5), (8), (9), (11 )} {(2),(4),(5),(8),(10),(l 1 )} {(2),(4),( 5),(9),(10),(l 1)} {(2), (4), (6), (7), (8), (9)} {(2), (4), (6), (7), (8), (10)} {(2),(4),(6),(7),(8),(11)} {(2), (4), (6), (7), (9), (10)} {(2 ),(4),(6),(7),(9),(11)} {(2),(4),(6),(7),(10),(l 1)} {(2), (4), (6), (8), (9), (10)} {(2),(4),(6),(8),(9),(11)} {(2), (4), (6), (8), (10), (11)} {(2),(4),(6),(9),(10),(l 1 )} {(2), (4), (7), (8), (9), (10)} {(2),(4),(7),(8),(9),(11)} {(2),(4),(7),(8),( 10),(l 1 )} {(2), (4), (7 ),(9),( 10),( 11 )} {(2),(4),(8),(9),(10),(l 1 )} {(2), (5), (6), (7), (8), (9)} {(2),(5),(6),(7),(8),(10)} {(2), (5), (6), (7), (8), (11 )} {(2 ), (5), (6), (7), (9), (10)} {(2), (5), (6), (7), (9), (11)} {(2),(5),(6),(7),(10),(l 1 )} {(2), (5), (6), (8), (9), (10)} {(2),(5),(6),(8),(9),( 11)} {(2),(5),(6),(8),(10),(l 1 )} {(2),(5),(6),(9),(10),(l 1 )} {(2), (5), (7), (8), (9), (10)} {(2),(5),(7),(8),(9),(11)} {(2), (5), (7),(8),(10),(l 1)} {(2),(5),(7),(9),(10),(l 1 )} {(2),(5),(8),(9),(10),(l 1)} {(2), (6), (7), (8), (9), (10)} {(2),(6),(7),(8),(9),(11)} { (2),(6),(7),(8),(10),(l 1 )} {(2),(6),(7),(9),(10),(l 1 )} {(2),(6),(8),(9),(10),(l 1 )} {(2),(7),(8),(9),(10),(l 1)} {(3), (4), (5), (6),(7),(8)} {(3), (4), (5), (6), (7), (9)} {(3), (4), (5), (6), (7), (10)} {(3),(4),(5),(6),(7),(11 )} {(3), (4), (5), (6), (8), (9)} {(3),(4),(5),( 6), (8), (10)} {(3), (4), (5), (6), (8), (11)} {(3), (4), (5), (6), (9), (10)} {(3),(4),(5),(6),(9),(11 )} {(3), (4), (5), (6), (10), (11)} {(3),( 4), (5), (7), (8), (9)} {(3), (4), (5), (7), (8), (10)} {(3), (4), (5), (7), (8), (11)} {(3), (4), (5), (7), (9), (10)} {(3), (4), (5), (7), (9), (11)} {(3),(4),(5),(7),(10),(l 1)} {(3), (4), (5), (8), (9), (10)} {(3), (4), (5), (8), (9), (11)} {(3),(4),(5),(8),(10),(l 1)} {(3), (4), (5), (9), (10), (11)} {(3), (4), (6), (7), (8), (9)} {(3), (4), (6), (7), (8), (10)} {(3), (4), (6), (7), (8), (11)} {(3), (4), (6), (7), (9), (10)} {(3),(4),( 6),(7),(9),(11)} {(3), (4), (6), (7), (10), (11)} {(3), (4), (6), (8), (9), (10)} {(3), (4), (6), (8), (9), (11)} {(3),(4),(6),(8),(10),(l 1)} {(3),(4),(6),(9),(10),(l 1)} {(3), (4), (7), (8), (9), (10)} {(3), (4), (7), (8), (9), (11)} {(3),(4),(7),(8),(10),(l 1)} {(3), (4), (7), (9), (10), (11)} {(3), (4), (8), (9), (10), (11)} {(3), (5), (6), (7), (8), (9)} {(3), (5), (6), (7), (8), (10)} {(3), (5), (6), (7), (8), (11)} {(3), (5), (6), (7), (9), (10)} {(3), (5), (6), (7), (9), (11)} {(3),(5),(6),(7),(10),(l 1)} {(3), (5), (6), (8), (9), (10)} {(3), (5), (6), (8), (9), (11)} { (3),(5),(6),(8),(10),(l 1)} {(3),(5),(6),(9),(10),(l 1)} {(3), (5), (7), (8), (9), (10)} {(3), (5), (7), (8), (9), (11)} {(3),(5),(7),(8),( 10), (11)} {(3), (5), (7), (9), (10), (11)} {(3), (5), (8), (9), (10), (11)} {(3), (6), (7), (8), (9), (10)} {(3), (6), (7), (8), (9), (11)} {(3),( 6), (7), (8), (10), (11)} {(3), (6), (7), (9), (10), (11)} {(3),(6),(8),(9),(10),(l 1)} {(3),(7),(8),(9),(10),(l 1)} {(4), (5), (6), (7), (8), (9)} {(4), (5), (6), (7), (8), (10)} {(4), (5), (6), (7), (8), (11 )} {(4), (5), (6), (7), (9), (10)} {(4), (5), (6), (7), (9), (11 )} {(4), (5), (6), (7 ),(10),(l 1)} {(4), (5), (6), (8), (9), (10)} {(4), (5), (6), (8), (9), (11)} {(4),(5),(6),(8),(10),(l 1)} {(4),(5),(6),(9),(10),(l 1)} {(4), (5), (7), (8), (9), (10)} {(4), (5), (7), (8), (9), (11)} {(4),(5),(7),(8),(10),(l 1)} {(4),(5),(7),(9),(10),(l 1)} {(4), (5), (8), (9), (10),

[0128]

[0129] 4),(8),(9),(10),(l 1 )} {(1 ),(3),(5),(6),(7),(8),(9)} {(1 ),(3),(5),(6),(7),(8),(10)} {(1 ),(3),(5),(6),(7),(8),(11)} {( 1 ),(3),(5),( 6),(7),(9),(10)} {(1 ),(3),(5),(6),(7),(9),(11 )} {(l),(3),(5),(6),(7),(10),(l 1)} {(1 ),(3),(5),(6),(8),(9),(10)} {( 1 ),(3),(5),(6), (8),(9),(11)} {( 1 ),(3),(5),(6),(8),(10),(l 1 )} {(1 ),(3),(5),(6),(9),(10),(l 1 )} {(1 ),(3),(5),(7),(8),(9),(10)} {(1 ),(3),(5),(7),( 8),(9),(11 )} {(1 ),(3),(5),(7),(8),(10),(l 1 )} {(1 ),(3),(5),(7),(9),(10),(l 1 )} {(l),(3),(5),(8),(9),(10),(l 1)} {(1 ),(3),(6),(7),( 8),(9),(10)} {(1),(3),(6),(7),(8),(9),(11)} {(l),(3),(6),(7),(8),(10),(l 1)} {(l),(3),(6),(7),(9),(10),(l 1)} {(1 ),(3),(6),(8),(9 ),(10),(l 1 )} {(1 ),(3),(7),(8),(9),(10),(l 1 )} {(1 ),(4),(5),(6),(7),(8),(9)} {(1 ),(4),(5),(6),(7),(8),(10)} {(1 ),(4),(5),(6),(7),( 8),(11 )} {(1), (4), (5), (6), (7), (9), (10)} {(1),(4),(5),(6),(7),(9),(11)} {(l),(4),(5),(6),(7),(10),(l 1)} {( 1 ),(4),(5),(6),(8),(9), (10)} {(1),(4),(5),(6),(8),(9),(11)} {(l),(4),(5),(6),(8),(10),(l 1)} {(1 ),(4),(5),(6),(9),(10),(l 1)} {(1),(4),(5),(7),(8),(9),( 10)} {( 1 ),(4),(5),(7),(8),(9),(11 )} {(1 ),(4),(5),(7),(8),(10),(l 1 )} {(l),(4),(5),(7),(9),(10),(l 1)} {(1 ),(4),(5),(8),(9),(10),( 11)} {(1), (4), (6), (7), (8), (9), (10)} {(1),(4),(6),(7),(8),(9),(11)} {(l),(4),(6),(7),(8),(10),(l 1)} {(1 ),(4),(6),(7),(9),(10),(l 1)} {(l),(4),(6),(8),(9),(10),(l 1)} {(l),(4),(7),(8),(9),(10),(l 1)} {(1), (5), (6), (7), (8), (9), (10)} {(1),(5),(6),(7),(8),(9),(11 )} {(l),(5),(6),(7),(8),(10),(l 1)} {(1 ),(5),(6),(7),(9),(10),(l 1 )} {(l),(5),(6),(8),(9),(10),(l 1)} {(1 ),(5),(7),(8),(9),(10),(l 1)} {( 1 ),(6),(7),(8),(9),(10),(l 1 )} {(2), (3), (4), (5), (6), (7), (8)} {(2), (3), (4), (5), (6), (7), (9)} {(2), (3), (4), (5), (6), (7), (10)} {( 2), (3), (4), (5), (6), (7), (11)} {(2), (3), (4), (5), (6), (8), (9)} {(2), (3), (4), (5), (6), (8), (10)} {(2), (3), (4), (5), (6), (8), (11)} {(2), (3), (4), (5), (6), (9), (10)} {(2), (3), (4), (5), (6), (9), (11)} {(2),(3),(4),(5),(6),(10),(l 1)} {(2), (3), (4), (5), (7), (8), (9)} {(2), (3), (4), (5), (7), (8), (10)} {(2), (3), (4), (5), (7), (8), (11)} {(2), (3), (4), (5), (7), (9), (10)} {(2), (3), (4), (5), (7), (9), (11)} {(2),(3),(4),(5),( 7),(10),(l 1 )} {(2), (3), (4), (5), (8), (9), (10)} {(2), (3), (4), (5), (8), (9), (11)} {(2),(3),(4),(5),(8),(10),(l 1)} {(2), (3), (4), (5), (9 ),(10),(l 1)} {(2), (3), (4), (6), (7), (8), (9)} {(2), (3), (4), (6), (7), (8), (10)} {(2), (3), (4), (6), (7), (8), (11)} {(2), (3), (4), (6), (7), (9),(10)} {(2), (3), (4), (6), (7), (9), (11)} {(2),(3),(4),(6),(7),(10),(l 1)} {(2), (3), (4), (6), (8), (9), (10)} {(2), (3), (4), (6), (8), (9), (1 1 )} {(2), (3), (4), (6), (8), (10),(l 1 )} {(2), (3), (4), (6), (9), (10),(l 1 )} {(2), (3), (4), (7), (8), (9), (10)} {(2), (3), (4), (7), (8), (9), (11 )} {(2),(3),(4),(7),(8),(10),(l 1)} {(2),(3),(4),(7),(9),(10),(l 1)} {(2),(3),(4),(8),(9),(10),(l 1)} {(2), (3), (5), (6), (7), (8), (9) } {(2), (3), (5), (6), (7), (8), (10)} {(2), (3), (5), (6), (7), (8), (11 )} {(2), (3), (5), (6), (7), (9), (10)} {(2), (3), (5), (6), (7), (9), (11 )} {( 2),(3),(5),(6),(7),(10),(l 1)} {(2), (3), (5), (6), (8), (9), (10)} {(2), (3), (5), (6), (8), (9), (11)} {(2),(3),(5),(6),(8),(10),(l 1)} {(2 ),(3),(5),(6),(9),(10),(l 1)} {(2), (3), (5), (7), (8), (9), (10)} {(2), (3), (5), (7), (8), (9), (11)} {(2),(3),(5),(7),(8),(10),(l 1)} {(2), (3),(5),(7),(9),(10),(l 1 )} {(2), (3), (5), (8), (9), (10),(l 1 )} {(2), (3), (6), (7), (8), (9), (10)} {(2), (3), (6), (7), (8), (9), (11 )} {(2),( 3),(6),(7),(8),(10),(l 1)} {(2),(3),(6),(7),(9),(10),(l 1)} {(2),(3),(6),(8),(9),(10),(l 1)} {(2),(3),(7),(8),(9),(10),(l 1)} {(2), (4), (5), (6), (7), (8), (9)} {(2), (4), (5), (6), (7), (8), (10)} {(2), (4), (5), (6), (7), (8), (11)} {(2), (4), (5), (6), (7), (9), (10)} {(2), (4), (5 ),(6),(7),(9),(11)} {(2),(4),(5),(6),(7),(10),(l 1)} {(2), (4), (5), (6), (8), (9), (10)} {(2), (4), (5), (6), (8), (9), (11)} {(2),(4),(5),( 6),(8),(10),(l 1)} {(2),(4),(5),(6),(9),(10),(l 1)} {(2), (4), (5), (7), (8), (9), (10)} {(2), (4), (5), (7), (8), (9), (11)} {(2), (4), (5), (7 ),(8),(10),(l 1)} {(2),(4),(5),(7),(9),(10),(l 1)} {(2),(4),(5),(8),(9),(10),(l 1)} {(2), (4), (6), (7), (8), (9), (10)} {(2), (4), (6), (7 ),(8),(9),(11)} {(2),(4),(6),(7),(8),(10),(l 1)} {(2),(4),(6),(7),(9),(10),(l 1)} {(2),(4),(6),(8),(9),(10),(l 1)} {(2), (4), (7), (8 ),(9),(10),(l 1 )} {(2), (5), (6), (7), (8), (9), (10)} {(2), (5), (6), (7), (8), (9), (11 )} {(2), (5), (6), (7), (8), (10),(l 1 )} {(2), (5), (6), (7), (9),(10),(l 1)} {(2),(5),(6),(8),(9),(10),(l 1)} {(2),(5),(7),(8),(9),(10),(l 1)} {(2),(6),(7),(8),(9),(10),(l 1)} {(3), (4), (5), (6),(7),(8),(9)} {(3), (4), (5), (6), (7), (8), (10)} {(3), (4), (5), (6), (7), (8), (11 )} {(3), (4), (5), (6), (7), (9), (10)} {(3), (4), (5), (6), (7), ( 9),(11)} {(3),(4),(5),(6),(7),(10),(l 1)} {(3), (4), (5), (6), (8), (9), (10)} {(3), (4), (5), (6), (8), (9), (11)} {(3), (4), (5), (6), (8), (10 ),(11)} {(3),(4),(5),(6),(9),(10),(l 1)} {(3), (4), (5), (7), (8), (9), (10)} {(3), (4), (5), (7), (8), (9), (11)} {(3), (4), (5), (7), (8), (10), (11)} {(3),(4),(5),(7),(9),(10),(l 1)} {(3),(4),(5),(8),(9),(10),(l 1)} {(3), (4), (6), (7), (8), (9), (10)} {(3), (4), (6), (7), (8), (9), ( 11)} {(3),(4),(6),(7),(8),(10),(l 1)} {(3),(4),(6),(7),(9),(10),(l 1)} {(3), (4), (6), (8), (9), (10), (11)} {(3), (4), (7), (8), (9), (10), (11)} {(3), (5), (6), (7), (8), (9), (10)} {(3), (5), (6), (7), (8), (9), (11)} {(3),(5),(6),(7),(8),(10),(l 1)} {(3),(5),(6),(7),(9),(10),( 11)} {(3), (5), (6), (8), (9), (10), (11)} {(3),(5),(7),(8),(9),(10),(l 1)} {(3),(6),(7),(8),(9),(10),(l 1)} {(4), (5), (6), (7), (8), (9), ( 10)} {(4), (5), (6), (7), (8), (9), (11)} {(4),(5),(6),(7),(8),(10),(l 1)} {(4),(5),(6),(7),(9),(10),(l 1)} {(4),(5),(6),(8),(9),(10),( 11)} {(4),(5),(7),(8),(9),(10),(l 1)} {(4), (6), (7), (8), (9), (10), (11)} {(5), (6), (7), (8), (9), (10), (11)};{ ( 1 ),(2),(3 ),(4),(5),(6),(7),(8) } {(1 ), (2), (3), (4), (5), (6), (7), (9)} {(1 ),(2),(3),(4),(5),(6),(7),(10)} {(1 ),(2),(3),(4),( 5),(6),(7),(11 )} {(1 ),(2),(3),(4),(5),(6),(8),(9)} {(1 ),(2),(3),(4),(5),(6),(8),(10)} {(1),(2),(3),(4),(5),(6),(8),(11)} {(1 ),(2),(3),(4),(5),(6),(9),(10)} {(1 ),(2),(3),(4),(5),(6),(9),(11 )} {(l),(2),(3),(4),(5),(6),(10),(l 1)} {(1 ),(2),(3),(4),(5),(7),(8),( 9)} { ( 1 ),(2),(3 ),(4),(5),(7),(8),( 10) } {(1 ),(2),(3),(4),(5),(7),(8),(11 )} { ( 1 ),(2),(3 ),(4),(5),(7),(9),( 10) } {(1 ),(2),(3),(4),(5),(7),(9),(11 )} {(1 ),(2),(3),(4),(5),(7),(10),(l 1 )} {(1 ),(2),(3),(4),(5),(8),(9),(10)} {(1),(2),(3),(4),(5),(8),(9),(11)} {(1 ),(2 ),(3),(4),(5),(8),(10),(l 1 )} {(1 ),(2),(3),(4),(5),(9),(10),(l 1 )} {(1 ), (2), (3), (4), (6), (7), (8), (9)} {(1 ), (2), (3), (4), (6), (7), (8), ( 10)} {( 1 ),(2),(3),(4),(6),(7),(8),(11 )} {(l);(2),(3),(4),(6),(7),(9),(10)} {(1),(2),(3),(4),(6),(7),(9),(11)} {(1 ),(2),(3),(4),( 6),(7),(10),(l 1 )} {(1 ),(2),(3),(4),(6),(8),(9),(10)} {(1),(2),(3),(4),(6),(8),(9),(11)} {(l),(2),(3),(4),(6),(8),(10),(l 1)} {(1 ),(2),(3),(4),(6),(9),(10),(l 1 )} {(1 ),(2),(3),(4),(7),(8),(9),(10)} {(1),(2),(3),(4),(7),(8),(9),(11)} {(1 ),(2),(3),(4),(7),(8), ( 10),(l 1 )} {(1 ),(2),(3),(4),(7),(9),(10),(l 1 )} {(1 ),(2),(3),(4),(8),(9),(10),(l 1 )} {(1 ),(2),(3),(5),(6),(7),(8),(9)} {(1),(2),(3 ),(5),(6),(7),(8),(10)}{(l),(2),(3),(5),(6),(7),(8),(ll)}{(l),(2),(3),(5),(6),(7),(9),(10)}{(l),(2),(3),(5),(6),(7),(9),(ll)} {(1 ),(2),(3),(5),(6),(7),(10),(l 1 )} {(1 ),(2),(3),(5),(6),(8),(9),(10)} {(1),(2),(3),(5),(6),(8),(9),(11)} {(1 ),(2),(3),(5),(6),( 8),( 10),( 11 )} { ( 1 ),(2),(3 ),(5),(6),(9),( 10),( 11 )} {(1 ),(2),(3),(5),(7),(8),(9),(10)} {(1 ),(2),(3),(5),(7),(8),(9),(11)} { ( 1 ),(2 ),(3),(5),(7),(8),(10),(l 1 )} {(1 ),(2),(3),(5),(7),(9),(10),(l 1 )} {(l),(2),(3),(5),(8),(9),(10),(l 1)} {(1 ), (2), (3), (6), (7), (8), (9 ),(10)} {(1 ),(2),(3),(6),(7),(8),(9),(11 )} {(1 ),(2),(3),(6),(7),(8),(10),(l 1 )} {(l),(2),(3),(6),(7),(9),(10),(l 1)} {(1),(2),(3), (6),(8),(9),(10),(l 1 )} {(1 ),(2),(3),(7),(8),(9),(10),(l 1 )} {(1 ), (2), (4), (5), (6), (7), (8), (9)} {(1 ),(2),(4),(5),(6),(7),(8),(10)} {(1 ),(2),(4),(5),(6),(7),(8),(11 )} {(1 ),(2),(4),(5),(6),(7),(9),(10)} {(1 ),(2),(4),(5),(6),(7),(9),(11 )} {(1 ),(2),(4),(5),(6),(7 ),(10),(l 1)} {(l);(2),(4),(5),(6),(8),(9),(10)} {(1 ),(2),(4),(5),(6),(8),(9),(11)} {(l),(2),(4),(5),(6),(8),(10),(l 1)} {(1 ),(2), (4),(5),(6),(9),(10),(l 1 )} {(1 ),(2),(4),(5),(7),(8),(9),(10)} {(1),(2),(4),(5),(7),(8),(9),(11)} {(1 ),(2),(4),(5),(7),(8),(10),( 11)} {( 1 ),(2),(4),(5),(7),(9),(10),(l 1 )} {(1 ),(2),(4),(5),(8),(9),(10),(l 1 )} {(1 ),(2),(4),(6),(7),(8),(9),(10)} {(1 ),(2),(4),(6 ),(7),(8),(9),( 11 )} { ( 1 ),(2),(4),(6),(7),(8),( 10),( 11 )} {(1),(2),(4),(6),(7),(9),(10),(l 1 )} {(1),(2),(4),(6),(8),(9),(10),(l 1 )} {(1 ),(2),(4),(7),(8),(9),(10),(l 1 )} {(1 ),(2),(5),(6),(7),(8),(9),(10)} {(1),(2),(5),(6),(7),(8),(9),(11)} {(1 ),(2),(5),(6),(7),( 8),(10),(l 1 )} { ( 1 ),(2),(5),(6),(7),(9),( 10),( 11 )} {(1 ),(2),(5),(6),(8),(9),(10),(l 1 )} {(1 ),(2),(5),(7),(8),(9),(10),(l 1 )} {(1 ), (2),(6),(7),(8),(9),(10),(l 1 )} { ( 1 ),(3 ),(4),(5),(6),(7),(8),(9) } {(1 ),(3),(4),(5),(6),(7),(8),(10)} {(1 ),(3),(4),(5),(6),(7),(8), (11)} {(1), (3), (4), (5), (6), (7), (9), (10)} {(1 ),(3),(4),(5),(6),(7),(9),(11 )} {(l),(3),(4),(5),(6),(7),(10),(l 1)} {(1 ),(3),(4),(5), (6), (8), (9), (10)} {(1),(3),(4),(5),(6),(8),(9),(11)} {(l),(3),(4),(5),(6),(8),(10),(l 1)} {(l),(3),(4),(5),(6),(9),(10),(l 1)} {( 1), (3), (4), (5), (7), (8), (9), (10)} {(1 ),(3),(4),(5),(7),(8),(9),(11 )} {(l),(3),(4),(5),(7),(8),(10),(l 1)} {(1), (3), (4), (5), (7), (9),(10),( 11)} {(1), (3), (4), (5), (8), (9), (10), (11)} {(1), (3), (4), (6), (7), (8), (9), (10)} {(1),(3),(4),(6),(7),(8),(9),(11)} {(1),(3),( 4),(6),(7),(8),(10),(l 1)} {(l),(3),(4),(6),(7),(9),(10),(l 1)} {(l),(3),(4),(6),(8),(9),(10),(l 1)} {(1), (3), (4), (7), (8), (9), (10),(11)} {(1 ),(3),(5),(6),(7),(8),(9),(10)} {(1 ),(3),(5),(6),(7),(8),(9),(11 )} {(1 ),(3),(5),(6),(7),(8),(10),(l 1 )} {(1 ),(3),(5),(6 ),(7),(9),(10),(l 1)} {(l),(3),(5),(6),(8),(9),(10),(l 1)} {(1), (3), (5), (7), (8), (9), (10), (11)} {(1), (3), (6), (7), (8), (9), (10), (11) } {(1), (4), (5), (6), (7), (8), (9), (10)} {(1), (4), (5), (6), (7), (8), (9), (11)} {(l),(4),(5),(6),(7),(8),(10),(l 1)} {(1),(4),(5),(6),(7), (9),(10),(l 1 )} {(1 ),(4),(5),(6),(8),(9),(10),(l 1 )} {(1 ),(4),(5),(7),(8),(9),(10),(l 1 )} {(1 ),(4),(6),(7),(8),(9),(10),(l 1 )} {(1 ),(5),(6),(7),(8),(9),(10),(l 1 )} {(2), (3), (4), (5), (6), (7), (8), (9)} {(2), (3), (4), (5), (6), (7), (8), (10)} {(2), (3), (4), (5), (6), (7), (8 ),(11)} {(2), (3), (4), (5), (6), (7), (9), (10)} {(2), (3), (4), (5), (6), (7), (9), (11 )} {(2), (3), (4), (5), (6), (7), (10),(l 1 )} {(2), (3), (4), (5 ),(6),(8),(9),(10)} {(2), (3), (4), (5), (6), (8), (9), (11)} {(2),(3),(4),(5),(6),(8),(10),(l 1)} {(2),(3),(4),(5),(6),(9),(10),(l 1)} { (2), (3), (4), (5), (7), (8), (9), (10)} {(2), (3), (4), (5), (7), (8), (9), (11)} {(2),(3),(4),(5),(7),(8),(10),(l 1)} {(2), (3), (4), (5), (7), (9 ),(10),(l 1)} {(2), (3), (4), (5), (8), (9), (10), (11)} {(2), (3), (4), (6), (7), (8), (9), (10)} {(2), (3), (4), (6), (7), (8), (9), (11)} {(2), (3), (4),(6),(7),(8),(10),(l 1)} {(2), (3), (4), (6), (7), (9), (10), (11)} {(2), (3), (4), (6), (8), (9), (10), (11)} {(2), (3), (4), (7), (8), (9), (10 ),(11 )} {(2), (3), (5), (6), (7), (8), (9), (10)} {(2), (3), (5), (6), (7), (8), (9), (11 )} {(2), (3), (5), (6), (7), (8), (10),(l 1 )} {(2),(3),(5),( 6),(7),(9),(10),(l 1)} {(2),(3),(5),(6),(8),(9),(10),(l 1)} {(2),(3),(5),(7),(8),(9),(10),(l 1)} {(2),(3),(6),(7),(8),(9),(10),(l 1 )} {(2), (4), (5), (6), (7), (8), (9), (10)} {(2), (4), (5), (6), (7), (8), (9), (11 )} {(2), (4), (5), (6), (7), (8), (10),(l 1 )} {(2),(4),(5),(6),(

[0130]

[0131] In one preferable embodiment, features (2) and (8) are combined (i.e. {(2), (8)}). In one preferable embodiment, the TSP present in the shell, such as in feature (8), is TSP-5. Therefore, the particle may comprise features (2) and (8), wherein in feature (8) the TSP present in the shell is TSP-5.

[0132] Alternatively or additionally, the particle or population of particles may comprise a specific expression provide. For instance, the particle or population of particles may be: (a) WGA positive and DiR negative; and / or (b) TSPAN14 negative and / or CD63 negative; and / or DiR negative and negative for a membrane stain such as a CellMask™ dye, a Vesi-Dye, a lipophilic dye, a CellBrite® stain, or a CytoLiner™ dye.

[0133] Alternatively or additionally, the particle or population of particles may have cytotoxic activity such as cytotoxic activity against Nalm6 cells, or may not have cytotoxic activity such as no cytotoxic activity against Nalm6 cells.Alternatively or additionally, the particle or population of particles may be resistant to any one or more of pH fluctuations, treatment with a protease, treatment with a detergent, high salt conditions, and / or freeze thaw cycles. For instance, the shell of the particle or population of particles may be resistant to any one or more of pH fluctuations, treatment with a protease, treatment with a detergent, high salt conditions, and / or freeze thaw cycles. Being resistant means that the particle, population of particles, shell of the particle, and / or shell of the population of particles is resistant to destruction, for example: when the pH of a surrounding solution changes; when there is the presence of a protease and / or detergent in a surrounding solution; when the ambient salt concentration of a surrounding solution changes, such as to a high salt condition where the concentration of salt is higher than 50 mmol / L, higher than 100 mmol / L, higher than 150 mmol / L, higher than 250 mmol / L, higher than 500 mmol / L or higher than 1000 mmol / L; and / or when subjected to freeze thaw cycles, such as at least 1, at least 2, at least 3, least 4, at least 5, at least 10, at least 20 or at least 500 freeze thaw cycles. Being resistant means that that the particle, population of particles, shell of the particle, and / or shell of the population of particles is not degraded, or not substantially degraded, such that its structure and / or function persists.

[0134] The particle or particles in the population of particles, may be attached to a membrane vesicle or phospholipid particle; and / or the shell and / or core of the particle may further comprise a toxin, such as a chemotherapeutic agent. Alternatively or additionally, the particle or particles in the population of particles, may comprise:

[0135] (a) a modified core protein such as a fusion protein; and / or

[0136] (b) a modified shell protein such as a fusion protein; and / or

[0137] (c) a shell protein modified at the c-terminus, such as a modification at the c- terminus of a thrombospondin; and / or

[0138] (d) a transgenic protein and / or an antibody or antigen binding fragment thereof. A modified protein, such as a modified core or shell protein, may be a fusion, variant, fragment or orthologue of the unmodified protein. The fusion protein may comprise an antibody or antibody binding fragment, such as a scFv, a VL and / or VH, a Fd, an Fv, an Fab, a Fab', a F(ab')2, an Fc fragment, an antibody mimetic, or a bispecific antibody.

[0139] Fragments, variants and orthologuesThe term “orthologue ” may refer to a gene that has diverged from another due to speciation (i.e. when a population becomes distinct species).

[0140] It will be appreciated that the invention extends to any nucleic acid or peptide or variant, derivative or analogue thereof, which comprises substantially the amino acid or nucleic acid sequences of any of the sequences or molecules referred to herein, including variants or fragments thereof. The terms “variant” and “fragment” can be a sequence that has at least 40% sequence identity with the amino acid / nucleotide / peptide sequences of any one of the sequences or molecules referred to herein, for example 40% identity with the nucleic acids or polypeptides described herein. Amino acid / polynucleotide / polypeptide sequences with a sequence identity which is greater than 50%, more preferably greater than 65%, 70%, 75%, and still more preferably greater than 80% sequence identity to any of the sequences referred to are also envisaged. Preferably, the amino acid / polynucleotide / polypeptide sequence has at least 85% identity with any of the sequences referred to, more preferably at least 90%, 92%, 95%, 97%, 98%, and most preferably at least 99% identity with any of the sequences referred to herein. The amino acid / polynucleotide / polypeptide sequence may have 100% identity with any of the sequences referred to herein.

[0141] Where reference is made to a variant molecule or variant polypeptide or nucleotide sequence, the skilled person will understand that one or more amino acid residue or nucleotide substitutions, deletions or additions, may be tolerated, optionally two substitutions may be tolerated in the sequence, such that it maintains its function. The skilled person will appreciate that 1, 2, 3, 4, 5 or more amino acid residues or nucleotides may be substituted, added or removed without affecting function. References to sequence identity may be determined by BLAST sequence alignment (www.ncbi.nlm.nih.gov / BLAST / ) using standard / default parameters. For example, the sequence may have at least 99% identity and still function according to the invention. In other embodiments, the sequence may have at least 98% identity and still function according to the invention. In another embodiment, the sequence may have at least 95% identity and still function according to the invention. In another embodiment, the sequence may have at least 90%, 85%, or 80% identity and still function according to the invention. In one embodiment, the variation and sequence identity may be according the full length sequence. In other embodiments, the variation may be limited to non-conserved sequencesand / or sequences outside of active sites, such as binding domains. Therefore, an active site or binding site of a protein may be 100% identical, whereas the flanking sequences may comprise the stated variations in identity.

[0142] Amino acid substitutions may be conservative substitutions. For example, a modified residue may comprise substantially similar properties as the wild-type substituted residue. For example, a substituted residue may comprise substantially similar or equal charge or hydrophobicity as the wild-type substituted residue. For example, a substituted residue may comprise substantially similar molecular weight or steric bulk as the wild-type substituted residue. With reference to “variant” nucleic acid sequences, the skilled person will appreciate that 1, 2, 3, 4, 5 or more codons may be substituted, added or removed without affecting function. For example, conservative substitutions may be considered.

[0143] Preferably the term “fragment” refers to a “functional fragment”. A functional fragment may refer to a fragment that has amino acids / nucleotides essential for performing a function of the full length fragment / polypeptide.

[0144] The skilled technician will appreciate how to calculate the percentage identity between two amino acid / polynucleotide / polypeptide sequences. In order to calculate the percentage identity between two amino acid / polynucleotide / polypeptide sequences, an alignment of the two sequences must first be prepared, followed by calculation of the sequence identity value. The percentage identity for two sequences may take different values depending on: (i) the method used to align the sequences, for example, ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or structural alignment from 3D comparison; and (ii) the parameters used by the alignment method, for example, local versus global alignment, the pair-score matrix used (e.g. BLOSUM62, PAM250, Gonnet etc.), and gap-penalty, e.g. functional form and constants.

[0145] Having made the alignment, there are many different ways of calculating percentage identity between the two sequences. For example, one may divide the number of identities by: (i) the length of shortest sequence; (ii) the length of alignment; (iii) the mean length of sequence; (iv) the number of non-gap positions; or (iv) the number of equivalenced positions excluding overhangs. Furthermore, it will be appreciated that percentage identity is also strongly length dependent. Therefore, the shorter a pair of sequences is, the higher the sequence identity one may expect to occur by chance.

[0146] Hence, it will be appreciated that the accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW(Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882) is a preferred way for generating multiple alignments of proteins or DNA in accordance with the invention. Suitable parameters for ClustalW may be as follows: For DNA alignments: Gap Open Penalty = 15.0, Gap Extension Penalty = 6.66, and Matrix = Identity. For protein alignments: Gap Open Penalty = 10.0, Gap Extension Penalty = 0.2, and Matrix = Gonnet. For DNA and Protein alignments: ENDGAP = -1, and GAPDIST = 4. Those skilled in the art will be aware that it may be necessary to vary these and other parameters for optimal sequence alignment.

[0147] Preferably, calculation of percentage identities between two amino acid / polynucleotide / polypeptide sequences may then be calculated from such an alignment as (N / T)* 100, where N is the number of positions at which the sequences share an identical residue, and T is the total number of positions compared including gaps but excluding overhangs. Hence, a most preferred method for calculating percentage identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters, for example, as set out above; and (ii) inserting the values of N and T into the following formula: Sequence Identity = (N / T)* 100.

[0148] Alternative methods for identifying similar sequences will be known to those skilled in the art. For example, a substantially similar nucleotide sequence will be encoded by a sequence which hybridizes to any sequences referred to herein or their complements under stringent conditions. By stringent conditions, we mean the nucleotide hybridises to filterbound DNA or RNA in 3x sodium chloride / sodium citrate (SSC) at approximately 45 °C followed by at least one wash in o.2x SSC / 0.1% SDS at approximately 20-65°C.

[0149] Alternatively, a substantially similar polypeptide may differ by at least 1, but less than 5, 10, 20, 50 or 100 amino acids from the polypeptide sequences described herein.

[0150] Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence described herein could be varied or changed without substantially affecting the sequence of the protein encoded thereby, to provide a variant thereof. Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent change. Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequence, which are altered by the substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example, small non-polar, hydrophobicamino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. The polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. The positively charged (basic) amino acids include lysine, arginine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. It will therefore be appreciated which amino acids may be replaced with an amino acid having similar biophysical properties, and the skilled technician will know the nucleotide sequences encoding these amino acids.

[0151] Where a reference to a polypeptide sequence refers to a sequence comprising a precursor or pro-peptide sequence, the skilled person will recognise that, in some embodiments, reference to the sequence may refer only to the mature polypeptide. For example, the precursor residues and signal peptide may not be part of the mature polypeptide that is in the proteinaceous particle according to the invention. Accordingly, reference to variants of such sequences, may only refer to the mature polypeptide part of the given sequence.

[0152] The “antibody binding fragment” can mean a portion of the antibody which retains a functional activity. A functional activity can be, for example antigen binding activity or specificity. A functional activity can also be, for example, an effector function provided by an antibody constant region. Such fragments include, for example individual heavy or light chains and fragments thereof, such as VL, VH and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments such as F(ab')2; single chain Fv (scFv); and Fc fragments. The term "”VL fragment” can mean a fragment of the light chain of a human monoclonal antibody which includes all or part of the light chain variable region, including the CDRs. A VL fragment can further include light chain constant region sequences. The term “VH fragment” can means a fragment of the heavy chain of a human monoclonal antibody which includes all or part of the heavy chain variable region, including the CDRs. The term “Fd fragment” can mean the heavy chain variable region coupled to the first heavy chain constant region, i.e. VH and CH-i. The “Fd fragment” does not include the light chain, or the second and third constant regions of the heavy chain. The term “Fv fragment” can mean a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the variable regions of the heavy and light chains, and absent of the constant regions of the heavy and light chains. The variable regions of the heavy and light chains include, for example, the CDRs. For example, an Fv fragmentincludes all or part of the amino terminal variable region of about no amino acids of both the heavy and light chains. The term “Fab fragment” can mean a monovalent antigenbinding fragment of a human monoclonal antibody that is larger than an Fv fragment. For example, a Fab fragment includes the variable regions, and all or part of the first constant domain of the heavy and light chains. The term “Fab1fragment” can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes all of the light chain, all of the variable region of the heavy chain, and all or part of the first and second constant domains of the heavy chain. For example, a Fab' fragment can additionally include some or all of amino acid residues 220 to 330 of the heavy chain. The antibody fragment may alternatively comprise a Fab'2 fragment comprising the hinge portion of an antibody. The term “F(ab) fragment” can mean a bivalent antigen-binding fragment of a human monoclonal antibody. An F(ab) fragment includes, for example, all or part of the variable regions of two heavy chains-and two light chains, and can further include all or part of the first constant domains of two heavy chains and two light chains. The term “single chain Fv ( scFv )” can mean a fusion of the variable regions of the heavy (VH) and light chains (VL) connected with a short linker peptide. The antigen-binding fragment thereof may comprise or consist of any one of the antigen binding region sequences of the VL, any one of the antigen binding region sequences of the VH, or a combination of VL and VH antigen binding regions of a human antibody. The appropriate number and combination of VH and VL antigen binding region sequences may be determined by those skilled in the art depending on the desired affinity and specificity and the intended use of the antigen-binding fragment. Functional fragments or antigen-binding fragments of antibodies may be readily produced and isolated using methods well known to those skilled in the art. Such methods include, for example, proteolytic methods, recombinant methods and chemical synthesis. Proteolytic methods for the isolation of functional fragments comprise using human antibodies as a starting material. Enzymes suitable for proteolysis of human immunoglobulins may include, for example, papain, and pepsin. The appropriate enzyme may be readily chosen by one skilled in the art, depending on, for example, whether monovalent or bivalent fragments are required.

[0153] MoietiesA moiety may be associated with the particle. The term “associated” may be used in its broadest sense to describe a moiety associated with a particle such that the moiety and particle move substantially together as one unit when in bulk solution. The moiety may, for example, be associated with the outer surface of the particle (i.e. on the surface of the particle), and therefore exposed to the environment that is external to the particle. For instance, the moiety may be associated with the outer surface of the shell protein, and thus on the surface of the particle. Alternatively or additionally, the moiety may be associated with the core protein and / or interior of the shell protein, such that the moiety is not exposed to the environment that is external to the particle but rather may be exposed to the lumen of the particle. Alternatively or additionally, the moiety may be a transmembrane moiety, such that the moiety is exposed to the environment that is external to the particle and / or exposed to the interior lumen of the particle.

[0154] The moiety may be associated through a non-covalent interaction. Examples of non-covalent interactions include electrostatic interactions such as ionic interactions, hydrogen bonding and halogen bonding. Examples of non-covalent interactions also include Van der Waals forces and hydrophobic effects. The moiety may be biotinylated and associated with streptavidin (e.g. streptavidin conjugated to a moiety) on the surface of the particle. The moiety may alternatively be fused to the particle by a covalent interaction to create a fusion protein, such that the moiety is fused to the surface of the shell protein, and / or to the interior of the shell protein and / or to the core protein.

[0155] One or more linkers can optionally be included, in particular to generate the fusion protein. The linker may result in a fusion of two or more molecules. The linker physically separates and preferably preserves the functionality of at least one of the two more molecules that are fused. For example, the presence of a linker, may allow flexibility and enables the fusion to be positioned optimally for display on the surface of the particle or luminally according to what is required. Linkers according to the invention are useful in providing increased flexibility, improving pharmacokinetics (PK), increasing expression and improving biological activity of the fusion polypeptide constructs, and may also be used to ensure avoidance of steric hindrance and maintained functionality of the at least one of the two or more molecules. The linker may preferably be 10 amino acids or fewer in length. In some aspects, the linker is 9, 8, 6, 5, 4, 3, 2 amino acids in length or shorter. The linker can include any amino acids, such as Ala, Pro, Cys, and Gly. The linker may be a PEG linker, such as a PEG-biotin linker. The linker may result in a fusion between anamino group and streptavidin. One or more moiety may be directly or indirectly attached to the linker. For example, the one or more moiety may be attached indirectly to the linker via streptavidin. Thus, the particle may comprise a linker, such as an amine-PEG-biotin linker, wherein one end of the linker is attached to an amino group on the surface of the particle; optionally wherein streptavidin or a moiety is attached directly to the other end of the linker; and optionally wherein one or more moiety is attached to the streptavidin, such that the amino group, linker, streptavidin and / or moiety are on the external surface of the particle.

[0156] The moiety on the surface of the particle may be selected from any suitable molecule. For example, the moiety may be selected from one or more of a peptide and / or protein, a targeting peptide and / or targeting protein which binds to a molecule present on a cell to be targeted, a therapeutic moiety such as a receptor decoy, an endosomal escape moiety, an enzyme, a nuclease, a CRISPR-associated protein (Cas) such as SaCas9, SpCas9, Cas9, Cas 12, Cas 13 and variants and fusions thereof, a Transcription activatorlike effector nucleases (TALEN) and variants and fusions thereof, a meganuclease and variants and fusions thereof, a zinc finger nuclease and variants and fusions thereof, an antibody and / or antigen-binding variant or fragment thereof which may be biotinylated, a single chain variable fragment (scFv), VHH, a nanobody, a nucleic acid-binding protein and / or peptide, a RNA- and / or DNA-binding protein, viral-binding protein, a small molecule drug, a nucleic acid, a nucleic acid analogue, an unnatural nucleic acid, gRNA, miRNA, shRNA, siRNA, piRNA, PMO, DNA and a DNA plasmid encoding a therapeutic peptide and / or protein, a toxin, such as chlorotoxin and a chemotherapeutic agent.

[0157] The moiety may be a targeting moiety on the surface of the particle. Examples of targeting moieties a targeting peptide and / or targeting protein which binds to a molecule present on a cell to be targeted, optionally wherein the targeting peptide and / or targeting protein binds to a molecule present on a cell of the liver, preferably a hepatocyte; the heart, preferably a cardiomyocytes or a smooth muscle cell; the brain or the nervous system, preferable a neurone or a glial cell, most preferably a sensory neurone a motor neurone or an interneuron. A targeting moiety is any moiety which confers tropism or increases the tropism of the particle to a desired target, such as a desired cell type or tissue. The moiety may have therapeutic utility.

[0158] The particle may have on its surface one or more moiety each selected from a protein, a polysaccharide chain, and / or an extracellular matrix protein. Similarly, thepopulation of particles may comprise particles each having on their surface one or more moiety each selected from a protein, a polysaccharide chain, and / or an extracellular matrix protein. The moiety on the surface of the particle may be selected from a peptide binding protein or an RNA binding protein, optionally wherein the peptide binding protein is capable of binding a Cas protein, preferably Cas9 or Cast 2, or an adeno-associated virus (AAV), preferably an AAV capsid, and most preferably an AAV8 or AAV9 capsid. The moiety may be an agonist. An agonist is any substance that binds to a receptor on a cell and causes a physiological response, such as making the cell more active. Alternatively or in addition, the moiety may be an antagonist. An antagonist is any substance that binds to a receptor and prevents the effect of an agonist and / or blocks or dampens a biological response by binding to the receptor. Agonists and / or antagonists may be competitive, noncompetitive, and uncompetitive.

[0159] The particle may have at least 100, at least 1000, at least 10,000, at least 100,000 or at least at least 1,000,000 copies of said moiety. Thus, the particle may have 100-1000 copies, 100-10,000 copies, 100-100,000 copies, 100-1,000,000 copies, 1000-10,000 copies, 1000-100,000 copies, 1000-1,000,000 copies, 10,000-100,000 copies, 10,000-1,000,000 copies or 100,000-1,000,000 copies of each moiety. Similarly, the population of particles may comprise particles each having at least 100, at least 1000, at least 10,000, at least 100,000 or at least at least 1,000,000 copies of said moiety. Thus, the population of particles may comprise particles each having 100-1000 copies, 100-10,000 copies, 100-100,000 copies, 100-1,000,000 copies, 1000-10,000 copies, 1000-100,000 copies, 1000-1,000,000 copies, 10,000-100,000 copies, 10,000-1,000,000 copies or 100,000-1,000,000 copies of each moiety.

[0160] Targeting

[0161] The particle of the present invention may be targeted, for example to a desired cell type or tissue. This targeting is achieved by expressing on the surface of the particle a targeting moiety which binds to the target, such as a target expressed on the surface of a cell or tissue to be targeted. The targeting moiety may be any moiety identified above. The targeting moiety may be agonists or antagonists of receptors on the cell to be targeted, such as an immune cell.In more detail, the particle of the invention can be targeted, for example to particular cell types or tissues, by expressing on their surface a targeting moiety such as a peptide. Suitable peptides are those which bind to cell surface molecules such as receptors or their ligands found on the cell surface of the cell to be targeted. Examples of suitable targeting moieties are short peptides, scFv and complete proteins, so long as the targeting moiety can be engineered on the surface of the particle and preferably does not interfere with cargo carrying capacity of the particle. Peptide targeting moieties may typically be less than 100 amino acids in length, for example less than 50 amino acids in length, less than 30 amino acids in length, to a minimum length of 10, 5 or 3 amino acids. For example, peptide targeting moieties may be 3 to 5 amino acids, 3 to 10 amino acids, 3 to 30 amino acids, 3 to 50 amino acids, 3 to 100 amino acids, 5 to 10 amino acids, 5 to 30 amino acids, 5 to 50 amino acids, 5 to 100 amino acids, 10 to 30 amino acids, 10 to 50 amino acids, 10 to 100 amino acids, 30 to 50 amino acids, 30 to 100 amino acids or 50 to 100 amino acids in length.

[0162] Targeting moieties can be selected to target particular cells, subcellular locations, tissues, organs or other bodily compartments. Organs and cell types that may be targeted include: the brain, neuronal cells, the blood brain barrier, muscle tissue, the eye, lungs, liver, kidneys, heart, stomach, intestines, pancreas, red blood cells, white blood cells including B-cells and T-cells, lymph nodes, bone marrow, spleen and cancer cells.

[0163] Alternatively, or in addition, targeting moieties may target a diseased tissue such as a tumour. The targeting moiety may target the liver, the heart, the brain or neuronal tissue, hepatocytes, cardiomyocytes, cardiac smooth muscle cells, sensory neurons, motor neurons, interneurons or glia cells.

[0164] The targeting moiety target an immune cell for example by binding a receptor on the cell to be targeted. The targeting moiety may be an agonist or an antagonist. The receptor may be present on an immune cell, such as a neutrophil, an eosinophil, a basophil, a mast cell, a macrophage, a histocyte, a Kupffer cell, an alveolar macrophage, a dendritic cell, a B cell, a plasma cell, a memory B cell, a Killer T cell, a memory T cell, a T helper cell such as a population of TH1, TH2, TH3, TH17, TH9, or TFH cells, a Natural killer T cell, a CAR T-cell, an innate lymphoid cell and / or a natural killer cell.

[0165] Cargo MoleculeThe particle or population of particles may be loaded with a cargo molecule (i.e. cargo). The terms “load”, “loaded”, “loading”, “onto a cargo” and “into a particle” may be used in their broadest sense to describe a cargo molecule associated with a particle such that the particle and its cargo molecule move substantially together as one unit when in bulk solution. Thus, the cargo molecule may be fully encapsulated in the interior (i.e. within the lumen) of the particle, substantially encapsulated in the interior of the particle, or partially encapsulated in the interior of the particle. Alternatively, or in addition, the cargo molecule may be present on the surface (i.e. outside) of the particle. The cargo molecule may thus be inside and / or outside the particle. When the cargo molecule is inside the particle, it may also be possible to reduce or eliminate recognition by the innate immune system of the cargo molecule and thus reduce or eliminate acute inflammatory responses associated with the naked delivery of the cargo molecule.

[0166] The particle or population of particles may be used in a method of delivering the cargo molecule in vitro, in vivo, and / or in situ, such as delivering the cargo molecule to a cell and / or extracellular matrix of a tissue. The cargo molecule may be exogenous to the particle (i.e. an exogenous cargo molecule that is not naturally associated with the particle), or endogenous to the particle (i.e. an endogenous cargo molecule that is naturally associated with the particle).

[0167] The cargo molecule may be added to an isolated particle or population thereof. The cargo molecule may be selected from any suitable molecule. For example, the cargo molecule may be selected from one or more of a therapeutic cargo, a peptide and / or protein, an enzyme, a nuclease, a CRISPR-associated protein (Cas) such as SaCas9, SpCas9, Cas9, Cas 12, Cas 13 and variants and fusions thereof, a Transcription activatorlike effector nucleases (TALEN) and variants and fusions thereof, a meganuclease and variants and fusions thereof, a zinc finger nuclease and variants and fusions thereof, an antibody and / or antigen-binding variant or fragment thereof, a single chain variable fragment (scFv), VHH, a nanobody, a nucleic acid-binding protein and / or peptide, a RNA-and / or DNA-binding protein, a small molecule drug, a nucleic acid, a nucleic acid analogue, an unnatural nucleic acid, gRNA, miRNA, shRNA, siRNA, piRNA, PMO, DNA and a DNA plasmid encoding a therapeutic peptide and / or protein such as chlorotoxin, and a chemotherapeutic agent. In a preferred embodiment, the cargo molecule has therapeutic utility.The cargo molecule may alternatively or in addition be selected from enzymes, receptors such as decoy receptors, membrane proteins, transporters, cytokines, antigens, neoantigens, immune effector molecules, ribonuclear proteins, nucleic acid binding proteins, antibodies, nanobodies, antibody fragments, antibody-drug conjugates, gene editing proteins such as CRISPR effector proteins including Cas proteins, transcription activator-like effector nucleases (TALENs), meganucleases.

[0168] The cargo molecule may alternatively or in addition be selected from antibodies, intrabodies, nanobodies, single chain variable fragments (scFv), VHHs, affibodies, bi- and multispecific antibodies or binders including bispecific T-cell engagers (BiTEs), receptors, ligands, transporters, enzymes for e.g. ERT or gene editing, tumour suppressors, viral or bacterial inhibitors, cell component proteins, DNA repair inhibitors, nucleases, proteinases, integrases, transcription factors, growth factors, apoptosis inhibitors and inducers, toxins (for instance pseudomonas exotoxins), structural proteins, neurotrophic factors such as NT3 / 4, brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) and its individual subunits such as the 2.5S beta subunit, ion channels, membrane transporters, proteostasis factors, proteins involved in cellular signalling, translation- and transcription related proteins, nucleotide binding proteins, protein binding proteins, lipid binding proteins, glycosaminoglycans (GAGs) and GAG-binding proteins, metabolic proteins, cellular stress regulating proteins, inflammation and immune system regulating proteins such as cytokines and inhibitors of such cytokines (cytokines may include: CXCL8, GMCSF, interleukins including: IL-1 family, IL-2, IL-4, IL-6, IL-6-like, IL-9, IL-10, IL12, IL-13, IL- 17, Interferons including INF-alpha / beta / gamma, TNF family members, CD40 and CD40L, TRAIL, and TGF-beta family) mitochondrial proteins, and heat shock proteins, etc. The cargo protein may be a reporter protein such as green fluorescent protein (GFP) or nanoLuc. In one embodiment, the encoded protein is a CRISPR-associated (Cas) polypeptide (such as Cas9) with intact nuclease activity which is associated with (i.e. carries with it) an RNA strand that enables the Cas polypeptide to carry out its nuclease activity in a target cell once delivered by the peptide. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) components according to the present invention include CRISPR components that are derived from any bacterial source. The CRISPR components may come from class 1 or class 2, specifically the Cas type may be Cas type I, II, III, IV, V or VI. The specific Cas protein may be Cas9, Cas 12 (Cas 12a or Cas 12b), C2c2, Cpfl, CaslO, Cas 13 (cas 13 a, Cas 13b or Cas 13c), Cas3, a Cas 14 protein, a CasXprotein, or a CasY protein, CasMINI, or SuperFi-Cas9. The CRISPR protein may be a CRISPR nuclease, a CRISPR nickase, or a nuclease deficient CRISPR variant.

[0169] Alternatively, in another embodiment, the Cas polypeptide may be catalytically inactive, to enable targeted genetic engineering. Yet another alternative may be any other type of CRISPR effector such as the single RNA guided endonuclease Cpf 1.

[0170] The cargo molecule may alternatively or in addition be selected from the group comprising enzymes or transporters for lysosomal storage disorders, for instance glucocerebrosidases such as imiglucerase, alpha-galactosidase, alpha-L-iduronidase, iduronate-2-sulfatase and idursulfase, aryl sulfatase, galsulfase, acid-alpha glucosidase (GAA), sphingomyelinase, galactocerebrosidase, galactosylceramidase, ceramidase, alpha-N-acetylgalactosaminidase, beta-galactosidase, lysosomal acid lipase, acid sphingomyelinase, NPC1, NPC2, heparan sulfamidase, N-acetylglucosaminidase, heparan-a-glucosaminide-N-acetyltransferase, N-acetylglucosamine 6-sulfatase, galactose-6-sulfate sulfatase, galactose-6-sulfate sulfatase, hyaluronidase, alphaN -acetyl neuraminidase, GlcNAc phosphotransferase, mucolipinl, palmitoylprotein thioesterase, tripeptidyl peptidase I, palmitoyl-protein thioesterase 1, tripeptidyl peptidase 1, battenin, linclin, alpha-D-mannosidase, beta-mannosidase, aspartylglucosaminidase, alpha-L-fucosidase, cystinosin, cathepsin K, sialin, LAMP2, and hexoaminidase.

[0171] The cargo molecule may alternatively or in addition be selected from the group comprising enzymes associated with Urea cycle disorders including N- Acetylglutamate synthase, carbamoyl phosphate synthetase, ornithine transcarbamoylase, argininosuccinic acid synthase, argininosuccinic acid lyase, arginase, mitochondrial ornithine transporter, citrin, y+L amino acid transporter 1, uridine monophosphate synthase UMPS.

[0172] The cargo molecule may be e.g. an intracellular protein that modifies inflammatory responses, for instance epigenetic proteins such as methylases and bromodomains, or an intracellular protein that modifies muscle function, e.g. transcription factors such as MyoD or Myf5, proteins regulating muscle contractility e.g. myosin, actin, calcium / binding proteins such as troponin, or structural proteins such as Dystrophin, mini-dystrophin, micro-dystrophin, utrophin, titin, nebulin, dystrophin-associated proteins such as dystrobrevin, syntrophin, syncoilin, desmin, sarcoglycan, dystroglycan, sarcospan, agrin, and / or fukutin. The cargo is typically a protein or peptide of human origin unless indicated otherwise by their name, any other nomenclature, or as known to a person skilled in the art, and they can be found in various publicly available databases such as Uniprot, RCSB, etc.The cargo molecule may alternatively or in addition be an antigen / neoantigen, optionally wherein the antigen / neoantigen is suitable for use in cancer immunotherapy. Any antigen / neoantigen may be incorporated into the particle of the present invention. The antigens may be suitable for raising immune responses against pathogens such as bacteria, viruses, funguses or the antigen may be a tumour antigen useful in eliciting an immune response against a tumour for cancer immunotherapy. There may be one or more antigens / neoantigens present in any particle according to the invention.

[0173] Where the cargo molecule is a genetic cargo molecule such as a nucleic acid, the cargo molecule may have utility in gene therapy and / or gene editing. Nucleic acids are routinely used in gene therapy for the replacement of non-functional genes and for neutralization of disease-causing mutations via RNA interference (RNAi) effector molecules such as miRNAs, shRNAs and siRNAs. Exemplary genetic material cargos include: messenger RNA (mRNA), circular mRNA, Doggybone® DNA (dbDNA®), linear DNA, circular DNA, plasmid DNA, linear RNA, circular RNA, self-amplifying RNA or DNA, a viral genome either “naked” or within a capsid or a modified version of any of the above. As naked DNA and RNA are difficult to deliver in vivo due to rapid clearance, nucleases, lack of organ-specific distribution and low efficacy of cellular uptake, specialized gene delivery vehicles, such as viral vectors and cationic liposomes, are usually used for delivery. Loading particles with genetic material cargo has a number of advantages, such as overcoming mutagenic integration associated with viruses such as lentiviruses; and inflammatory toxicity and rapid clearance associated with liposomes.

[0174] The genetic material to be loaded into the particle is chosen on the basis of the desired effect of that genetic material on the cell into which it is intended to be delivered and the mechanism by which that effect is to be carried out. For example, the genetic material may be useful in gene therapy, for example in order to express a desired gene in a cell or group of cells. Such genetic material is typically in the form of plasmid DNA or viral vector encoding the desired gene and operatively linked to appropriate regulatory sequences such as promoters, enhancers and the like such that the plasmid DNA is expressed once it has been delivered to the cells to be treated. Exemplary viral cargos include: a viral vector which is an AAV vector or a lentiviral vector. In some embodiments, the viral vector is an AAV vector. In some embodiments, the AAV vector comprises a capsid from human AAV serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10, AAV11 or AAV12. In some embodiments, theAAV vector comprises an AAV viral genome comprising inverted terminal repeat (ITR) sequences from human AAV serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, r AAV10. In some embodiments, the AAV capsid and the AAV ITR are from the same serotype or from different serotypes. In some embodiments the viral vector comprises a viral capsid and a viral genome, the viral genome comprising one or more heterologous transgenes. In preferred embodiments, the heterologous transgene encodes a polypeptide or protein. The protein encoded with in the viral genome may be any one of the protein cargos according to the invention allowing the viral cargo to act as a gene replacement therapy.

[0175] Examples of diseases susceptible to gene therapy include genetic diseases such as haemophilia B (Factor IX), cystic fibrosis (CTFR), Phenylketonuria (PKU), ALS and spinal muscular atrophy (SMN-1).

[0176] Genetic material can also be used in gene silencing. Such gene silencing may be useful in therapy to switch off aberrant gene expression or in animal model studies to create single or more genetic knock outs. Typically, such genetic material is provided in the form of siRNAs.

[0177] Genetic material can also be used for example in immunisation to express one or more antigens against which it is desired to produce an immune response. Thus, the nucleic acid cargo to be loaded into the particle can encode one or more antigens against which is desired to produce an immune response, including but not limited to tumour antigens, antigens from pathogens such as viral, bacterial or fungal pathogens.

[0178] Genetic material, for example nucleic acid cargo molecules and / or nucleic acid that may be bound to a RNA / DNA binding protein or exogenously loaded into the particle may in addition be selected from the group comprising shRNA, siRNA, saRNA, miRNA, an anti-miRNA, mRNA, modified mRNA, gRNA, pri-miRNA, pre-miRNA, circular RNA, piRNA, tRNA, rRNA, snRNA, IncRNA, ribozymes, mini -circle DNA, plasmid DNA, RNA / DNA vectors, trans-splicing oligonucleotides, splice-switching oligonucleotides, CRISPR guide strands, morpholinos (PMO) antisense oligonucleotides (ASO), peptidenucleic acids (PNA), a viral genome and viral genetic material (for instance a naked AAV genome), but essentially any type of nucleic acid molecule can be delivered by the particles of the present invention. Both single-stranded and double-stranded nucleic acid molecules are within the scope of the present invention, and the nucleic acid molecule may be naturally occurring (such as RNA or DNA) or may be a chemically synthesised RNAand / or DNA molecule which may comprise chemically modified nucleotides such as 2’-O-Me, 2’-O- Allyl, 2’-0-M0E, 2’-F, 2’-CE, 2’-EA 2’-FANA, LNA, CLNA, ENA, PNA, phosphorothioates, tricyclo-DNA, thionucleotides, phosphorami date, PNA, PMO, etc.

[0179] The cargo molecule, such as the genetic material, may be modified. For example, the genetic cargo molecule may comprise: (i) single stranded 2’-O-methyl ribose modifications, single stranded 2’ methoxy-ethyl backbone chemistry, single stranded phosphoroamidate backbone chemistry, single stranded methylphosphonate backbone chemistry and / or single stranded phospohorothioate backbone chemistry; (ii) antisense modified oligonucleotides, antisense modified oligonucleotides comprising 2’-0-Me ribose modifications, antisense modified oligonucleotides comprising peptide nucleic acids, antisense modified oligonucleotides designed to induce exon skipping, antisense modified oligonucleotides which inhibit hairpin loops, and / or trans-splicing antisense modified oligonucleotides; and / or (iii) unnatural oligonucleotides selected from 2’-0-Me ribose modified oligonucleotides, morpholino, thio-nucleotides, chemically modified siRNAs and / or peptide nucleic acids.

[0180] The cargo molecule may be a small molecule. Non-limiting examples of small molecules include anticancer agents such as doxorubicin, methotrexate, 5 -fluorouracil or other nucleoside analogues such as cytosine arabinoside, proteasome inhibitors such as bortezomib, or kinase inhibitors such as imatinib or seliciclib, or NSAIDs such as naproxen, aspirin, or celecoxib, antibiotics such as heracillin, or antihypertensives such as ACE inhibitors such as enalapril, ARBs such as candesartan, cyclic dinucleotides, etc. The present invention is naturally applicable also to other small molecules without departing from the gist of the invention, as would be clear to a person skilled in the art.

[0181] The cargo molecule may be present in the particle, or each particle in a population of particles, at a copy number per particle of at least 1, at least 2, at least 5, at least 10, at least 25, at least 50, at least 100, at least 500, at least 1000, at least 10000 or at least 100000. Thus, the particle may have 1-2, 1-5, 1-10, 1-25, 1-50, 1-100, 1-500, 1-1000, 1-10000, 1-100000, 2-5, 2-10, 2-25, 2-50, 2-100, 2-500, 2-1000, 2-10000, 2-100000, 5-10, 5-25, 5-50, 5-100, 5-500, 5-1000, 5-10000, 5-100000, 10-25, 10-50, 10-100, 10-500, 10-1000, 10-10000, 10-100000, 25-50, 25-100, 25-500, 25-1000, 25-10000, 25-100000, 50-100, 50-500, 50-1000, 50-10000, 50-100000, 100-500, 100-1000, 100-10000, 100-100000, 500-1000, 500-10000, 500-100000, 1000-10000, 1000-100000 or 10000-100000 copies of each cargo molecule per particle, or per each particle in a population of particles.Production and Isolation Methods

[0182] Provided is a method of producing and / or isolating a particle or population of particles as defined above. The particle or population thereof may be produced and / or isolated from a cell (a producer cell), a cell culture medium, a cell lysate and / or a physiological fluid. The producer cell may be modified to express the core, shell, moiety and / or cargo molecule according to the invention. Therefore, provided is a method of producing a modified cell capable of producing the particle according to the invention, the method comprising introducing into the cell a nucleotide sequence encoding the core, shell, moiety and / or cargo molecule.

[0183] The particle or population thereof may be produced and / or isolated without the need for a producer cell, for example by synthetic means.

[0184] Suitable cells for production of particles will be apparent to the skilled person. Any particle-producing cell can be utilized. Suitable physiological fluids from which particles can be isolated will also be apparent to the skilled person. Particles can be collected from a cell culture medium, a cell lysate and / or a physiological fluid by any suitable method. Particles may be isolated from a suitable cell bank. Alternatively, particles may be isolated from any autologous patient-derived, heterologous haplotype-matched or heterologous stem cells so to reduce or avoid the generation of an immune response in a patient to whom the particles are delivered.

[0185] Examples of producer cells include a somatic cell, a germ cell, a muscle cell, a neural cell, an endothelial cell, a polarised cell, HEK-293T, HeLa, MSC, A549, C2C12, HMEC-1, HUVEC, PANCI, U373 or a T cell such as a resting CD4+ or CD8+ T cell, an activated CD4+ or CD8+ T cell, a cytotoxic T cell, a CD3+ cell, a Natural Killer (NK) cell a U20S cell or a CHO cell. In one embodiment, the producer cell is selected from one or more of HEK-293T, HeLa, MSC and A549 cells.

[0186] Examples of physiological fluids include saliva, cerebrospinal fluid, urine, blood, synovial fluid, amniotic fluid, pericardial fluid, peritoneal, pleural fluid, vaginal discharge, bile, milk, semen, aqueous humour, faeces, interstitial fluid, plasma, perspiration, tears, fluids containing visible blood, lymph, menstrual fluid, mucus and pus. In one embodiment, the physiological fluid is selected from one or more of plasma, blood, urine, bile, saliva, interstitial fluid and cerebrospinal fluid.Also provided is a method of isolating the particle or population thereof according to the invention. The particle or population thereof may be isolated from a cell, cell lysate, conditioned media, and / or physiological fluid. The isolation method may comprise:

[0187] (a) providing the cell in a liquid suspension, cell lysate, the conditioned media, and / or the physiological fluid;

[0188] (b) centrifuging and / or filtering the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid, to form a cell-free and debris-free liquid; and / or

[0189] (c) centrifuging and / or filtering the cell-free and debris-free liquid to collect the particle.

[0190] The cell may be a cell as defined above. Alternatively or additionally, the cell lysate, conditioned media and / or physiological fluid may be from a cell as defined above.

[0191] The isolation method may not comprise one or more of ultracentrifugation, size exclusion chromatography and ultrafiltration. Alternatively or additionally, the isolation method may comprise a step of precipitation, such as PEG precipitation.

[0192] The isolation method may comprise one or more of the following steps (I) to (IV). (I) Using or obtaining the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid, and centrifuging the in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid. Centrifugation may take place at about 100g, about 250g, about 500g, about 1000g, about 2500g, about 5000g or about 10000g to provide a cell-free and debris-free liquid. Centrifugation may take place at 100g-250g, 100g-500g, 100g- 1000g, 100g-2500g, 100g-5000g, 100g- 10000g, 250g-500g, 250g-1000g, 250g-2500g, 250g-5000g, 250g-10000g, 500g-1000g, 500g-2500g, 500g-5000g, 500g-10000g, 1000g-2500g, 1000g-5000g, 1000g-10000g, 2500g-5000g, 2500g-10000g or 5000g- 10000g. Differential centrifugation may be used.

[0193] (II) The cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid may be filtered such as by size exclusion chromatography, tangential flow filtration and / or spin filtration, to form a cell-free and debris-free liquid. Appropriate size filters may be selected (for example, filters with a molecular weight cut-off filter for 1000 kDa, 300kDa, 100 kDa, lOkDa or 1 kDa.

[0194] (III) The cell-free and debris-free liquid may be subjected to iodixanol density gradient centrifugation. Iodixanol density gradient centrifugation is a technique used to separate biological particles, like viruses, organelles, or cells, based on their density, usinga gradient of iodixanol solutions in a centrifuge. A density gradient is created by layering iodixanol solutions of varying concentrations in a centrifuge tube. The sample containing the particles to be separated is placed on top of the gradient. The tube is then centrifuged, and the particles migrate through the gradient based on their density, with denser particles settling to the bottom of the tube. After centrifugation, the gradient is fractionated, and the fractions containing the separated particles are collected. Advantages of iodixanol include that it is biocompatible, non-toxic, non-ionic, and isosmotic, making it suitable for isolating biological and biological-related samples. Stable gradients are formed that are easier to prepare than, for example, sucrose gradients. The technique is versatile and can be used for separating a wide range of biological particles, including viruses, organelles, cells, and macromolecules. It is also relatively rapid unlike conventional methods that require prolonged ultracentrifugation time, salt density adjustment, or dialysis. A iodixanol density gradient of between 1% and 80% may be used. For example, a density gradient between l%-3%, l%-6%, 1%-12%, 1%-14%, 1%-16%, 1%-18%, l%-25%, 1%-40%, l%-60%, l%-70%, l%-80%, 3%-6%, 3%-12%, 3%-14%, 3%-16%, 3%-18%, 3%-25%, 3%-40%, 3%-60%, 3%-70%, 3%-80%, 6%-12%, 6%-14%, 6%-16%, 6%-18%, 6%-25%, 6%-40%, 6%-60%, 6%-70%, 6%-80%, 12%-14%, 12%-16%, 12%-18%, 12%-25%, 12%-40%, 12%-60%, 12%-70%, 12%-80%, 14%-16%, 14%-18%, 14%-25%, 14%-40%, 14%-60%, 14%-70%, 14%-80%, 16%-18%, 16%-25%, 16%-40%, 16%-60%, 16%-70%, 16%-80%, 18%-25%, 18%-40%, 18%-60%, 18%-70%, 18%-80%, 25%-40%, 25%-60%, 25%-70%, 25%-80%, 40%-60%, 40%-70%, 40%-80%, 60%-70%, 60%-80% and 70%-80%. In one preferable embodiment, the iodixanol density gradient is between 6% and 60%. Any one of the discrete percentage iodixanol concentrations may be repeated. For example, the tube may comprise twelve fractions as follow from top to bottom before centrifugation: faction 1 - sample; fraction 2 - 6%; fraction 3 - 12%; fraction 4 - 14%; fraction 5 - 16%; fraction 6 - 18%; fraction 7 - 25%; fraction 8 - 25%; fraction 9 - 40%: fraction 10 - 40%; fraction 11 - 60%; and fraction 12 - 60%. The particle of the invention may be collected from the 25% and / or 60% iodixanol fractions.

[0195] (IV) Ca2+ may be added to the cell-free and debris-free liquid and / or to the collected particle. The presence of Ca2+ may stabilise the particle, shell and / or core. Ca2+ may be present at a concentration of about 0. ImM, about 0.5mM, about 0.9mM, about 1,2mM, about 2mM, about 5mM or about 9mM. Thus, Ca2+ may be present at a concentration of 0.1mM-0.5mM, 0.1mM-0.9mM, 0.1mM-1.2mM, 0.1mM-2mM, O.lmM-5mM, 0.1mM-9mM, 0.5mM-0.9mM, 0.5mM-1.2mM, 0.5mM-2mM, 0.5mM-5mM, 0.5mM-9mM, 0.9mM-1.2mM, 0.9mM-2mM, 0.9mM-5mM, 0.9mM-9mM, 1.2mM-2mM, 1.2mM-5mM, 1.2mM-9mM, 2mM-5mM, 2mM-9mM, and 5mM-9mM. In one preferable embodiment, Ca2+ is present at a physiological concentration, such as a concentration of about 0.9mM. The amount of calcium during and after purification may be proportional to the amount of starting material (as the particle components will get concentrated into a small volume). The proteimion (i.e. Ca2+ ion) ratios may change during the method or remain the same or substantially the same during the method.

[0196] The isolation method may comprise one or more of the following:

[0197] (a) contacting the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid with a substrate, wherein the particle adheres to the substrate, optionally wherein the cell also adheres to the substrate;

[0198] (b) washing the substrate to leave the particle adhered to the substrate; and (c) collecting the particle by eluting the particle from the substrate;

[0199] The cell may be a cell as defined above. Alternatively or additionally, the cell lysate, conditioned media and / or physiological fluid may be from a cell as defined above. The substrate may be separation beads or a lipid bilayer, such as a supported lipid bilayer (SLB). The step of eluting the particles from the substrate may comprise washing the substrate with a solvent comprising an agent capable of detaching the particle from the substrate in order to obtain an eluate of the particle, optionally wherein the agent is imidazole.

[0200] Isolated particles may be further purified, concentrated and / or diluted as appropriate.The isolated particle may already represent, either in whole or in part, the particles comprised in the compositions of the invention, for example due to the endogenous expression in the host cell of the cargo molecule. Alternatively or in addition, isolated particles may be manipulated to produce the particles comprised in the compositions of the invention, for example through the addition of additional molecules.

[0201] Thus the composition of the invention may be produced by transforming, transfecting and / or transducing a host cell with a nucleic acid construct encoding a moiety and / or a cargo molecule as defined above. The nucleic acid construct is then expressed in the host cell allowing particles to be obtained from the host cell. The nucleic acid construct may be transiently and / or stably introduced into the host cell. Stable introduction of the nucleic acid construct may be preferable.

[0202] Alternatively, or in addition, a particle may be obtained, for example from one or more host cell (i.e. producer cell), and one or more component of the invention introduced exogenously, for example by electroporation and / or transfection. For example, a nucleic acid cargo molecule produced by cell-free syntheses may be electroporated and / or transfected into the particle.

[0203] The host cell may be cultured. As used herein, “cultured” is to be construed broadly as any method by which any cell is sustained and / or grown. Typically, cells will be cultured under controlled conditions that would be apparent and / or can be determined by the skilled person. Alternatively, or additionally, cells may be “maintained”, meaning that defining characteristics of the cell are not altered. For example, a maintained stem cell would not differentiate. Alternatively, or additionally cells may be “expanded” meaning that the number of cells is increased. When being expanded, cells may maintain their defining characteristics or acquire new defining characteristics (for example, if during expansion, the cell also differentiates). When being cultured, maintained and / or expanded, cells may be passaged as necessary. Passaging comprises replenishing the culture medium with new culture medium, for example as components in the culture medium are used up and / or degrade. Passaging may involve adding new culture medium without removing the old culture medium. Passaging may also involve removal of some or all of the culture medium, and adding new culture medium. Cells may also be transferred from a previous culture vessel to a new culture vessel during passaging. During passaging, a medium having the same composition may be used. Alternatively, a medium having a different composition may be used (i.e. the media switched in whole or in part). Therefore, duringpassaging, any of the components in the culture medium may be replenished. The cells described herein may be cultured, maintained and / or expanded under adherent conditions (i.e. being attached to a solid support) or suspension conditions (i.e. as a colloid in the culture medium).

[0204] The cell may be cultured for: 1-2 days, 1-5 days, 1-7 days, 1-10 days, 1-12 days, 1-14 days, 1-20 days, 1-30 days, 2-5 days, 2-7 days, 2-10 days, 2-12 days, 2-14 days, 2-20 days, 2-30 days, 5-7 days, 5-10 days, 5-12 days, 5-14 days, 5-20 days, 5-30 days, 7-10 days, 7-12 days, 7-14 days, 7-20 days, 7-30 days, 10-12 days, 10-14 days, 10-20 days, 10-30 days, 12-14 days, 12-20 days, 12-30 days, 14-20 days, 14-30 days, or 20-30 days. The cell may be cultured for at least 1 day, at least 2 days, at least 5 days, at least 7 days, at least 10 days, at least 12 days, at least 14 days, at least 20 days, or at least 30 days.

[0205] The host cell may be cultured in a bioreactor, such as a hollow-fibre bioreactor, to produce a conditioned media and the particle obtained from the conditioned media. The use of a bioreactor to culture the host cell may allow for the generation of a large quantities of particle-containing conditioned media. Optionally, the particles may be purified from the conditioned media using one or more of liquid chromatography, tangential flow filtration, ultracentrifugation (UC), density-gradient separation, antibody precipitation, polymer precipitation and the purification methodology set out in the previous section.

[0206] Thus, a further advantage of the present invention is that the particle composition may be produced with minimal steps. For example, no further substantive processing of the particle may be necessary following isolation of the particle from a host cell.

[0207] Alternatively, it may be possible to load an isolated particle with, for example a cargo molecule, in a single step, for example by transfecting an isolated particle with a cargo molecule. In such a way, the invention also provides a platform technology in which a desired particle composition can be quickly, efficiently and robustly produced by selecting appropriate components from a previously generated particle producing host cells and / or particles, and additional components such as desired cargo molecules. The particleproducing host cells, particles and additional components such as desired cargo molecules may be selected from a previously generated library.

[0208] When a population of particles is produced, at least 5%, at least 10%, at least 20%, at least 50%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and / or at least 95% of all particles in the population may possess the desired structural characteristics. Alternatively or additionally, when a population of particles is produced, atleast 5%, at least 10%, at least 20%, at least 50%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and / or at least 95% of all particles in the population may possess the desired functional characteristics.

[0209] A moiety and / or cargo may be passively loaded into particles or actively loaded by exogenous loading methods as described. The moiety and / or cargo may be loaded passively into the particles by the therapeutic cargo being present in the cytosol of the particle-producing cells. Such passive loading applies, for instance, to nucleic acids, small molecules, viruses, soluble proteins or membrane proteins that are naturally loaded into the particles. In certain embodiments the moiety and / or cargo is actively loaded into the particles of the present invention. One form of active loading of cargos involves exogenous active loading which involves cargo being loaded using any known exogenous loading method including: electroporation, transfection with transfection reagents such a cationic transfection agents, lipofectamine, conjugation of the cargo to a membrane anchoring moiety such as a lipid or cholesterol tail or loading by means of a cell penetrating peptide (CPP), either in the form of a CPP-cargo conjugate or in the form of a CPP-cargo non-covalent complex or any combination of these methods. Again, this type of active loading may result in the moiety and / or cargo being located on the inside of the particle, on the outside of the particle or located within the membrane of the particle. Any of the moieties and / or cargos as defined above may be loaded exogenously.

[0210] Also provided is a particle or population of particles obtained or obtainable by the method of the invention. In one preferable embodiment, the particle or population of particles is not cytotoxic. The particle or population of particles may not be cytotoxic due to the absence of cytotoxic activity of the particle(s) per se (i.e. the absence of cytotoxic activity of the particle(s) themselves minus any cargo). The particle or population of particles may modulate the growth of a cell, such as a target cell, for instance through sequestration and / or delivery of growth factors and / or cytokines. Modulation may be taken to mean promoting or inhibiting the growth of a cell, such as promoting or inhibiting the growth of a target cell. Modulation of the growth of a cell may be due to the particle per se and / or due to the cargo.

[0211] Compositions and Therapeutic ApplicationsCompositions of the invention comprise at least one particle, or population of particles, as set out in other sections of this disclosure. The compositions may be pharmaceutical composition, substantially devoid of aggregates of particles of the invention, substantially devoid of extracellular vesicles, and / or comprise a homogenous or substantially homogenous population of particles of the invention.

[0212] The compositions of the invention may themselves be used for therapeutic applications, and / or for targeted delivery of a cargo molecule. In addition, the compositions of the invention may be used as a research tool, a diagnostic tool, an imaging tool, biological reference material, an experimental control and / or an experimental standard, optionally wherein the particle or composition is immobilised to a solid support.

[0213] Compositions comprising particles of the invention, including particles that are and that are not loaded with a cargo molecule, may be useful for vaccination, treating immune-privileged sites such as the eye, delivering a cargo molecule across the blood brain barrier, treating acute conditions such as severe combined immunodeficiency and treating chronic conditions such as myotonic dystrophy.

[0214] The use of the compositions to deliver a cargo molecule offers a number of advantages over conventional means of delivering cargo molecules. For example, when a cargo molecule is delivered using a composition of the invention, it may be protected from degradation and may be more stable; a cargo molecule may be delivered to a target tissue, such as a specific type of cancer, more efficiently and / or more specifically than if not associated with a particle of the invention. In addition, the cargo molecule may be less likely to elicit an immune response when contained within the particles as it is not freely available for detection by immune cells and / or binding to antibodies. Other advantages of the use of compositions of the invention to deliver cargo molecules include avoiding drug resistance, such as the upregulation of drug transporters such as ABC-transporters, rapid tissue internalisation, single particle uptake, wide therapeutic index, broad biodistribution and good bioavailability.

[0215] The compositions of the invention may be loaded with any cargo molecule that has utility in the treatment and / or prevention of a condition, disease or disorder. The cargo molecule to be loaded into or on the particle is chosen on the basis of the desired effect on the cell and / or tissue into which it is intended to be delivered and the mechanism by which that effect is to be carried out. A single cargo molecule may be incorporated into or on the particle. Alternatively, more than one cargo molecule may be incorporated into or on theparticle. The more than one cargo molecules may act on the same or different targets to bring about their therapeutic and / or preventative effect.

[0216] The cargo molecule loaded into the composition may be a cargo molecule that is not used to generate an immune response. The cargo molecule may be selected to provide a therapeutic benefit itself, and is not intended to be used to generate an immune response against the cargo molecule. The cargo molecule to be incorporated into the composition may be useful, for example, in the prophylaxis and / or treatment and / or alleviation of a variety of diseases and conditions, typically via the delivery of essentially any type of drug cargo, such as for instance mRNA, antisense or splice-switching oligonucleotides, siRNA, pDNA, peptides, proteins, antibodies, antibody-drug conjugates, gene editing technology such as CRISPR-Cas9, TALENs, meganucleases, or vesicle-based cargos such as viruses (e.g. AAVs, lentiviruses, etc.) or EVs (exosomes, microvesicles and the like). Nonlimiting examples of diseases and conditions that are suitable targets for treatment using the composition herein include the following non-limiting examples: Crohn’s disease, ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, sarcoidosis, idiopathic pulmonary fibrosis, psoriasis, tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), deficiency of the interleukin- 1 receptor antagonist (DIRA), endometriosis, autoimmune hepatitis, scleroderma, myositis, stroke, acute spinal cord injury, vasculitis, Guillain-Barre syndrome, acute myocardial infarction, ARDS, sepsis, meningitis, encephalitis, liver failure, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), kidney failure, heart failure or any acute or chronic organ failure and the associated underlying aetiology, graft-vs-host disease, Duchenne muscular dystrophy and other muscular dystrophies, In-born errors of metabolism including: Disorders of carbohydrate metabolism e.g., G6PD deficiency galactosemia, hereditary fructose intolerance, fructose 1,6-diphosphatase deficiency and the glycogen storage diseases, Disorders of organic acid metabolism (organic acidurias) such as alkaptonuria, 2-hydroxy glutaric acidurias, methylmalonic or propionic acidemia, multiple carboxylase deficiency, Disorders of amino acid metabolism such as phenylketonuria, maple syrup urine disease, glutaric acidemia type 1, Aminoacidopathies e.g., hereditary tyrosinemia, nonketotic hyperglycinemia, and homocystinuria, Hereditary tyrosinemia, Fanconi syndrome, Primary Lactic Acidoses e.g., pyruvate dehydrogenase, pyruvate carboxylase and cytochrome oxidase deficiencies, Disorders of fatty acid oxidation and mitochondrial metabolism such as short, medium, andlong- chain acyl-CoA dehydrogenase deficiencies also known as Beta-oxidation defects, Reye’s syndrome, Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD.), MELAS, MERFF, pyruvate dehydrogenase deficiency, Disorders of porphyrin metabolism such as acute intermittent porphyria, Disorders of purine or pyrimidine metabolism such as Lesch-Nyhan syndrome, Disorders of steroid metabolism such as lipoid congenital adrenal hyperplasia, congenital adrenal hyperplasia, Disorders of mitochondrial function such as Kearns-Sayre syndrome, Disorders of peroxisomal function such as Zellweger syndrome and neonatal adrenoleukodystrophy, congenital adrenal hyperplasia or SmithLemli-Opitz, Menkes syndrome, neonatal hemochromatosis, Urea cycle disorders such as N-Acetylglutamate synthase deficiency, carbamoyl phosphate synthetase deficiency, ornithine transcarbamoylase deficiency, citrullinemia (deficiency of argininosuccinic acid synthase), argininosuccinic aciduria (deficiency of argininosuccinic acid lyase), argininemia (deficiency of arginase), hyperomithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (deficiency of the mitochondrial ornithine transporter), citrullinemia II (deficiency of citrin, an aspartate glutamate transporter), lysinuric protein intolerance (mutation in y+L amino acid transporter 1, orotic aciduria (deficiency in the enzyme uridine monophosphate synthase UMPS), all of the lysosomal storage diseases, for instance Alpha-mannosidosis, Betamannosidosis, Aspartylglucosaminuria, Cholesteryl Ester Storage Disease, Cystinosis, Danon Disease, Fabry Disease, Farber Disease, Fucosidosis, Galactosialidosis, Gaucher Disease Type I, Gaucher Disease Type II, Gaucher Disease Type III, GM1 Gangliosidosis Type I, GM1 Gangliosidosis Type II, GM1 Gangliosidosis Type III, GM2 - Sandhoff disease, GM2 - Tay-Sachs disease, GM2 -Gangliosidosis, AB variant, Mucolipidosis II, Krabbe Disease, Lysosomal acid lipase deficiency, Metachromatic Leukodystrophy, MPS I -Hurler Syndrome, MPS I - Scheie Syndrome, MPS I Hurler-Scheie Syndrome, MPS II - Hunter Syndrome, MPS IIIA -Sanfilippo Syndrome Type A, MPS IIIB - Sanfilippo Syndrome Type B, MPS IIIB -Sanfilippo Syndrome Type C, MPS IIIB - Sanfilippo Syndrome Type D, MPS IV Morquio Type A, MPS IV - Morquio Type B, MPS IX - Hyaluronidase Deficiency, MPS VI -Maroteaux-Lamy, MPS VII - Sly Syndrome, Mucolipidosis I - Sialidosis, Mucolipidosis IIIC, Mucolipidosis Type IV, Mucopolysaccharidosis, Multiple Sulfatase Deficiency, Neuronal Ceroid Lipofuscinosis Tl, Neuronal Ceroid Lipofuscinosis T2, Neuronal Ceroid Lipofuscinosis T3, Neuronal Ceroid Lipofuscinosis T4, Neuronal Ceroid Lipofuscinosis T5, Neuronal Ceroid Lipofuscinosis T6, Neuronal Ceroid Lipofuscinosis T7, NeuronalCeroid Lipofuscinosis T8, Neuronal Ceroid Lipofuscinosis T9, Neuronal Ceroid Lipofuscinosis T10, Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C, Pompe Disease, Pycnodysostosis, Salla Disease, Schindler Disease and Wolman Disease, etc. cystic fibrosis, primary ciliary dyskinesia, pulmonary alveolar proteinosis, ARC syndrome, Rett syndrome, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, GBA associated Parkinson’s disease, Huntington’s disease and other trinucleotide repeat-related diseases, dementia, ALS, cancer-induced cachexia, anorexia, diabetes mellitus type 2, and various cancers. Virtually all types of cancer are relevant disease targets for the present invention, for instance, Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia, Adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, Anal cancer, Appendix cancer, Astrocytoma, cerebellar or cerebral, Basal -cell carcinoma, Bile duct cancer, Bladder cancer, Bone tumour, Brainstem glioma, Brain cancer, Brain tumour (cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumours, visual pathway and hypothalamic glioma), Breast cancer, Bronchial adenomas / carcinoids, Burkitt's lymphoma, Carcinoid tumour (childhood, gastrointestinal), Carcinoma of unknown primary, Central nervous system lymphoma, Cerebellar astrocytoma / Malignant glioma, Cervical cancer, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Chronic myeloproliferative disorders, Colon Cancer, Cutaneous T-cell lymphoma, Desmoplastic small round cell tumour, Endometrial cancer, Ependymoma, Esophageal cancer, Extracranial germ cell tumour, Extragonadal Germ cell tumour, Extrahepatic bile duct cancer, Eye Cancer (Intraocular melanoma, Retinoblastoma), Gallbladder cancer, Gastric (Stomach) cancer, Gastrointestinal Carcinoid Tumour, Gastrointestinal stromal tumour (GIST), Germ cell tumour (extracranial, extragonadal, or ovarian), Gestational trophoblastic tumour, Glioma (glioma of the brain stem, Cerebral Astrocytoma, Visual Pathway and Hypothalamic glioma), Gastric carcinoid, Hairy cell leukemia, Head and neck cancer, Heart cancer, Hepatocellular (liver) cancer, Hodgkin lymphoma, Hypopharyngeal cancer, Intraocular Melanoma, Islet Cell Carcinoma (Endocrine Pancreas), Kaposi sarcoma, Kidney cancer (renal cell cancer), Laryngeal Cancer, Leukemias ((acute lymphoblastic (also called acute lymphocytic leukemia), acute myeloid (also called acute myelogenous leukemia), chronic lymphocytic (also called chronic lymphocytic leukemia), chronic myelogenous (also called chronic myeloid leukemia), hairy cell leukemia)), Lip and Oral Cavity Cancer,Liposarcoma, Liver Cancer (Primary), Lung Cancer (Non-Small Cell, Small Cell), Lymphomas, Burkitt lymphoma, cutaneous T-Cell lymphoma, Hodgkin lymphoma, NonHodgkin, Medulloblastoma, Merkel Cell Carcinoma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Mouth Cancer, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma / Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic / Myeloproliferative Diseases, Myelogenous Leukemia, Chronic Myeloid Leukemia (Acute, Chronic), Myeloma, Nasal cavity and paranasal sinus cancer, Nasopharyngeal carcinoma, Neuroblastoma, Oral Cancer, Oropharyngeal cancer, Osteosarcoma / malignant fibrous histiocytoma of bone, Ovarian cancer, Ovarian epithelial cancer (Surface epithelial-stromal tumour), Ovarian germ cell tumour, Ovarian low malignant potential tumour, Pancreatic cancer, Pancreatic islet cell cancer, Parathyroid cancer, Penile cancer, Pharyngeal cancer, Pheochromocytoma, Pineal astrocytoma, Pineal germinoma, Pineoblastoma and supratentorial primitive neuroectodermal tumours, Pituitary adenoma, Pleuropulmonary blastoma, Prostate cancer, Rectal cancer, Renal cell carcinoma (kidney cancer), Retinoblastoma, Rhabdomyosarcoma, Salivary gland cancer, Sarcoma (Ewing family of tumours sarcoma, Kaposi sarcoma, soft tissue sarcoma, uterine sarcoma), Sezary syndrome, Skin cancer (nonmelanoma, melanoma), Small intestine cancer, Squamous cell, Squamous neck cancer, Stomach cancer, Supratentorial primitive neuroectodermal tumour, Testicular cancer, Throat cancer, Thymoma and Thymic carcinoma, Thyroid cancer, Transitional cell cancer of the renal pelvis and ureter, Urethral cancer, Uterine cancer, Uterine sarcoma, Vaginal cancer, Vulvar cancer, Waldenstrom macroglobulinemia, Wilms’ tumour, genetic disorders, CNS conditions, neuro-degenerative disorders, liver disorders, heart disorders, Phenylketonuria, heart failure and / or ALS.

[0217] In a preferred embodiment, the disease or condition may be selected from Alzheimer’s disease, autoimmune conditions, cancer such as pancreatic or colorectal cancer, cardiovascular disease, cystic fibrosis, Duchenne muscular dystrophy, haemophilia, Huntington’s disease, lysosomal storage disease, liver disorders, macular degeneration, myotonic dystrophy, neuromuscular disease, Parkinson’s disease, sepsis, spinal muscular atrophy, stroke, genetic disorders, CNS conditions, neuro-degenerative disorders, heart disorders, Phenylketonuria, heart failure or ALS. Alternatively or additionally, the composition of the invention may be used for wound healing, tissue repair, reversing scarring, reversing fibrosis, promoting extracellular matrix normalisation, modulating cellmigration, cell killing in a subject, targeted cell killing in a subject and / or gene therapy and / or gene editing. Alternatively or additionally, the composition of the invention may be used for use in modulating the growth of a cell, such as modulating the growth of a target cell, for instance through sequestration and / or delivery of growth factors and / or cytokines. Modulation may be taken to mean promoting or inhibiting the growth of a cell, such as promoting or inhibiting the growth of a target cell.

[0218] Thus, provided is a composition comprising a particle according to the present invention and at least one pharmaceutically acceptable excipient, for use in a method of therapy in a subject. Also provided is a composition comprising a particle according to the present invention and at least one pharmaceutically acceptable excipient, for use in a method of treating and / or preventing at least one of the therapeutic indications set out above.

[0219] Also provided is the use of a composition comprising a particle according to the present invention and at least one pharmaceutically acceptable excipient for the manufacture of a medicament for therapy. Also provided is the use of a composition comprising a particle according to the present invention and at least one pharmaceutically acceptable excipient, for the manufacture of a medicament for treating and / or preventing at least one of the therapeutic indications set out above.

[0220] Also provided is a method of treatment comprising providing a particle according to the present invention and at least one pharmaceutically acceptable excipient to a patient in need thereof. Also provided is a method of treatment and / or prevention comprising providing a particle according to the present invention and at least one pharmaceutically acceptable excipient to a patient in need thereof, wherein at least one of the therapeutic indications set out above is treated and / or prevented.

[0221] The use in medicine or method of treatment (collectively “the treatment”) may be by delivery of any kind of cargo according to the invention. For instance the treatment may be by delivery of functional proteins as protein replacement therapy, delivery of mRNA encoding for functional proteins to also act as a protein replacement therapy. Such a protein replacement therapy may, for instance, be an enzyme replacement therapy (ERT) for diseases caused by inborn errors in metabolism such as Phenylketonuria, urea cycle disorders, or lysosomal storage disorders. The treatment may be by delivery of: gene silencing RNAs, splice switching RNAs, or CRISPR-Cas9 for gene editing. The treatment may be gene therapy by delivery of plasmid DNA, mini-circles or viral gene therapies suchas AAVs or lentiviruses. The treatment may be by presentation of an antigen or neoantigen for immunotherapy, in effect acting as a vaccine to induce an immune response. For instance the particle may act by delivery and / or presentation of a tumour antigen for cancer immunotherapy, or viral, bacterial or fungal antigens for immunization against pathogens. The treatment may be by delivery of small molecules, antibodies and antibody-drug conjugates capable of mediating a therapeutic effect once delivered into a cell or the extracellular matrix. In one embodiment, the treatment or therapy may be effected by the particles comprising more than one type of therapeutic cargo, i.e. the therapeutic cargo may be a mixture of protein, nucleic acid, virus, viral genome, antigen and / or small molecule.

[0222] Delivery / Administration

[0223] The particle or population of particles of the invention may be administered by any suitable means. Administration to a human or animal subject may be selected from parenteral, intramuscular, intracerebral, intravascular (including intravenous), subcutaneous, intranasal, intracardiac, intracerebroventricular, intraperitoneal or transdermal administration. Typically, the method of delivery is by injection. Preferably the injection is intramuscular or intravascular (e.g. intravenous). A physician will be able to determine the required route of administration for each particular patient.

[0224] The particle or population of particles are preferably delivered as a composition. The composition may be formulated for any suitable means of administration, including parenteral, intramuscular, intracerebral, intravascular (including intravenous), intracardiac, intracerebroventricular, intraperitoneal, subcutaneous, intranasal or transdermal administration. Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. The particle or population of particles of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharmaceutically acceptable carriers or excipients and the like in addition to the particles.

[0225] A "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to a subject. Typical pharmaceutically acceptablecarriers include, but are not limited to, binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc); fillers (e.g. lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc); lubricants (e.g. magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, com starch, polyethylene glycols, sodium benzoate, sodium acetate, etc); disintegrates (e.g. starch, sodium starch glycolate, etc); or wetting agents (e.g. sodium lauryl sulphate, etc).

[0226] The term "excipient" or "carrier" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. The terms encompass any of the agents approved by a regulatory agency such as the FDA or EMEA or listed in the U. S. Pharmacopeia for use in animals, including humans, as well as any carrier or diluent that does not cause significant irritation to a subject and does not abrogate the biological activity and properties of the therapeutic cargo. Included are excipients and carriers that are useful in preparing a pharmaceutical composition and are generally safe and non-toxic.

[0227] Further exemplary excipients include degradation or loss of activity stabiliser excipients such as proteins such as human serum albumin, polyols such as glycerol, sorbitol and erythritol, amino acids such as arginine, aspartic acid, glutamic acid, lysine, proline, glycine, histidine and methionine, polymers such as polyvinylpyrrolidone and hydroxypropyl cellulose, surfactants such as polysorbate 80, polysorbate 20 and pluronicF68, antioxidants such as ascorbic acid and alpha-tocopherol (vitamin E), buffers such as acetate, succinate, citrate, phosphate, histidine, tri s(hydroxymethyl)aminom ethane (TRIS), metal ion / chelators such as Ca2+, Zn2+ and EDTA, Cyclodextrin based such as hydroxypropyl B-cyclodextrin and others such as polyanions and salts, stabilisers or bulking agents such as lactose, trehalose, dextrose, sucrose, sorbitol, glycerol, albumin, gelatin, mannitol and dextran, or preservatives such as benzyl alcohol, m-cresol, phenol, 2-phenoxy ethanol.

[0228] The compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions. Thus, for example, the compositions may contain additional compatible pharmaceutically-active materials or may contain additional materials useful in physically formulating various dosage forms of the composition of present invention, such as dyes, flavouring agents, preservatives,antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions provided herein.

[0229] A therapeutically effective amount of composition is administered. The dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. Optimum dosages may vary depending on the relative potency of individual particles, and can generally be estimated based on EC50s found to be effective in vitro and in in vivo animal models. In general, dosage is from 0.01 mg / kg to 100 mg per kg of body weight. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1 mg / kg to 10 mg / kg of body weight, according to the potency of the specific particles, the age, weight and condition of the subject to be treated, the severity of the disease and the frequency and route of administration. Different dosages of the particle and / or composition may be administered depending on whether administration is by intramuscular injection or systemic (intravenous or subcutaneous) injection. Preferably, the dose of a single intramuscular injection is in the range of about 5 to 20 pg. Preferably, the dose of single or multiple systemic injections is in the range of 10 to 100 mg / kg of body weight.

[0230] It will be clear to the skilled artisan that when describing medical and scientific uses and applications of the particles, the present invention normally relates to a plurality of particles, i.e. a population of particles which may comprise thousands, millions, billions or even trillions of particles. Particles may be present in concentrations such as about 105, 108, 1010, 1011, 1012, 1013, 1014, 1015, 1018, 1025,1030particles per unit of volume (for instance per ml), or any other number larger, smaller or anywhere in between. In the same vein, the term “population”, which may e.g. relate to a particle comprising certain cargo molecules shall be understood to encompass a plurality of entities constituting such a population. In other words, individual particles when present in a plurality constitute a particle population. Thus, naturally, the present invention pertains both to individual particles and populations comprising particles, as will be clear to the skilled person. The dosages of particles when applied in vivo may naturally vary considerably depending on the disease to be treated, the administration route, the activity and effects of the cargomolecule of interest, any targeting moieties present on the particles, the pharmaceutical formulation, etc.

[0231] The composition according to the present invention may be formulated by any known method of formulation including but not limited to

[0232] • Oral formulations - Tablet, Capsule, Sustained release, liquid

[0233] • Intravenous Formulations

[0234] • Parenteral Formulations

[0235] • Topical Formulations - cutaneous administration: cream, ointment, gel, paste, powder

[0236] • Modified release Formulations - sustained release formulation

[0237] • Liquid or lyophilized formulations

[0238] • Nebulized formulations

[0239] Additional routes of administration by which the particles / compositions of the invention may be administered to a human or animal subject include auricular (otic), buccal, conjunctival, cutaneous, dental, electro-osmosis, endocervical, endosinusial, endotracheal, enteral, epidural, extra-amniotic, extracorporeal, hemodialysis, infiltration, interstitial, intra-abdominal, intra-amniotic, intra-arterial, intra-articular, intrabiliary, intrabronchial, intrabursal, intracardiac, intracartilaginous, intracaudal, intracavemous, intracavitary, intracerebral, intracerebroventricular, intracisternal, intracorneal, intracoronal (dental), intracoronary, intracorporus cavernosum, intradermal, intradiscal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralesional, intraluminal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraocular, intraovarian, intraperi cardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intrathecal, intrathoracic, intratubular, intratumour, intratym panic, intrauterine, intravascular, intravenous, intravenous bolus, intravenous drip, intraventricular, intravesical, intravitreal, iontophoresis, irrigation, laryngeal, nasal, nasogastric, occlusive dressing technique, ophthalmic, oral, oropharyngeal, other, parenteral, percutaneous, periarticular, peridural, perineural, periodontal, rectal, respiratory (inhalation), retrobulbar, soft tissue, subarachnoid, subconjunctival, subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transplacental, transtracheal, transtympanic, ureteral, urethral, and / or vaginal administration, and / or any combination of the above administration routes, which typically depends on the disease to be treatedand / or the characteristics of the particles, the cargo molecule in question, or the particle population as such.

[0240] Due to particle clearance (and breakdown of any cargo molecule), the patient may have to be treated repeatedly, for example once or more daily, weekly, monthly or yearly.

[0241] Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the particle in physiological fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy, wherein the particle is administered in maintenance doses, ranging from 0.01 mg / kg to 100 mg per kg of body weight, once or more daily, to once every 20 years. Thus, it is envisaged that any dosage regime would be applicable to the engineered particles of the invention. The dosage regime chosen will depend on the cargo being delivered by the particles and the disease to be treated and any additional therapies being administered which will be determined by the skilled physician. It is envisaged that the particles of the present invention will be administered multiple times, i.e. more than 1 time but normally more than 2 times or for chronic, long-term treatment (i.e. administered tens to hundreds to thousands of times). Preferably, if the cargo is an antigen that is being administered as a vaccine, the immunization schedule will involve two or more administrations of the polypeptide, spread out over several weeks. Similarly, if the cargo is e.g. an RNA agent such as an siRNA or mRNA or a protein such as an antibody or an enzyme or a transporter, the particles comprising the cargo in question will likely be administered more than once, normally multiple times as part of a chronic treatment regimen.

[0242] A composition of the invention may be co-administered with one or more other agent. The one or more other agent may be administered separately to the composition of the invention, at substantially the same time as the composition of the invention, or as a single composition comprising the particle of the invention in combination with the one or more other agent. Thus, combination therapy comprising the particles of the invention and one or more other agent is envisaged. The one or more other agent may be loaded into the particle, for example it may be fully, substantially or partially encapsulated inside the particle, or bound to the surface of the particle. By way of example, the composition of the invention may be co-administered with a cell-penetrating peptide (CCP) to assist intracellular delivery and / or cell-specific targeting.The particle may be particularly suited to the delivery of cargo molecules in vitro and / or in situ. When delivered in situ, the particles are produced in the patient tissue by particle host cells (i.e. producer cells) present in the patient. The host cells present in the patient may have been produced by any suitable methods, and introduced into the patent.

[0243] All of the embodiments and features described herein (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined with any of the above aspects or embodiments in any combination, unless stated otherwise with reference to a specific combinations, for example, combinations where at least some of such features and / or steps are mutually exclusive.

[0244] The following non-limiting examples illustrate the invention.

[0245] Example 1 - Materials and Methods

[0246] Cell Culture

[0247] HEK-293T, HeLa, C2C12 and PANCI cells were cultured in high glucose DMEM (Gibco) supplemented with 10% FBS (Gibco). Myotubes were differentiated from C2C12 by seeding cells at high density while exchanging media for DMEM supplemented with 2% Horse Serum. Cord blood Mesenchymal Stem Cells (MSC(CB)) were cultured in RPMI 1640 (Gibco) supplemented with 4ng / mL Fgf2 and 20% FBS (Gibco) and A549 cells were cultured in Ham’s F-12K (Kaighn’s) Nutrient Mixture supplemented with 15% FBS. HMEC-1 cells were cultured in MCDB131 (without L-glutamine; Gibco) supplemented with lOng / mL EGF, Ipg / mL hydrocortisone, lOmM Glutamine and 10% FBS. HUVEC were cultured in F-12K supplemented with 0. Img / mL heparin, O. Olmg / mL endothelial cell growth supplement (ECGS) and 10% FBS. U373 cells were cultured in EMEM supplemented with 2mM glutamine, 1% non-essential amino acids, ImM sodium pyruvate and 10% FBS. Nalm6 cells were grown in RPMI supplemented with 10% FBA. All cell culture was performed in a humidified incubator at 37°C and 5% CO2.

[0248] T cells were isolated from leukapheresis reduction system (LRS) cones (‘blood cones’) obtained from healthy donors. The Oxford Radcliffe Biobank (ORB) approved access to consented and pseudonymized tissue samples under the ORB research tissuebankNHS REC ethics, reference 19 / SC / 0173. CD8+ T cells were isolated by negative selection (RosetteSep Human CD8+ T cell enrichment cocktail, Stemcell technologies, 15023). CD8+ T cells were then either used as is (resting CD8+ pool) or further differentiated into CTLs using Dynabeads (Thermo, 11132D; antiCD3 / anti-CD28).

[0249] Resting and activated samples were grown in RIO medium (RPMI 1640, Gibco) supplemented with 1% L-Glutamine, 10% FBS, 1% Penicillin-Streptomycin, and 50 Units / mL of recombinant human IL-2 (PeproTech). For CTLs, the Dynabeads were removed after three days and cells were seeded in fresh complete RIO medium at 1E106 cells / mL for two days.

[0250] Primary fibroblast / myofibroblasts were obtained from nodular tissue from patients with Dupuytren’s disease undergoing derma fasciectomy. Tissue samples were dissected into small pieces and digested in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) with type I collagenase 4mg / ml (Worthington Biochemical Corporation) + DNase I (Roche Diagnostics) for up to 3 hours at 37 °C. Digested tissue fragments were filtered through a 70-pm cell strainer, and the cell suspension was centrifuged at 1500 rpm for lOmins, washed a further 2 times in 50mls of DMEM with 5% FBS and 1% penicillinstreptomycin and the isolated cells were cultured in the same media and used until passage 5.

[0251] Generation of Constructs

[0252] Codon-optimized DNA sequences coding for human CD63, human CD81, human CD9, human TSPAN2, human TSPAN14, human PTGFRN, human PTTG1IP, human Lamp2B, human N-transferrinRl, human HSPA8, human HSP90AA1, human N-syntenin, human BASP1, human TSG101 and mClover3 were synthesized (IDT) as gene fragments and cloned downstream of the CMV promoter in a custom lentiviral backbone using PaqCl. All expression cassettes were confirmed by sequencing.

[0253] Generation of Stable Cell Lines

[0254] Lentiviral supernatants were generated by co-transfection of HEK-293T cells with psPAX, VSV-G and the plasmid containing each of the EV marker proteins fused to mClover3 via a flexible linker using Img / mL PEI. 48 hours post transfection lentiviral supernatants were collected cleared at 500 x g at 4°C and filter sterilized using a 0.45pm filter. Supernatants were aliquoted and frozen at -80°C.For the generation of stable cell lines, HEK-293T, HeLa, A549 and MSC (CB) cells were plated in 6 well plates (Corning). Twenty-four hours later, lentiviral supernatant were added with lOpg / mL polybrene. Twenty-four hours later lentiviral supernatant was removed, cells were allowed to recover for forty-eight hours prior to selection with 2pg / mL puromycin (brand). Cells were passaged at least five times under puromycin selection.

[0255] Transient Transfection

[0256] HEK-293T cells were plated at 60% confluence into a 12-well plate (Coming) or a 15-cm dish (Corning) for SEC analyses. The next day, 1.4pg total DNA (12-well) and 50pg total DNA (15cm plate) was combined with OptiMEM. Then 3.5pg (12-well) and 125pg (15cm plate) of PEI was combined with OptiMEM in a separate tube. Opti-DNA and Opti-PEI solutions were combined in a 1: 1 ratio, vortexed, and allowed to sit at RT for 20 minutes. The mixture was added to each plate in a dropwise manner. The transfection media was changed to OptiMEM the following day, and EVs were harvested 48 hrs after medium change when cells had reached 90% confluence.

[0257] EV (Particle) Isolation

[0258] CM protocol - Conditioned media (CM) collected from 12-well plates. First, CM was pre-cleared at 500xg for 10 mins at 4°C. The supernatant was then subjected to 4000xg for 20 mins at 4°C. CM EVs were then used for downstream nanoflow cytometry analyses

[0259] SEC protocol - Conditioned media (CM) collected from 15cm plates. First, CM was pre-cleared at 500xg for 10 mins at 4°C. The supernatant was then subjected to 4000xg for 20 mins at 4°C. The resulting supernatant was concentrated using tangential flow filtration (VivaFlow 100 kDa MWCO) down to around lOmL. Concentrated EV media was then subjected to spin filtration using Millipore Amico 100 kDa MWCO to further concentrate media to allow for injection on size exclusion column. 0.5-lmL of concentrated EVs were injected (ImL reduced dead space syringe) and run through the Sepharose 4 Fast Flow resin in a Tricorn 10 / 300 column in IxPBS using the Akta Start system. EVs were eluted in 0.5mL fractions in low protein binding tubes (Corning, Pyrex 12X75mm disposable rimless culture tubes) and combined for downstream analyses. All steps conducted at 4°C.ThrED particle isolation

[0260] Conditioned media (CM) collected from 15cm plates. First, CM was pre-cleared at 500xg for 10 mins at 4°C. The supernatant was then subjected to 4000xg for 20 mins at 4°C. IxPBS supplemented with 0.9mM physiological extracellular Ca2+ (0.1g CaC12 / L; pH 7.2) were used for all following steps to stabilize Thrombospondin- 1 shell. The resulting supernatant was concentrated using tangential flow filtration (VivaFlow 100 kDa MWCO) down to around lOmL. The lOmL concentrated EV media was then reconcentrated following addition of 200mL of IxPBS Ca2+ to prevent particle and protein aggregation. Concentrated EV media was then subjected to spin filtration using Millipore Amicon 100 kDa MWCO to further concentrate media down to 0.5mL to allow for addition to the top of density gradient.

[0261] All iodixanol solution were produced using 60% stock OptiPrep (Sigma-Aldrich), filter sterilized (0.22pm) MilliQ H20, Phenol Red (0.5% Sigma- Aldrich), filter sterilized (0.22pm) 5xPBS-MK (250 ml PBS 10X, 2.5 ml IM MgCl2, 6.25 ml IM KC1, H2O up to 500 ml), and 5M NaCl for the 6% solution only.

[0262] 6%, 12%, 14%, 16%, 18%, 25%, 40% and 60% iodixanol solutions were prepared. Then poured as follows, 2mL 60%, 2mL 40%, 2mL 25%, ImL 18%, ImL 16%, ImL 14%, ImL 12% and ImL 6%. 0.5mL of concentrated sample volume is added carefully to the top of the Beckmann-Coulter 13.2mL thinwall ultra-clear ultracentrifuge tube.

[0263] Samples were spun overnight for 16 hrs at 28,500 RPM and 4°C in a SW41Ti rotor. The next day, fractions were collected. Fraction 1 is 0.5mL and fractions 2-12 are ImL. A buffer exchange was performed to increase sample stability and facilitate downstream analyses. Each fraction was spun separately and iodixanol was exchanged for IxPBS Ca2+ using a Millipore Amicon 100 kDa MWCO spin filter. Samples were concentrated down to 100-300pL depending on analyses.

[0264] nanoFCM

[0265] EV samples from crude CM and SEC purifications were analysed of the flow nanoanalyzer (nanoFCM) which enabled single particle analysis as well as sizing and concentration measurements. The instrument was calibrated using QC beads (200nm PE and AF488 fluorophore conjugated polystyrene beads) and Sizing beads (S16M-exo beads from 40-200nm in diameter silica nanosphere cocktail). EV samples were diluted toachieve the optimal 2,000-12,000 particle counts / min. Calibration of standards allowed determination of concentration, size distribution, proportion of particles with fluorescence, and the mean fluorescence intensity for each sample.

[0266] Mean Fluorescence Intensity (MFI) calibration allowed the conversion of vesicle brightness into number of molecules per vesicle. This was done using a bead supported lipid bilayer (BSLB) on 200nm silica nanospheres using a mixture of NTA and Atto-488 labelled lipids which provide a 1: 1 ratio of fluorophore to lipid. A standard curve of MESF and BSLB beads were used to determine molecules / pm2 and then molecules / vesicle based on vesicle surface area (pm2).

[0267] Triton-X-100 treatment of nanoparticle solutions was conducted to determine the proportion of detergent resistant particles in each sample. 40pL of sample was run to determine the baseline measurement (all nanoparticles). Triton-X-100 was added to a final concentration of 0.2%, vortexed for 30 sec then re-run immediately on the nanoFCM to determine the proportion of remaining, detergent resistant particles (protein-bound non-vesicular particles).

[0268] EV and protein particles (ThrEDs) were stained to determine their composition at the single-molecule level. 1E10 particles were used for all stainings in a volume of lOOuL diluted in IxPBS. Samples and stains were added to a 0.6mL Eppendorf tube and rotated overnight at 4°C. IpL of 2mg / mL WGA-647 (Thermo Fisher; binds GlcNac modified protein residues) and 0.5pL of 1000X CellMask488 (Thermo Fisher; uniform binding of plasma membrane) were used together. 1 pL of CD63-PE (BD Pharmingen, 556020) was used to detect TSPAN14 and CD63 colocalization in vesicles across cell lines. IpL of ApoE (BioRad, VPA00665) was used to detect lipoproteins. Fraction 12 from iodixanol density gradient containing proteinaceous ThrEds were used at the same concentration above but diluted in IxPBS Ca2+. 2pL of mouse anti -human Serglycin (C-l 1; Santa Cruz Biotechnology, sc-374657) and IpL of TSP1-CF568 (Thermo Fisher, clone A6.1, MA513398) were used together. IpL of goat anti-mouse 488 secondary antibody was added after primary overnight incubation and left for 2 hrs. Samples were diluted 1: 100 prior to measurement on nanoFCM to remove background signal.

[0269] Western Blotting

[0270] EV preparations from size exclusion chromatography purifications were used for western blotting as samples from 12-well conditioned media purifications were notsufficiently concentrated for detected by western blotting. EV fractions were pooled and sodium deoxycholate (ThermoFisher) was added to a final concentration of 1%, samples were rotated for 15 minutes. NuPage LDS Sample Buffer (4x; Thermo Fischer) supplemented with NuPage Sample Reducing Agent (10x; Thermo Fisher) was added to a final lx concentration then boiled at 95°C for 5 minutes. ThrEDs were prepared similarly, but without the initial sodium deoxycholate detergent.

[0271] Whole cell lysate (WCL) preparations were generated by washing a 15cm plate in IxPBS then adding IxRIPA buffer supplemented with protease inhibitors (Merck, cOmplete, Mini, EDTA-free Protease inhibitor cocktail). Samples were aliquoted and sonicated for 2 minutes. LDS sample buffer and reducing agent were added as above then samples were boiled at 95°C for 5 minutes

[0272] Protein concentrations for western blotting was normalized using the detergent compatible (DC) protein assay. A standard curve was generated to determine sample concentrations. 6pg of nanoparticle preparations and WCL were added to each well (~1E9 particles).

[0273] Samples were run on a Bis-Tris 4-12% SDS PAGE gel using MOPS buffer. Proteins were then transferred onto a PVDF membrane activated in 100% methanol. The gel was transferred using NuPAGE transfer buffer with 20% methanol. Membranes were blocked for 1 hours in 5% skim milk at RT then incubated overnight at 4°C with mouse anti-GFP antibody (Biolegend, 1:1000) or mouse anti-beta-actin antibody (Santa Cruz, sc-8432, 1:1000) or mouse anti-Thrombospondinl antibody (Thermo Fisher, clone A6.1, MA513398). Membranes were then washed in TBST prior to incubation in goat antimouse HRP conjugated secondary antibody (Cell Signaling Technologies, 1:10,000) for 1 hour at room temperature. Membranes were washed again in TBST prior to visualization. ECL (BioRad Clarity Western ECL) was added prior to imaging on the ChemiDoc using chemiluminescence.

[0274] Confocal microscopy

[0275] Confocal images were acquired with the Zeiss 980 Airyscan 2 microscope using 40x (EC Plan-Neofluar 40x / 1.30 Oil DIC) and 63x (Plan- Apochromat 63x / 1.4 Oil DIC) objectives. 405nm, 445nm, 488nm, 514nm and 649nm diode lasers and 561nm and 594nm DPSS lasers were used to image samples with combinations of DAPI, mClover3, Alexa555 and MemBrite640 / 660. Spectral detector 32 channels GaAsP PMT plus 2 channels MA-PM and Axiocam 506 mono detectors were used. Images were taken with 4x averaging to achieve optimal signal to noise ratio, exposure time and laser power settings were kept consistent between all samples to ensure accurate representations and colocalization quantification.

[0276] Cells were plated in growth media at 30% confluence on sterilized square cover slips (High Precision Nol.5H 22x22mm) coated with poly-D-lysine. The following day, cells imaged with mClover3 and DAPI channels only were washed in IxPBS and fixed using 4% paraformaldehyde (PF A) for 20 mins at RT. Fixed cells were washed 5 times with IxPBS prior to mounting with VectaShield HardSet Antifade mounting media with DAPI on SuperFrost Plus 25x75x1.0mm slides (VWR). Images were taken at 40x magnification using oil immersion.

[0277] Cells imaged for colocalization analysis were plated and fixed as above. Prior to mounting, immunostaining was carried out using the Endosomal Marker Antibody Sampler Kit from Cell Signaling Technologies (#12666) containing EEA1 (C45B10) Rabbit mAb 3288, Rab7 (D95F2) XP Rabbit mAb 9367 and Rabi 1 (D4F5) XP Rabbit mAb 5589. Fixed cells were first blocked for 60 mins in blocking buffer (IxPBS, 1% BSA, 0.3% Triton-X-100). Blocking buffer was then exchanged for the primary antibody solution (Rab7 1:50, IxPBS, 1%BSA, 0.3% Triton-X-100) and incubated overnight at 4°C. Samples were rinsed 3 times in IxPBS for 5 mins each. Next, samples were incubated in Alexa555 conjugated goat-anti-rabbit secondary antibody for 2 hrs (samples protected from light in staining chamber). Again, samples were rinsed 3 times in IxPBS for 5 mins each. Coverslips were mounted with VectaShield HardSet Antifade mounting media with DAPI on SuperFrost Plus 25x75x1.0mm slides (VWR). Images were taken at 63x magnification using oil immersion.

[0278] Cells imaged for colocalization analysis using membrane dye MemBrite 640 / 660 were stained prior to fixation to avoid unintentional labelling of internal structures. Cells were plates as above. The following day, growth media was removed from cells and washed with IxPBS 2 times. lOOOx prestaining solution was diluted in IxPBS and added to cells for 5 mins at 37°C in cell culture incubators. Prestaining buffer was then exchanged for lOOOx MemBrite640 / 660 diluted in IxPBS and incubated for 5 mins at 37°C (HEK-293T) or 1 min at 37°C (A549, due to fast internalization in this cell line). Cells were then rinsed twice with IxPBS, then fixed and mounted as above. Images were taken at 63x magnification using oil immersion.dSTORM microscopy

[0279] The Oxford NanoImager (ONI) microscope was used to generate 2D SMLM (single molecule localization microscopy) images using dSTORM (direct Stochastic Optical Reconstruction Microscopy). Single particle resolution of lipid and protein-encapsulated nanoparticles was achieved using the lOOx objective lens (1.4 Numerical Aperture) in oilimmersion. 405nm, 488nm, 561nm and 640nm lasers were used with 2 channels (with dichroic mirror split at 640nm). All calibrations, controls and images were performed at 27°C with a super-critical TIRF (total internal reflection fluorescence) angle of 54°.

[0280] Cells were plated in 15cm plates and isolated per the SEC or iodixanol protocols above. 1E10 particles were diluted to a final volume of 300pL (IxPBS for EVs IxPBS Ca2+ for SMAP-like particles). DiR was used as a membrane stain instead of CellMask due to favourable blinking qualities. 4pL of 2.5mg / mL DiR and 1 pL of 2mg / mL WGA-AF568 or 2pL of Img / mL WGA-AF488 were incubated overnight while rotating at 4°C. Alternatively, 4pL of 2.5mg / mL DiR, 2pL of mouse anti-human Serglycin (C-l 1; Santa Cruz Biotechnology, sc-374657) and IpL of TSP1-CF568 (Thermo Fisher, clone A6.1, MA513398) were used together. IpL of goat anti-mouse 488 secondary antibody was added after primary overnight incubation and left for 2 hrs. After staining, samples were re-purified using the size exclusion column to reduce noise in the imaging chamber and to remove all soluble proteins present to avoid false positive detection of protein particles due to protein aggregate staining with WGA, Thrombospondin- 1 or Serglycin.

[0281] Imaging chamber was prepared the same day as imaging using Ibidi VI 0.4 channel slide (#80608) and 1.5H 25x75mm cover slips. Poly-D-lysine was added and incubated for 2 hrs. Each chamber was washed with IxPBS 3 times. Stained and re-purified samples (1E9 particles) were added to each chamber. Samples were allowed to settle overnight at 4°C. Unbound particles were washed out with IxPBS 3 times. Samples were imaged in dSTORM buffer (320pL IxPBS, 40pL 50% glucose, 40pL 2-Mercaptoethylamine»HCl (2-MEA), 4pL glucose-oxidase). First, 640nm laser was used to excite DiR, then the 561nm laser was used to excite the Alexa568 dye or CF568, followed by the 488 laser used to excite the Alexa488 dye or mClover3. The 405nm laser was used to reactivate fluorophores to promote and stabilize blinking. 10,000 frames were acquired per fluor ophore.Cytotoxicity Assay

[0282] Cytotoxicity of proteinaceous particles (ThrEDs and SMAPs) was assessed by measuring the viability of Nalm6 cells. 2.0E4 cells were combined at a 1: 100 ratio with particles in a round bottom 96-well plate for 72 hours before harvesting. Cells were stained with Live / DeadTM Fixable eF780 dye (Invitrogen) followed by 4 % PFA fixation. After fixation, cells were permeabilised with 0.1 % Saponin w / v HBSS for 20 mins at RT. Cells were then blocked with 5 % BSA w / v HBSS for 1 hour at RT prior to staining with 1 pg / ml anti-cleaved caspase-3 (Cell Signalling, Code) for 1 hour at 4 °C. The cells were then washed twice with 200 pl 0.02% Saponin w / v HBSS and analysed on a BD Fortessa. Data was analysed using FlowJo vlO.10.0.

[0283] Supported Lipid Bilayer (SLB) Targeting

[0284] Glass coverslips (Nexterion) were plasma cleaned and mounted onto p-Slide VI 0.4 (six channel chambers). DOPC (l,2-dioleoyl-sn-glycero-3 -phosphocholine) and NTA (l,2-di-(9Z-octadecenoyl)-sn-glycero-3-[(N-(5-amino-l-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt)) lipids are combined and added to each chamber. NTA lipids were used at a final concentration of 12.5% to bind His tagged proteins. Channels were washed with HBS+0.1% BSA in between each of the following steps. Following removal of free lipids, the channels were blocked with HBS+ 3% BSA for 30 minutes. Then 8xHis-tagged GFP-nAb were added to the channel and left to equilibrate, binding with NTA lipids, for 1 hour. After removing unbound nAb, Thbsl-GFP ThrEDs were added for 1 hour. Unbound ThrEDs were washed away thoroughly.

[0285] IBIDI channels were first imaged by confocal microscopy to determine degree of Thbsl-GFP - GFP-nAb binding. Then, samples were fixed with 4% PFA and 0.25% Gluteraldehyde for 1 hour at 4°C. After washing fixation medium out of the channels the samples are imaged by dSTORM to determine the structure of particles bound to the SLB.

[0286] Wounding and migration assay

[0287] The evening before the wounding assay, 34.0E4 to 38.0E4 A549, primary fibroblasts or senescent fibroblasts recipient cells were plated into a Incucyte Imagelock 96-well microplate (BA-04856). The next day, when cells were 100% confluent, the Incucyte 96-Well Woundmaker tool was used to generate 96 uniform scratches. After washing 3 times with PBS, extracellular particles were added. The plate is then added into the Incucyte andimaged using the 20x objective every 2 hours over 120 hours to capture wound closure. Wound healing was then assessed using the Incucyte Scratch Wound Analysis Software Module.

[0288] Image Analysis

[0289] The CODI platform was used to analyse dSTORM images acquired with the ONI system. The clustering and counting application with clustering essentials settings was used. Drift at Minimum Entropy (DME) drift correction was run prior to all other filtering and analysis. Then, frame index was filtered to exclude the initial localizations peak as the laser is turned on to exclude localizations detected from epifluorescence, and any localizations outside of the designated light program settings. Sigma (nm) was filtered to the base of the localizations distribution gaussian peak. Localization precisions (nm) was filtered to the base of the peak at 20nm to ensure maximum resolution and the removal of any localizations outside the optimal range. Regions of interest were highlights and the number of localizations within each particle of interest was determined using the contained clustering localisations function to ensure the number of localisations fell within the acceptable range of about 10% of the number of total frames acquired per fluorophore (300 for 3000 frames). Display sigma (nm) was set to 6nm. Regions of interest were saved as.tiff and.png files direct from the CODI software to produce representative micrographs.

[0290] Statistical Analysis

[0291] Excel was used to perform statistical analysis and generate graphs. Differences between two groups were assessed by Student’s t-test.

[0292] Example 2 - EV marker screen highlights a significant unlabelled subpopulation in cell lines

[0293] The initial aim was to quantify differential extracellular vesicle (EV) marker profiles in subpopulations across different cells lines. Stable overexpression of a panel of 15 proteins (Figure 1A) was conducted in 4 adherent cell lines as we hypothesized different proteins would exhibit differential loading across different cell lines. 60 polyclonal stable cell lines were established to compare EV marker potential across HEK-293 T, A549, HeLa and MSC(CB). First, a high throughput assay was validated in HEK-293T using transient transfection (Figure 8A) to ensure EVs isolated using size exclusion chromatography (SEC) and conditioned media (CM) yield similar proportions of GFP+particles using nanoflow cytometry. 14 of 15 EV anchors confirm SEC and CM yield similar values (Figure 8B). Given the exception, N-syntenin, was barely significant (P=0.04) it was concluded the CM screening assay yields EVs of sufficient quality to estimate differential localization of EV markers.

[0294] Each cell lines exhibited different patterns of EV marker loading. In HEK-293T, CD63 marks -93.0% of vesicles (Figures IB and C) corresponding to 99 copies per vesicle (Figure 1G). TSPAN14 is the fourth strongest marker but has the highest number of copies at 148 per vesicle, which represents a significant increase in loading (Figure 1G). In A549, PTGFRN is the most abundant marker at -44.2% (Figure IB and C) and newly described protein PTTG1IP was the brightest with an MFI of 2172 (Figure ID), with A549 generally being the dimmest cell line overall. In HeLa TSPAN14 labels -84% of EVs (Figures IB and C) containing about 59 copies per vesicle (Figure 1G). MSC(CB) also show a low total amount of labelling with TSPAN14 being the best at -48.1% (Figures IB and C) and BASP1 containing the greatest number of copies (Figure ID). Given percent localization and MFI do not always correlate, choice of anchor may depend on application (labelling more vesicles or a greater loading efficiency).

[0295] The most striking finding from this screen, however, is that 2 of 4 cell lines exhibit very low overall extracellular particle (EP) labelling, A549: PTGFRN -44.2%, and MSC(CB): TSPAN14 -48.1% (Figures IB and C), seen in the columns of their respective screen. In both cases, fewer than 50% of EPs were labelled. Given the protein panel represents the most common and abundant EV proteins studied, this finding was surprising. Each unlabelled particle was in the expected size range of EVs and within the detection limit of the nanofl ow cytometer (Figure IB; 40nm-200nm).

[0296] Example 3 - Subpopulation analysis identifies non-vesicular population of proteinaceous particles

[0297] The identity of the unlabelled population was further studied, including by using single particle analysis to understand subpopulation profiles released from different cell lines. First, to determine if low labelling proportion is due to mutually exclusive EV marker sorting, EVs were labelled with both top markers, TSPAN14 and CD63 (Figure 1).However, overall labelling of EVs did not increase significantly. HEK-293T produce a more homogeneous type of vesicle that were 79.0% double positive for both markers. HeLa (19.9%), A549 (16.3%) and MSC (CB; 6.7%) produce significantly fewer double positive EVs with concomitant increase of TSPAN14+subpopulations and double negative subpopulations (Figure 2B).

[0298] This negative population was suspected to be lipoproteins, therefore, ApoE was probed. The percentage of ApoE positive vesicles was low. HeLa contained the most at 11.6% and MSC(CB) contained the least at 1.5% (Figure 2C). These percentages were insufficient to account for all double negative particles. Next, it was investigated whether these particles were a third subpopulation of EVs that are TSPAN14' CD63'. To assess this hypothesis, EV preparations were isolated by SEC then treated with 0.2% Triton-X-100. However, a proportion of Triton-X-100 resistant particles were detected in all cell lines (Figure 2D) proportional, but not equal to, the amount of double negative particles observed. This meant that TSPAN14' CD63' did not completely account for the remainder. Whole EV preparations were stained with Cell Mask 488 (lipid stain) and WGA-AF647 (GlcNac-protein stain) to assess the gross biomolecular makeup of this subpopulation, which revealed the presence of non-membrane bound glycosylated protein particles in HEK-293T (5.6%), A549 (18.1%), HeLa (7.6%) and MSC (CB; 4.0%; Figure 2E), confirming the 2D SMLM data (Figure 9), which detected EPs similar in size to EVs that were DiR' and WGA+. These protein particles co-isolated with EV preparations in both CM and SEC isolation methods. WGA staining confirmed this previously undescribed population were Triton-X-100 resistant, non-lipidic, Glc-Nac-protein containing nanoparticles identical in size to EVs (Figures 1, 2, and 9)

[0299] Example 4 - Thrombospondin Encapsulated Dense Particles (ThrEDs) are a novel, ubiquitous and constitutive non-vesicular extracellular particle (NVEP) subpopulation

[0300] Supra Molecular Attack Particles (SMAPs), first characterized in activated CD8+cells (CTLs), are proteinaceous particles encapsulated by a Thrombospondin shell.

[0301] Released from multicore granules (MCG), they kill target cells at the immune synapse (IS) with their characteristic cytotoxic core. SMAPs or SMAP-like particles have not previously been identified in non-immune cell lines.To corroborate the identity of WGA+CM7WGA+DiR' protein particles as SMAP-like particles, a new method to achieve a pure preparation is required. Given EVs and the novel EPs are identical in size (Figures 1 and 9) size exclusion chromatography is not a useful methodology. This may also explain why these particles have not been identified before; they co-isolate with EVs even under stringent isolation methods (SEC, UC, UF, TFF, CM). CTL derived SMAPs are extremely dense, therefore, an iodixanol density gradient, typically used for EV-AAV purification, was employed (Figure 3 A). This gradient separates EVs from EV-AAV conjugates and AAVs. In wild type HEK-293T and A549 cells, three peaks were observed. EVs localize to fractions 3-6 (Figure 3B), (confirmed by nanoflow cytometry, Figure 10J). nanoFCM analysis on the third peak (f 11-12) identified a population of WGA DiR particles, identical in size to fractions 3-6, with a purity of 91.4 to 91.5% for A549 and HEK-293T, respectfully (Figure 3C). The second peak in fraction 8 contained both EVs like fraction 4 and dense rings similar to fraction 12 (Figures 10J, 1 IF, and G), and may contain hybrid EV-SMAP-like particles or typical EPs of different density than f4 and fl2. EM images confirmed the presence of both EVs and dense fl2 like particles in f8, supporting its identity as a hybrid fraction (Figure 3G). dSTORM images of fraction 12 particles confirmed the absence of membrane bound particles (Figure 3D). Importantly, 2D-SMLM showed that these protein particles had a shell structure which was WGA+and Thrombospondin, and identical in size and morphology to SMAPs (Figures 3D and F).

[0302] Given that HEK-293T and A549 do not produce cytotoxic proteins, SMAP components Thbs-1 and Srgn were investigated. 4.5% of the particles were double positive in WT HEK-293T. In A549, 65.5% of particles contained the main shell component (Thbs-1) and 54.7% were double positive (Figure 3E). dSTORM imaging confirmed that the WGA+ protein shell was composed in part by Thbsl (Figure 3F). TEM imaging confirmed single particle imaging, highlighting a ring structure containing a dense core, permeable to uric acid stain (Figure 3G). Thrombospondin- 1 was detected in both cell types predominantly in its full-length form and was highly enriched in particles compared to whole cell lysate (Figure 3H).

[0303] Thbsl monomers contained ~13 binding sites for divalent calcium ions. The Ca2+induced stabilization of particles, into their ‘holo-Thbsl’ confirmation, further confirms Thbsl forms the particle’s shell (Figures 11 A and B). An 8-fold increase in HEK-293T and 20-fold increase in A549 EP concentration in fraction 12 was seen upon bufferexchange to PBS supplemented with 0.9mM CaCh (Figure 31). Their destabilization in regular PBS (Gibco; 10010023) also explained the failure to previously identify these particles (Figure 11). Calcium induced stabilization was also reversible; when particles were treated with EDTA they largely disassembled, with only larger particles and smaller particle ‘subunits’, potentially composed of Thrombospondin bound to cargo, remaining (Figures 11C, D, and E). Presence of calcium also changed particle morphology as seen by EM, where the shell (composed partly of Thrombospondins) appeared bulkier and as a condensate of subunits (Figure 11H-K).

[0304] The release kinetics of these proteinaceous NVEPs may be another reason they have not been previously described. While EVs are collected after 48 hours incubation, it was found that collection of ThrEDs after 96 hours yielded the most particles (Figures 10G, H, and I). The level of Thrombospondin protein in cells was highest at Day 3 and dropped significantly at Day 4 and Day 5. This drop in cells was paired with an increase in Thbs+protein particles released in conditioned media. The collection of these novel NVEPs happened at Day 4 when cells remained viable (Figures 10A and B) and particle production was favoured (Figures 101 and J).

[0305] Novel, calcium stabilized protein particles were identified in 6 additional cell lines; C2C12 (mouse myoblasts), myotubes (differentiated from C2C12), HMEC-1 (immortalized endothelial), HUVEC (primary endothelial), PANCI (pancreatic epithelioid carcinoma), and U373 (glioblastoma astrocytoma;). Donor matched human tissue of plasma, CD8+ resting cells and cytotoxic T lymphocytes also contained constitutively released proteinaceous EPs distinct from SMAPs, released without stimulation into the conditioned media (Figures 3 J, K, and 18)

[0306] Taken together with the finding their average size was not significantly different from CTL-derived SMAPs (Figure 9) the findings support that the WGA+DiR protein particles, named Thrombospondin Encapsulated Dense Particles (ThrEDs), exhibited similarity with SMAPs in terms of composition and morphology. However, they were released constitutively as opposed to upon polarized activation at target cells.

[0307] Example 5 - ThrEDs compose a novel class of proteinaceous particles including the SMAP subtypeConditioned media from CD8+resting cells, activated CTLs and fasted human plasma were collected to study the morphology, composition and function of ThrEDs (Figure 18 A) to assess their similarity or difference to cell culture EPs.

[0308] The migration profiles of human tissue EPs were generally similar to A549 where 3 main peaks were observed (f3-4, f8, fl 1-12; Figure 4A). However, the large particle count in f 1-2 of fasted plasma was likely circulating lipoproteins (despite fasting). The EM analysis on these 3 peaks showed EPs like those in A549; the typical “cup” shape of EVs in f4, a mix of EVs and spherical dense protein particles in f8 (often in proximity and potentially bound) and in fl2, where it can be possible to distinguish Thrombospondin subunits forming the spherical shell encapsulating the densely stained core. Single particle analysis and super-resolution imaging corroborated the presence of Thrombospondins and Serglycin across tissues as well as the signature shell structure (Figures 4C, D, E, F, and 18C)

[0309] Unexpectedly, the constitutive EPs from human tissue contained a maximum of 1.6% Granzyme B+PerforinU particles. It was hypothesized that particles from human tissue would be cytotoxic like SMAPs. However, the Granzyme B Perforin 1" particles, which composed 98.8 - 87.3% of tissue ThrEDs, may have a distinct function to SMAPs (Figure 4K). To assess this, SMAPs (NK-92 cell) and ThrEDs (A549, Plasma) were placed on Nalm6 cells in a killing assay. SMAPs killed with -98% efficiency through the Granzyme B mediated cleavage of Caspase 3. ThrEDs from both sources show no killing activity and no activation of Caspase 3 cleavage (Figures 4G, H, I, and J). While SMAPs and ThrEDs have some similar proteins and morphology (Figure 4J), suggesting a similar overall signature, their functions may be dictated by the specialized proteins unique to each type. CTLs are particularly interesting as they release non-cytotoxic ThrEDs constitutively, and cytotoxic SMAPs towards the antigen presenting cell at the immune synapse to induce killing. In other words, two proteinaceous particle subtypes released from one cell have diametrically opposed function depending on cellular context.

[0310] Example 6 - ThrEDs proteomics reveal a unique marker and extracellular matrix functional signature

[0311] The absence of typical EV markers in F12 confirm that ThrEDs are distinct from extracellular vesicles. However, as seen with exomeres and supermeres, proteinsassociated with EVs are present in ThrEDs. HspA8 and Hsp90AAl, the most frequently detected EV proteins (included in the initial screen (Figure 1)), localize to F 11-12, and may be common to vesicular and non-vesicular EPs. For example, cleaved Syndecan-1 and BASP1 are among common ThrEDs proteins (Figures 5, 12, and 17).

[0312] Proteomics analyses conducted on EVs frequently reflect both their producer cell and cellular state. Therefore, it was hypothesized that the protein profiles of ThrEDs from different cell types would be highly variable with potentially distinct functions. However, generally, ThrEDs proteins were different from their producer cell’s profile (Figure 12A) and had an overall similar matrix composition between source types (Figures 5 A and C), with ECM collagens, proteoglycans and glycoproteins highly enriched. These proteins composed groups of direct ECM components, ECM regulators, matrix affiliated proteins and secreted factors (Figures 5C, 12C, and D). Interestingly, COMP, also known as Thrombospondin 5, was identified as high abundance in all ThrEDs samples (Figure 5B). Immune cells did not express COMP making it a unique Thrombospondin marker for ThrEDs and a strong candidate to distinguish between particle subpopulations. 80.8% of particles present in circulation are Thbs5 / COMP+suggesting ThrEDs not SMAPs were present predominantly in plasma (Figures 4C and F).

[0313] Thrombospondin proteins composed a part of the ThrEDs shell structure. This class of protein is particularly difficult to fold properly, given numerous cysteines which form disulphide bonds, and the binding of calcium required for proper oligomerization (trimers / pentamers). They must also undergo additional modification in the Golgi for proper glycosylation. At incubation Day 3, Thrombospondin 1 expression is maximal before dropping off at Day 4 and being completely lost by Day 5 (Figure 10C).

[0314] Thrombospondin accumulation may cause significant stress to the ER and protein homeostasis of the cell. Interestingly, ThrEDs released at Day 4 also contain abundant amounts of Calreticulin, an ER chaperone which assists in folding Thrombospondins (Figure 4).

[0315] Similarly, many proteins present in ThrEDs exhibited interactions with one another (Figure 5D). One notable class of these interactions was protein-chaperone interactions. SACS and SERPINF1 both in the top 59 common, abundant proteins bind numerous other ThrEDs proteins and function to protect again ER stress induced apoptosis (Figure ION). SERPINA2 has a similar role specifically in the ER unfolded protein response (UPR;Figures 10M and 12C). SERPINH1, or HSP47, is particularly interesting as its role is to ensure proper folding of collagen molecules, one of the most abundant ThrEDs proteins classes (Figures 5C, ION, and 12C).

[0316] The isoelectric point of proteins may also play a critical and / or an important role in strengthening protein-protein interactions in ThrEDs, increasing particle formation and stability. The 3 Thrombospondin proteins bind with high fidelity to other abundant ThrEDs proteins (Figure 5D), and these binding events often involve calcium or other divalent ions, like copper and nickel, which further strengthens the binding affinity due to many weak interactions. The interaction between Thrombospondins and Fibronectin l is a strong example of a protein-protein interaction strengthened through opposing pls (Figure 5E). Generally, moieties with additional charge-charge interaction have a higher abundance in ThrEDs (Figure 5E). In addition to the shell’s interactions, the overall isoelectric point profile of the ThrEDs protein matrix is primarily acidic and therefore negatively charged. The extreme calcium stabilization effect observed may be due to the importance of charge in the formation of particles; many weak interactions may therefore function cooperatively to maintain the dense ring-core structure. (Figures 3 and 11) Generally, this complement of proteins is involved in ECM construction, integrity, remodelling, cell migration and wound healing (Figures 5F, G, and H). ITIH1, 2, 3 and 4, which bind hyaluronan (HA; Figure 12C) were present in all ThrEDs and bind water to hydrate the ECM in addition to serving as a scaffold, signalling molecule and regulator of cell adhesion, motility and proliferation / differentiation. Collagen 1 A, the most abundant form of collagen, was another universally abundant ThrED component. ECM regulators include secreted SERPINs such as SERPINH1, SERPINA2 and SERPINF1 (Figure 12D) involved in cell proteostatic pathways in addition to their matrix regulatory function. SERPINE1, SERPINI1, SERPINB3, SDC1, FSLT1, IGFBP6 (Figures 12C and D) are all involved in ECM modification to facilitate cell migration. In addition, SERPINF2, FLG2, PTPRK, CLSTIN1, CNTN1, CSTA, NRCAM and DSC1, common to all samples (Figures 5 A, 12 A, and 13B), are all involved in cell adhesion function to initiate the cell’s orientation and establish polarized function (Figures 5G-J).

[0317] To better understand why A549, an epithelial cell non-small cell lung adenocarcinoma line, produce a greater proportion of ThrEDs compared to other cell lines (Figures 1, 2, and 3), the cell lysates of producer cells at Day 4 were analysed. It was hypothesized that the strong polarization of CTLs inducing spacio-temporal control overSMAP release may be important for the general release of proteinaceous EPs. The analysis of differentially expressed proteins found that HEK-293T only has 2 GO terms relating to cell polarity, while A549 has 53 involved in early (initiation), middle (establishment), and late (maintenance) polarization (Figure 5G). The cellular machinery involved in cell polarity may therefore be important for the production and release of ThrEDs. Interestingly, many of the proteins responsible for the polarization of producer cells then localize into released ThrEDs and sort into the ECM functional matrix web (Figures 5H and J), likely due to the tight relationship between cells and the ECM in polarization. Furthermore, despite HEK293’s lack of overall polarity related protein enrichment, similar polarity proteins localized with high abundance into HEK293 derived ThrEDs including RHOA, R0CK2, CDC42, MAPK1, AKT1, among others (Figures 5H, I, and J). These proteins may initially function within cells, functionally orienting them within their environment and later, within ThrEDs, regulating the reorganization of the ECM with concomitant signalling to nearby cells. Additionally, this suggests there is a conserved mechanism to sort these components into ThrEDs regardless of the number of copies per cell, accounting for the similarity in overall ThrEDs protein matrix composition (Figure 5C).

[0318] Example 7 - ThrEDs in human tissue and cell culture in function in wound healing and fibrosis reversal

[0319] The extracellular matrix is a network of proteins and polysaccharides which surround cells in tissues and organs, providing dynamic support to regulate cellular adhesion, migration, proliferation and differentiation. Remodelling of the ECM to accommodate these functions is tightly regulated to maintain homeostasis. Dysregulation of these processes leads to pathologies including fibrosis, a condition defined by excessive ECM deposition leading to thickened, scarred tissue. For example, Dupuytren’s disease is characterized by excessive local accumulation of myofibroblasts and ECM within nodules on ligaments of the palm leading to permanent flexion in the fingers.

[0320] A wounding assay monitoring cell migration across a uniform scratch was used to investigate the ability of ThrEDs to modulate cell migration. First, A549 recipient cells were used to assess the function of EPs and ThrEDs isolated from A549 cells and plasma (Figure 19).Scratch wound migration results:

[0321] A549 ThrEDs and Plasma ThrEDs lead to faster wound healing (closing of a gap created by a uniform scratch across a well), in a dose dependent manner, compared to a PBS control and extracellular particle pool (Figures 19A and B).

[0322] A549 ThrEDs and Hybrids lead to faster wound healing compared to EVs and the PBS control (Figure 19C)

[0323] Mechanism of Action:

[0324] A549 cells treated with ThrEDs exhibited much higher levels of active Racl / 2 / 3 and they had clear punctate phosphorylated Focal Adhesion Kinase, which is important and / or critical for migration (Figures 19D and E).

[0325] The ability to positively affect cell migration was then assessed in primary myofibroblasts isolated from nodular tissue in Dupuytren’s disease (Figures 6 and 20). Fibroblasts migrate quickly in the early wound to secrete ECM components and signalling molecules to promote healing. Myofibroblasts are activated fibroblasts with reduced migration capacity that exhibit contractile functions in the late wound.

[0326] Scratch wound migration results:

[0327] The morphology of myofibroblasts treated with ThrEDs and Hybrids was completely different to myofibroblasts treated with EVs and PBS (Figures 6C and 20 A). EVs caused myofibroblasts to spread very thin on the surface and are very tightly packed - treated cells migrated and closed the wound more slowly. ThrEDs and Hybrids caused myofibroblasts to revert to a spindle-shaped morphology characteristic of fibroblasts and caused a rapid rate of migration within the first 24 hours.

[0328] Mechanism of action:

[0329] - Rac 1 / 2 / 3 increased in ThrEDs treated myofibroblasts (Figures 6H and I) and pFAK was reduced in cells treated with ThrEDs as they undergo myofibroblast to fibroblast transition. p-FAK puncta are still observed in ThrEDs treated cells (Figures 6H and J)

[0330] The number of fibronectin positive particles was significantly greater in ThrEDs treated scratches suggesting ThrEDs may help lay down or nucleate ECM in the scratch to facilitate migration in addition to their effects directly on cells (Figures 6 K and L).Intracellular Fibronectin 1 and collagenl Al levels were higher in cells treated with ThrEDs. (Figure 6K)

[0331] Smooth muscle actin is the best marker to detect fibroblast or myofibroblast morphology. After only 24hrs post ThrEDs administration, the amount of fibrillar smooth muscle actin decreased (Figure 6E) and colocalized less with Phalloidin (actin; Figure 6F) however the total amount of SMA remains similar after 24 hours (Figure 6G), it is the organization that changes. The morphology of cells remained as fibroblast for at least 5 days post administration (Figures 5C and 20A).

[0332] Example 8 - ThrEDs are a novel therapeutic vehicle

[0333] Given ThrEDs were shown to be stable in circulation, they were ideal candidates to be used as a novel class of therapeutic vehicle and present distinct advantages over vesicular strategies.

[0334] A Thrombospondin- l-mClover3 chimera was used to conduct a proof-of-concept study. A549 cells transiently transfected with the construct and their EP were analysed. A549 released fewer EPs overall (Figure IE), however a greater proportion of these were ThrEDs (Figures 2F and 31). As such, with a -35% transfection efficiency 2.8% of EPs are GFP+, however, Triton-X-100 treatment increased this proportion to 42.5%, demonstrating ThrEDs incorporate the GFP fusion into the non-lipidic population (Figure 7 A). High resolution iodixanol separation confirmed the presence of Thbsl-GFP predominantly in Fl 1-12 with a smaller but significant population in F8.

[0335] To determine whether this GFP cargo incorporation could be used to functionalize ThrEDs, a supported lipid bilayer (SLB) was used to capture GFP+ThrEDs using a GFP nanobody attached to the SLB’s NTA lipids by its HIS tag (Figure 7F). A clear significant increase in particle binding to the cell surface mimic (SLB) in the presence of the GFP nanobody was observed (Figures 7G and H) highlighting successful functionalization and specificity of binding despite high concentration of glycosylated protein particles which may have been ‘sticky’. When SLBs were fixed and imaged by super-resolution dSTORM, the ThrEDs maintain their dense ring structure following GFP incorporation and SLB binding highlighting strong particle stability throughout functionalization (Figure 71).

[0336] Example 9 - DiscussionPreviously undescribed NVEP subtype in cell culture and human tissue co-isolate with EVs Extracellular Particle heterogeneity has presented both a challenge and opportunity to better understand particle mediated cell-cell communication and necessitated the writing of guidelines to enhance the rigor, reproducibility and transparency of EV and EP research. Despite compliant investigation of extracellular vesicle preparations, the novel NVEP class, Thrombospondin Encapsulated Dense Particles (ThrEDs) went unnoticed. ThrEDs and EVs have similar size profiles (Figures 1, 3, 4, and 9) and therefore co-purify using common size exclusion columns and functionalized columns including CaptoCore.

[0337] Methods such as TFF and ultrafiltration (UF) lead to co-isolation for the same reason. The density of ThrEDs also causes them to co-isolate with EVs isolated using differential ultracentrifugation protocols.

[0338] Additionally, these particles may not have been previously detected due to their release kinetics and buffer requirements. EVs are typically collected from conditioned media (OptiMEM) at 48 hours, however we found there is a shift to ThrEDs production over EV production at Days 4 and 5 (Figures 10G, H, and I). This may be because cells are stressed but viable at Day 4 and significantly lose viability on Day 5 in OptiMEM (Figure 10A). On Day 4, cells increase the expression of chaperones and proteins related to the endoplasmic reticulum -associated degradation pathway, suggesting the proteostasis of the cell is disrupted (Figure 10M). Cells may transition to releasing ThrEDs over EVs at Day 4 as it may be more efficient to regulate proteostasis by exporting densely packed protein particles than EVs which typically require the ESCRT machinery and is energetically expensive. ThrEDs condensate formation may also be faster than EV production since maximal Thrombospondin 1 expression in cells at Day 3 is quickly lost on Day 4, when particles are most concentrated (Figure IOC). The chaperones upregulated during cell stress also localize within ThrEDs supporting rapid biogenesis and release (Figure ION).

[0339] Initiating in the ER under cellular protein stress, Thrombospondin proteins that accumulate at the ER, in significantly higher calcium levels than the cytosol, awaiting proper folding through calreticulin may spontaneously adopt a more thermodynamically stable confirmation by encapsulating a dense condensate core of ECM related proteins as they transition through the cell’s secretory pathway. Meaning the biogenesis of ThrEDs may be self-catalysed via Thrombospondin mediated nucleation. ‘Encapsulation’ byThrombospondin may therefore imply a shell (Figures 3 and 4) or through the mechanism of particle condensation / nucleation. There are other ThrEDs proteins, like Agrin, which exhibit this strong binding and condensation property to ECM proteins.

[0340] This hypothesis is supported by the proteomics profile of ThrEDs protein-protein and charged-charge interactions (Figure 5) in addition to the dramatic stabilization of particles by calcium (Figure 11) which bind to the calcium binding proteins and neutralize the acidic, negatively charge particle microenvironment. Therefore, the stripping away of ions from buffers simplifies reagents but also removes physiological context. The lack of Ca2+ions in commonly used physiological buffers likely also contributed to the unnoticed particles. It is also possible that local calcium microenvironments may be important for the disassembly of ThrEDs, for example stabilized in the ECM (high calcium) and destabilized near cells and in the cell cytosol (low calcium).

[0341] The intermediate density Fraction 8 contains both EVs and ThrEDs and is interesting as it suggests these EP subtypes may bind and function cooperatively. For example, the co-delivery of an EV and a ThrED would be beneficial to facilitate navigation through the ECM via ThrED-MMP remodelling where lipids or a transmembrane protein from the EVs are required to elicit a specific signalling cascade in the recipient cell. The hybrids from F8 have slightly stronger migration bioactivity on A549 and myofibroblast cells compared to F12 alone (Figures 6, 19, and 20), with both F12 and F8 mediating the myofibroblast to fibroblast transition equally (Figures 6 and 20).

[0342] ThrEDs and SMAPs function cooperatively towards a ‘repair or kill’ paradigm

[0343] The uniform protein matrix composition despite variable producer sources (Figure 5) suggests ThrEDs are a conserved particle type that increase cell survival, promoting their ubiquitous nature. Although SMAPs and ThrEDs have different functions, there protein profiles are similar. Both contain ECM proteins / ECM interacting proteins, proteoglycans, glycoproteins, signalling molecules, chaperones and the unifying Thrombospondin shell. Many proteins in SMAPs also bind to calcium for stability or function including, Perforinl one of its cytotoxic effectors, and calreticulin, which supports the folding of Thrombospondins in the ER. The overall GO term profiles are similar, barring cytotoxicity, with a strong contribution of cell adhesion and biological adhesion terms appearing for SMAPs and similar adhesion properties in ThrEDs (Figures 13, 15, and 16). In specialized cells including CTLs EPs are released with tight spacio-temporalcontrol to facilitate adhesion onto the APC resulting in strong cytotoxicity. In nonspecialized cells, the constitutive release of ThrEDs facilitates the modulation of the ECM to promote healing following wounding (Figures 6, 19, and 20). Generally, their dense structures protect internal, condensate cargo but are not limited by the biophysical properties of a lipid bilayer to enable cargo release (EVs). The concentrated delivery of their respective effectors leads to a rapid and robust response in recipient cells.

[0344] This class of non-vesicular extracellular particle may therefore function cooperatively to maintain cell and tissue homeostasis through a ‘heal or kill’ paradigm. For example, it has been shown that the formation of fibrotic tissue around a tumour due to ECM and fibroblast dysregulation results in restricted immune access to the core promoting resistance and tumour growth. The activation of myofibroblast to fibroblast transition promoting migration and ECM turnover may allow immune infiltration and SMAP mediated CTL killing of antigen presenting cells. If ThrEDs cannot re-establish physiological conditions, diseased cells express moieties making them a cytotoxic target.

[0345] Wound healing

[0346] Collagen is the most abundant protein in the body and constitutes -30% of all tissues. The important and / or critical role collagen plays in the ECM highlights the matrix’s importance. Accordingly, the ECM is the common denominators in chronic disease as fibrosis and ECM remodelling are essential to numerous pathologies. The proper regulation of the extracellular matrix is important as it is a dynamic environment that influences cell and tissue behaviour.

[0347] ThrEDs are highly enriched in ECM components and associated proteins (Figures 5 and 12). Interestingly proteins and GO terms for both the positive and negative regulation of functions such as proteolytic activity, fibril organization and cell adhesion. ThrEDs accelerate cell migration in a scratch more than EVs and PBS control, promoting wound healing (Figures 6, 19, and 20). They also induce a transition from fibrotic myofibroblasts to non-fibrotic fibroblasts initiating at only 24 hours with lasting effects (Figures 6 and 20). ThrEDs may promote healing without slipping into excess healing and fibrosis due to presence of positive and negative regulating enzymes within ThrEDs which maintain an equilibrium. The EPs may also signal to fibrotic cells that they are in a “soft” environment as opposed to a “hard” fibrotic environment, promoting the transition to a non-fibrotic phenotype.In addition to having a balanced group of proteins, ThrEDs also contain groups of multiple effectors that perform similar functions, for example, the production of ‘soft’ matrix signals. These aim to indicate reduced mechanical tension in the ECM. MMPs degrade existing over deposited, stiff fibres and re-order those required for normal function. ITIH1, 2, 3 and 4 in addition to proteoglycan including Aggrecan (Figure 12) promote tissue hydration through their binding to hyaluronic acid which lowers ECM rigidity and decreases long range transmission of mechanical stress signals. The presence of multiple effectors may explain why dramatic effects are observed before the 24-hour mark, for example the loss of smooth muscle actin in myofibroblasts treated with ThrEDs which is maintain for at least 5 days (Figures 6 and 20).

[0348] ThrEDs also contain groups of multiple effectors that perform similar pro-migratory functions. For example, TGF0, RhoA, Cdc42, ARP complex subunits 1 through 5 and MMPs are all involved in promoting cell migration during wound healing through signalling or catalysing reorganization. While collagens I, III and XV, fibronectin, laminins, lysyl oxidase (crosslinker) provide direct architectural support as well as signalling cues to cells, partially via mechanotransduction. This functional redundancy across multiple aspects is likely the reason for a robust and rapid response.

[0349] Confocal imaging identified a significant increase in FN1+ particles in the scratch wounds treated with ThrEDs. This suggests fibronectin 1 positive particles deposited in the wound function to nucleate the formation of new matrix against which cells can migrate and to close the wound. Wound healing is dependent on the re-establishment of lost ECM. The protein matrix composition (Figures 5 and 12) contains additional proteins such and Agrin and even Thrombospondin which may also catalyse this formation (Figures 5 and 12). This also suggests a dual ThrEDs-ECM and ThrEDs-cell mechanism of action.

[0350] io murker potential

[0351] Of the 59 common, abundant proteins present in all ThrEDs samples more than half have been identified in EV preparation from biological fluids (urine, plasma) as biomarkers for diseases including pancreatic and colorectal cancer. It is likely that given differential ultracentrifugation was used, ThrEDs compose part of the preparation and can also be used as a biomarkers. Given the tight relationship between the ECM and ThrEDs these EPs may provide additional, distinct disease information given the dysregulation of the ECM across multiple pathologies. Furthermore, the increase in ThrEDs release overEVs under stress conditions (Figure 10) and that they are stable in circulation and can be purified from plasma (Figure 4) supports the notion that these proteinaceous particles are strong disease biomarker candidates.

[0352] Collagen fragments released into circulation during ECM remodelling serve a strong prognostic biomarker in multiples diseases. The Pro-Cl fragment, also known as N-terminal C propeptide or PINP, present at high abundance in ThrEDs (Figure 6) are used to predict diseases including cancer, arthritis, osteoporosis and fibrosis (including heart failure) based on the proportion of formation fragments Pro-Cl, Pro-C3 and Pro-C4 relative to degradation fragments C1M, C3M and C4M. In fact, in cancer patients with high and low levels of fibrosis have drastically different prognoses due to cancer associated fibroblasts (CAFs). The identification of a high-fibrotic phenotype early on may be beneficial to patients by targeting their CAFs. Interestingly, the Granzyme B dependent cleavage of Collagen IV (C4G fragment) was required for immune infiltration into a tumour, presenting another link between ThrEDs and SMAPs, where SMAPs retain a function of their parent NVEP type to use this Granzyme B fragment as a predictive biomarker.

[0353] More generally, matrikines are peptide fragments from other ECM proteins that act as signalling molecules to modulate wound healing, inflammation, cancer progression and fibrosis. The abundance of ECM proteins in ThrEDs and their tight light with the matrix suggests these matrikines may be detectable in ThrEDs to serve as a novel biomarker. Serglycin is another protein used as a biomarker for cancers. Using machine learning, Serglycin was one of four novel osteosarcoma biomarkers that had high diagnostic value relating to immune cell infiltration

[0354] Engineering

[0355] The encapsulation of therapeutic moieties has been shown to improve their pharmacokinetic and pharmacodynamic profiles. For example, the albumin bound and encapsulated form of Paclitaxel (Taxol), a chemotherapeutic medication, named Abraxane is ~130nm in diameter. Abraxane has greater efficacy in some cancers due to accumulation in tumours due to the albumin conjugation and is better tolerated by patients. The conjugation or encapsulation of therapeutics in endogenously produced protein particles present significant advantages.The inventors showed that Thrombospondin 1-GFP form dense particles which bind to GFP-nAb functionalized cell membrane mimics (SLBs) with a high degree of specificity, binding only to the cell membrane via the antibodies and not by sticking together or onto the membrane alone (Figure 7). The ability to target ThrEDs containing a densely packed core of ECM regulators to sites of injury or fibrotic disease would result in a robust but controlled response due to proteins that function on either side of an equilibrium, dampening excess deposition.

[0356] ThrEDs present significant advantages over EVs given their lack of a lipid bilayer. Fusogenic proteins are not required for the delivery of cargo to the ECM matrix, cell membrane or cytosol. A change in the calcium microenvironment, which are distinct in these environments, may be sufficient to release a high concentration of functional cargo in a localized area. The potential biogenesis via condensation of protein moieties supported by charge-charge interactions would facilitate the bottom-up production of particles ex vivo compared to EVs. The density of these particles may also overcome a major issue with low copy number in EVs given they are dense are their components are abundant in each particle. Furthermore, ThrEDs may function as more that a static therapeutic vehicle. Their abundance of ECM remodelling enzymes will likely facilitate migration of particle into difficult to access areas like solid tumours. ThrEDs can therefore be used to both enhance their natural function in fibrosis and wound healing through targeting and can also be used to treat any pathologies that require delivery of concentrated payloads in difficult to reach tissues.

[0357] Example 10 - Thrombospondin composition of ThrEDs

[0358] The Thrombospondin composition of ThrEDs was investigated using nanoflow cytometry (nanoFCM) and flow cytometry (Cytek Northern Lights) analyses. To properly assess the enrichment of TSPs in ThrEDs, the extracellular particle (EP) pool and the EP pool treated with 0.3% Triton-X-100 were also analysed. The EP pool contains vesicular EPs including extracellular vesicles (EV), lipoproteins and non-vesicular particles (NVEP) including ThrEDs (Figure 21).

[0359] Thrombospondin- 1-Atto488 was detected in 21.50% of the EP pool by Cytek Northern Lights and 12.10% by nanoFCM. Triton-X-100 lysis of vesicular particles increased the proportion of TSP-1+ particles to 31.10%. Enrichment of ThrEDs usingiodixanol gradient density gradient ultracentrifugation (DGUC) further increased TSP-1-Atto488+ to 58.20% by Cytek Northern Lights and 69.50% by nanoFCM.

[0360] Thrombospondin-4-AF488 was detected in 4.52% of the EP pool by Cytek Northern Lights and 3.30% by nanoFCM. Triton-X-100 lysis of vesicular particles increased the proportion of TSP-4+ particles to 10.90%. DGUC fraction 11 and 12 ThrEDs were 22.30% TSP-4+ by Cytek Northern Lights and 29.50% by nanoFCM. Thrombospondin-5-AF488 was detected in 17.20% of the EP pool by Cytek Northern Lights and 5.40% by nanoFCM. Triton-X-100 lysis of vesicular particles increased the proportion of TSP-5+ particles to 27.80%. DGUC fraction 11 and 12 ThrEDs were 67.70% TSP-5+ by Cytek Northern Lights and 65.60% by nanoFCM (Figure 22).

[0361] Collectively, these results highlighted that the iodixanol density gradient ultracentrifugation (DGUC) technique enriches ThrEDs in fractions 11 and 12 from the EP pool, increasing the proportion of TSP+ ThrEDs of interest. The data demonstrated that TSP-1 and TSP-5 are the predominant thrombospondin markers in ThrEDs, with TSP-1 detected in approximately 58-70% of ThrEDs and TSP-5 detected in approximately 66-68% of ThrEDs. TSP-4 is present in a smaller proportion of ThrEDs, at approximately 22-30%.

[0362] Further analysis of the data revealed that all the larger particles gated in the high-density fractions (Fl 1 / 12) are TSP-1 positive and TSP-5 positive (double positive), and about 30% are triple positive for TSP-1, TSP-4 and TSP-5. The negative particles in the heavy fractions are very small compared to positive particles, such that the Cytek analyser may miss them entirely and only detect the larger, positive particles.

[0363] The gating strategy for nanoflow cytometry and flow cytometry is shown in Figure 23. For nanoFCM, the correct gating is based on low FITC background from the antibody only control rather than the higher background from the isotype control. For the Cytek Northern Lights flow cytometer, the gating strategy distinguishes background signal from salt and protein (Pl) from extracellular particles (P2). The scatter and sizing profiles of unstained EPs are shown in Figure 24.

[0364] These findings demonstrate that ThrEDs may comprise TSP-1 and TSP-5 in the shell without necessarily comprising TSP-4. This is in contrast to SMAPs, which have been reported to be predominantly TSP-1 and TSP-4 positive. TSP-5 / COMP may therefore serve as a marker to distinguish ThrEDs from SMAPs in a sample.

Claims

CLAIMS1. An isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, further wherein:(a) the particle or core comprises or consists of one or more of an extracellular matrix component, a protein, a glycoprotein, a proteoglycan such as serglycin, and a polysaccharide; and(b) the particle or shell comprises or consists of one or more of full-length protein selected from a thrombospondin such as TSP-1, TSP-2, TSP-3, TSP-4 or TSP-5, serglycin, calreticulin, calmodulin, calumenin, cathepsinD, HRNBPA2B1, HS90AA1, HSPA8, syndecan such as cleaved syndecan-1, BASP1, galectin-1 or galectin-7; or a fragment, variant or orthologue of anyone thereof.

2. The particle of claim 1, wherein:(a) the particle or core comprises or consists of one or more of GZMB, ITIH1, ITIH2, ITIH3, ITIH4, collagen such as collagen 1 A, a SERPIN such as SERPINA2, SERPINB3, SERPINE1, SERPINF1, SERPINF2, SERPINH1 and / or SERPINI1, SDC1, FSLT1, IGFBP6, FLG2, PTPRK, CLSTIN1, CNTN1, CSTA, NRCAM, a Granzyme such as GranzymeB, a perforin such as perforin- 1, and D SCI; or a fragment, variant or orthologue of anyone thereof; and / or(b) the particle or core does not comprise a lipid and / or a phospholipid; or a fragment, variant or orthologue of anyone thereof; and / or(c) the particle or shell comprises or consists of one or more of full-length WGA, LGALS1, TSP-1, TSP-4 and TSP-5; or a fragment, variant or orthologue of anyone thereof; and / or(d) the particle or shell comprises or consists of one or more of full-length TSP-1, TSP-4 and TSP-5; such as full-length TSP-5; and / or(e) the particle or shell does not comprise a lipid bilayer, plasma membrane, a lipid, a phospholipid membrane, a Granzyme such as GranzymeB, Perforin, CD63, CD81, CD9, TSG101, and / or Alix; or a fragment, variant or orthologue of anyone thereof.

3. The particle of claim 1 or 2, wherein the particle or core comprises or consists of a polypeptide sequence as set out in Table 1; or a fragment, variant or orthologue of anyone thereof.

4. The particle of any one of the previous claims, wherein:(a) the particle is WGA positive and DiR negative; and / or(b) the particle is TSPAN14 negative and / or CD63 negative; and / or(c) the particle is DiR negative and negative for a membrane stain;(d) the particle does not have cytotoxic activity, such as no cytotoxic activity against Nalm6 cells; and / or(e) the particle or shell is resistant to pH fluctuations, treatment with a protease, treatment with a detergent, high salt conditions, and / or freeze thaw cycles.

5. The particle of any one of the previous claims, wherein the particle or core has a density of:(a) at least 0.1 g / mL, at least 0.50 g / mL, at least 1.00 g / mL, at least 1.25 g / mL, at least 1.50 g / mL or at least 2.00 g / mL; or(b) 0.50-1.00 g / mL, 0.50-1.25 g / mL, 0.50-1.50 g / mL, 0.50-2.00 g / mL, 1.00-1.25 g / mL, 1.00-1.50 g / mL, 1.00-2.00 g / mL, 1.25-1.50 g / mL, 1.25-2.00 g / mL or 1.50- 2.00 g / mL.

6. The particle of any one of the previous claims, wherein the particle has a diameter of:(a) 30-50 nm, 30-100 nm, 30-125 nm, 30-150 nm, 30-200 nm, 30-300 nm, 50-100 nm, 50-125 nm, 50-150 nm, 50-200 nm, 50-300nm, 100-125 nm, 100-150 nm, 100- 200 nm, 100-300nm, 125-150 nm, 125-200 nm, 125-300nm, 150-200 nm or 150- 300nm; or(b) greater than 30nm, greater than 50 nm, greater than 100 nm, greater than 125 nm or greater than 150 nm.

7. The particle according to any one of the previous claims, wherein:(a) the particle is attached to a membrane vesicle or phospholipid particle; and / or (b) the shell and / or core of the particle further comprise a toxin, such as a chemotherapeutic agent.

8. The particle according to any one of the previous claims, comprising:(a) a modified core protein such as a fusion protein; and / or(b) a modified shell protein such as a fusion protein; and / or(c) a shell protein modified at the c-terminus, such as a modification at the c- terminus of a thrombospondin; and / or(d) a transgenic protein and / or an antibody or antigen binding fragment thereof.

9. The particle according to claim 8, wherein the fusion protein comprises an antibody or antibody binding fragment, such as a scFv, a VL and / or VH, a Fd, an Fv, an Fab, a Fab', a F(ab')2, an Fc fragment, an antibody mimetic, or a bispecific antibody.

10. The particle according to any one of the previous claims, wherein:(a) the shell protein is fused to a moiety on the surface of the particle; and / or (b) the shell protein and / or core protein is fused to a cargo molecule; and / or (c) the shell protein is not PEGylated; and / or(d) the shell protein is PEGylated.optionally for use in a method of delivering the cargo molecule in vitro, in vivo, and / or in situ, such as delivering the cargo molecule to a cell and / or extracellular matrix of a tissue.

11. The particle according to claim 10, wherein the moiety on the surface of the particle is selected from one or more of a peptide and / or protein, a targeting peptide and / or targeting protein which binds to a molecule present on a cell to be targeted, a therapeuticmoiety such as a receptor decoy, an endosomal escape moiety, an enzyme, a glycoprotein, a proteoglycan such as serglycin, a polysaccharide, a nuclease, a CRISPR-associated protein (Cas) such as SaCas9, SpCas9, Cas9, Cast 2, Cast 3 and variants and fusions thereof, a Transcription activator-like effector nucleases (TALEN) and variants and fusions thereof, a meganuclease and variants and fusions thereof, a zinc finger nuclease and variants and fusions thereof, an antibody and / or antigen-binding variant or fragment thereof, a single chain variable fragment (scFv), VHH, a nanobody, a nucleic acid-binding protein and / or peptide, a RNA- and / or DNA-binding protein, viral-binding protein, a small molecule drug, a nucleic acid, a nucleic acid analogue, an unnatural nucleic acid, gRNA, miRNA, shRNA, siRNA, piRNA, PMO, DNA and a DNA plasmid encoding a therapeutic peptide and / or protein, a toxin, such as chlorotoxin, and a chemotherapeutic agent; optionally wherein:(a) the moiety on the surface of the particle is a targeting peptide and / or targeting protein which binds to a molecule present on a cell to be targeted, optionally wherein the targeting peptide and / or targeting protein binds to a molecule present on a cell of the liver, preferably a hepatocyte; the heart, preferably a cardiomyocytes or a smooth muscle cell; the brain or the nervous system, preferable a neurone or a glial cell, most preferably a sensory neurone a motor neurone or an interneuron; and / or(b) the moiety on the surface of the particle is selected from a peptide binding protein or an RNA binding protein, optionally wherein the peptide binding protein is capable of binding a Cas protein, preferably Cas9 or Cas 12, or an adeno- associated virus (AAV), preferably an AAV capsid, and most preferably an AAV8 or AAV9 capsid.

12. The particle according to claim 10 or 11, wherein the cargo molecule is:(a) inside or outside the particle; and / or(b) an exogenous cargo molecule; and / or(c) an endogenous cargo molecule; and / or(d) present at a copy number per particle of at least 2, at least 5, at least 10, at least 25, at least 50, at least 100, at least 500, at least 1000, at least 10,000 or at least 100,000.

13. The particle according to any one of claims 10-12, wherein the cargo molecule is selected from one or more of a therapeutic cargo, a peptide and / or protein, an enzyme, a glycoprotein, a proteoglycan such as serglycin, a polysaccharide, a nuclease, a CRISPR-associated protein (Cas) such as SaCas9, SpCas9, Cas9, Cast 2, Cast 3 and variants and fusions thereof, a Transcription activator-like effector nucleases (TALEN) and variants and fusions thereof, a meganuclease and variants and fusions thereof, a zinc finger nuclease and variants and fusions thereof, an antibody and / or antigen-binding variant or fragment thereof, a single chain variable fragment (scFv), VHH, a nanobody, a nucleic acid-binding protein and / or peptide, a RNA- and / or DNA-binding protein, viral-binding protein, a small molecule drug, a nucleic acid, a nucleic acid analogue, an unnatural nucleic acid, gRNA, miRNA, shRNA, siRNA, piRNA, PMO, DNA and a DNA plasmid encoding a therapeutic peptide and / or protein, a toxin, such as chlorotoxin, and a chemotherapeutic agent; optionally wherein:(a) the cargo molecule is a targeting peptide and / or targeting protein which binds to a molecule present on a cell to be targeted, optionally wherein the targeting peptide and / or targeting protein binds to a molecule present on a cell of the liver, preferably a hepatocyte; the heart, preferably a cardiomyocytes or a smooth muscle cell; the brain or the nervous system, preferable a neurone or a glial cell, most preferably a sensory neurone a motor neurone or an interneuron; and / or(b) the cargo molecule is selected from a peptide binding protein or an RNA binding protein, optionally wherein the peptide binding protein is capable of binding a Cas protein, preferably Cas9 or Cas 12, or an adeno-associated virus (AAV), preferably an AAV capsid, and most preferably an AAV8 or AAV9 capsid.

14. A cell capable of producing the particle according to any of the previous claims, optionally wherein the cell is:(a) modified to express the core, shell, moiety and / or cargo molecule; and / or(b) the cell is a somatic cell, a germ cell, a muscle cell, a neural cell, an endothelial cell, a polarised cell, HEK-293T, HeLa, MSC, A549, C2C12, HMEC-1, HUVEC, PANCI, U373 or a T cell such as a resting CD4+ or CD8+ T cell, an activated CD4+ or CD8+ T cell, a cytotoxic T cell, a CD3+ cell, a Natural Killer (NK) cell a U20S cell or a CHO cell.

15. A method of producing a modified cell capable of producing the particle according to any one of claims 1-13, the method comprising introducing into the cell a nucleotide sequence encoding the core, shell, moiety and / or cargo molecule.

16. A method of isolating the particle according to any one of claims 1-13 from a cell, cell lysate, conditioned media, and / or physiological fluid such as plasma, blood, urine, bile, saliva, interstitial fluid or cerebrospinal fluid, the method comprising:(a) providing the cell in a liquid suspension, cell lysate, the conditioned media, and / or the physiological fluid;(b) centrifuging and / or filtering the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid, to form a cell-free and debris-free liquid; and / or(c) centrifuging and / or filtering the cell-free and debris-free liquid to collect the particle;optionally wherein the cell is a cell according to claim 14; and / or the cell lysate, conditioned media or physiological fluid is from a cell according to claim 14.

17. The method according to claim 16, wherein the method:(a) does not comprise a step of ultracentrifugation, size exclusion chromatography and / or ultrafiltration; and / or(b) comprises a step of precipitation, such as PEG precipitation.

18. The method according to claim 16 or 17, wherein:(a) the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid is centrifuged at 100-5000g, such as by differential centrifugation, to form the cell-free and debris-free liquid; and / or(b) the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid is filtered such as by size exclusion chromatography, tangential flow filtration and / or spin filtration, to form the cell-free and debris-free liquid; and / or(c) the cell-free and debris-free liquid is subjected to iodixanol density gradient centrifugation, optionally wherein the particle is collected from the 25% and / or 60% iodixanol fraction; and / or(d) Ca2+is added to the cell-free and debris-free liquid and / or to the collected particle.

19. A method of isolating the particle according to any one of claims 1-13 from a cell, cell lysate, conditioned media and / or physiological fluid, the method comprising:(a) contacting the cell in a liquid suspension, the cell lysate, the conditioned media and / or the physiological fluid with a substrate, wherein the particle adheres to the substrate, optionally wherein the cell also adheres to the substrate;(b) washing the substrate to leave the particle adhered to the substrate; and (c) collecting the particle by eluting the particle from the substrate;optionally wherein the cell is a cell according to claim 14; and / or the cell lysate, conditioned media or physiological fluid is from a cell according to claim 14.

20. A particle obtained or obtainable by the method of any one of claims 16-19.

21. The particle according to claim 20, wherein the particle is not cytotoxic.

22. A composition comprising the particle according to any one of claims 1-13, 20 or 21, optionally wherein:(a) the composition is a pharmaceutical composition; and / or(b) the composition is substantially devoid of aggregates of particles; and / or (c) the composition is substantially devoid of extracellular vesicles; and / or(d) particles in the composition are homogenous or substantially homogenous.

23. The particle according to any one of claims 1-13, 20 or 21, or the composition according to claim 22:(a) for use as a medicament; and / or(b) for use in treating or preventing a disease or a condition of a subject; and / or (c) for use in a method of treating and / or preventing Alzheimer’s disease, autoimmune conditions, cancer such as pancreatic or colorectal cancer, cardiovascular disease, cystic fibrosis, Duchenne muscular dystrophy, haemophilia, Huntington’s disease, lysosomal storage disease, liver disorders, macular degeneration, myotonic dystrophy, neuromuscular disease, Parkinson’s disease, sepsis, spinal muscular atrophy, stroke, genetic disorders, CNS conditions, neuro- degenerative disorders, heart disorders, Phenylketonuria, heart failure or ALS; and / or(d) for use in wound healing, tissue repair, reversing scarring, reversing fibrosis, promoting extracellular matrix normalisation and / or modulating cell migration; (e) for use in cell killing in a subject; and / or(f) for use in targeted cell killing in a subject; and / or(g) for use in gene therapy and / or gene editing; and / or(h) for use in modulating the growth of a cell, such as modulating the growth of a target cell.

24. A method of treating or preventing disease in a subject comprising administering to a subject the particle according to any one of claims 1-13, 20 or 21, or the composition according to claim 22, optionally:(a) wherein the disease is Alzheimer’s disease, an autoimmune condition, cancer such as pancreatic or colorectal cancer, cardiovascular disease, cystic fibrosis, Duchenne muscular dystrophy, haemophilia, Huntington’s disease, a lysosomal storage disease, a liver disorder, macular degeneration, myotonic dystrophy,neuromuscular disease, Parkinson’s disease, sepsis, spinal muscular atrophy, stroke, a genetic disorder, a CNS condition, a neuro-degenerative disorder, a heart disorder, Phenylketonuria, heart failure or ALS; and / or(b) wherein wound healing is promoted, tissue repair is promoted, scarring is reversed, fibrosis is reversed, extracellular matrix is normalised and / or cell migration is modulated; and / or(c) comprising cell killing in the subject; and / or(d) comprising targeted cell killing in the subject; and / or(e) comprising gene therapy and / or gene editing; and / or(f) modulating the growth of a cell, such as modulating the growth of a target cell.

25. The in vitro or ex vivo use of the particle according to any one of claims 1-13, 20 or 21, or the composition according to claim 22, as a research tool, a diagnostic tool, an imaging tool, a biological reference material, an experimental control and / or an experimental standard; optionally wherein the particle or the composition is immobilised to a solid support.

26. An isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, wherein:(a) the core comprises one or more extracellular matrix component selected from a collagen, a proteoglycan, a glycoprotein, a SERPIN, and an ITIH protein;(b) the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5), or fragments, variants or orthologues thereof; and(c) the particle does not comprise a lipid bilayer.

27. The particle of claim 26, wherein the shell further comprises thrombospondin-4 (TSP-4) or a fragment, variant or orthologue thereof.

28. The particle of claim 26 or 27, wherein the particle does not comprise granzyme B and / or perforin-1.

29. The particle of claim 28, wherein the particle does not have cytotoxic activity.

30. The particle of any one of claims 26-29, wherein the core comprises one or more of collagen 1A, fibronectin 1 (FN1), ITIH1, ITIH2, ITIH3, ITIH4, serglycin, and one or more SERPIN selected from SERPINA2, SERPINB3, SERPINE1, SERPINF1, SERPINF2, SERPINH1 and SERPINI1.

31. The particle of any one of claims 26-30, wherein the particle is obtainable from a non-immune cell, optionally wherein the non-immune cell is selected from HEK-293T, A549, HeLa, MSC, PANCI, U373, C2C12, HMEC-1 and HUVEC.

32. The particle of any one of claims 26-31, wherein the particle is detergent resistant.

33. The particle of any one of claims 26-32, wherein the particle is stabilised by calcium ions, optionally at a concentration of 0.5mM to 9mM Ca2+.

34. The particle of any one of claims 26-33, wherein the particle has a density corresponding to fractions 11 and / or 12 of an iodixanol density gradient comprising 6%, 12%, 14%, 16%, 18%, 25%, 40% and 60% iodixanol.

35. The particle of any one of claims 26-34, wherein the particle is WGA positive and DiR negative, and / or CellMask negative.

36. The particle of any one of claims 26-35, wherein the particle is TSPAN14 negative, CD63 negative, CD81 negative and CD9 negative.

37. An isolated and / or engineered proteinaceous particle, wherein the particle comprises a core and a shell surrounding the core, wherein:(a) the core comprises one or more extracellular matrix component;(b) the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5); (c) the particle does not comprise a lipid bilayer;(d) the particle does not comprise granzyme B and / or perforin-1; and(e) the particle is not cytotoxic.

38. A method of isolating the particle of any one of claim 26-37, the method comprising:(a) providing conditioned media from a cell cultured for at least 48 hours, at least 72 hours or about 96 hours;(b) subjecting the conditioned media to iodixanol density gradient ultracentrifugation; and(c) collecting the particle from the 40% and / or 60% iodixanol fraction; optionally wherein Ca2+ is present during one or more steps at a concentration of 0.5mM to 9mM.

39. The particle of any one of claims 26-37, or a composition comprising said particle, for use in wound healing, tissue repair, reversing fibrosis, and / or promoting extracellular matrix normalisation.

40. The particle of any one of claims 26-37, or a composition comprising said particle, for use in treating Dupuytren's disease.

41. The particle of any one of claims 26-37, or a composition comprising said particle, for use as a therapeutic delivery vehicle.

42. An in vitro method of identifying or distinguishing ThrEDs from SMAPs in a sample, the method comprising detecting the presence of TSP-5 (COMP) in the sample, wherein the presence of TSP-5 (COMP) is indicative of ThrEDs.

43. A population of particles, wherein each particle in the population comprises a core and a shell surrounding the core, wherein the shell comprises thrombospondin-1 (TSP-1) and thrombospondin-5 (TSP-5), the particle does not comprise a lipid bilayer, and at least 30% of the particles in the population are TSP-1 positive and TSP-5 positive.

44. The population of claim 43, wherein up to about 30% of the particles are TSP-1 positive, TSP -4 positive and TSP-5 positive.

45. The population of claim 43 or 44, wherein the particles do not comprise granzyme B and / or perforin-1 and are not cytotoxic.